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A B S T R A C T
Living systems are formed and defined by the complex interplay of a va-
riety of biological networks, implicating the need of an accurate but flex-
ible regulation mechanism. Phosphorylation networks comprising the in-
terrelationships between kinases, phosphatases, and their substrates take
on a leading part in the cellular regulation system, and are of fundamen-
tal importance for the function and robustness of essentially all biological
activities including cell division, signal transduction, metabolism, and cell
motility.
Despite the undoubted relevance of phosphorylation networks, rather lit-
tle is known about their architecture and organization so far. In fact, due
to technological developments, the amount of phosphoproteome data has
been growing in recent years, resulting in the listing and characterization
of phosphoproteins and their sites of phosphorylation in a variety of organ-
isms. Nevertheless, the dependencies between kinases, phosphatases and
phosphoproteins are mostly not understood and only for few kinases and
phosphatases their immediate downstream targets are known. Linking the
kinome and phosphatome to the phosphoproteome still remains a challeng-
ing task.
In this study I analyzed and explored the raw data from a collaborative
project which used label–free, quantitative phosphoproteomics in order to
determine the relationships between 97 kinases, 27 phosphatases, and more
than 1000 phosphoproteins in the yeast Saccharomyces cerevisiae. We system-
atically detected and identified phosphopeptides that showed a significant
and reproducible change in their abundance upon the removal (or inacti-
vation) of each of the kinases or phosphatases, thereby describing the first
system–wide in vivo phosphorylation network of Saccharomyces cerevisiae.
Our analysis revealed a high degree of interconnectedness within the net-
work, as the inactivation of most kinases and phosphatases did not only af-
fect potential direct targets but large parts of the phosphorylation network.
This outcome argues for a considerable robustness in the architecture of
the phosphorylation–dependent control machinery and supports the idea
that signaling pathways do not act in a simple linear manner, an observa-
tion of consequence for drug development and for describing organismal
homeostasis.
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Z U S A M M E N FA S S U N G
Lebende Systeme beruhen auf dem komplexen Zusammenspiel verschie-
dener zellulärer Netzwerke, ein Mechanismus, der sowohl präzise als auch
flexible Regulierungsmöglichkeiten erfordert. Phosphorylierungsnetzwerke
beschreiben die Zusammenhänge zwischen Kinasen, Phosphatasen und
ihren Substraten. Sie spielen eine wichtige Rolle im zellulären Kontroll-
system und sind für den Ablauf im Grunde aller biologischen Prozesse,
einschliesslich Zellteilung, Signalübertragung, Metabolismus und Zellmoti-
lität, von grundlegender Bedeutung.
Obwohl die Bedeutsamkeit von Phosphorylierungsnetzwerken unbestrit-
ten ist, ist über deren Architektur und Gestalt bis zum heutigen Zeitpunkt
nur wenig bekannt. So werden zwar aufgrund technischer Fortschritte im-
mer grössere Mengen an Phosphoproteom–Daten erzeugt, was zu einem
stetigen Anstieg bekannter Phosphoproteine und ihren Phosphorylierungs-
stellen führt, allerdings sind die Zusammenhänge und Abhängigkeiten der
Kinasen, Phosphatasen und Substrate untereinander zum grossen Teil im-
mer noch unbekannt. Bis dato konnte nur für eine kleine Anzahl von Ki-
nasen die direkten Zielproteine identifiziert werden und die Verknüpfung
von Kinom und Phosphatom mit dem Phosphoproteom stellt immer noch
eine grosse Herausforderung dar.
In der vorliegenden Arbeit analysierte und untersuchte ich die mittels
quantitativer Phosphoproteomik erzeugten Rohdaten eines gemeinschaft-
lichen Projekts mit dem Ziel, die Beziehungen zwischen 97 Kinasen, 27
Phosphatasen und über 1000 Phosphoproteinen in der Hefe Saccharomyces
cerevisiae zu beschreiben und zu erläutern. Systematisch identifizierten wir
Phosphopeptide, die, als Reaktion auf die Inaktivierung einer bestimmten
Kinase oder Phosphatase, eine signifikante und reproduzierbare Änderung
in ihrer Abundanz aufwiesen. Auf diese Weise konnten wir das erste sys-
temweite in vivo Phosphorylierungsnetzwerk von Saccharomyces cerevisiae
beschreiben. Unsere Analyse machte dabei den hohen Grad an Vernetzung
und Interaktion innerhalb des Netzwerks deutlich, da die Inaktivierung der
meisten Kinasen und Phosphatasen nicht nur nachgeschaltete Phosphopro-
teine, sondern oft grössere Teile des Netzwerks beeinflusste. Dieses Ergeb-
nis weist auf eine erhebliche Robustheit im phosphorylierungsbasierten
Regulierungssystem der Zelle hin und bestärkt die Annahme, dass Sig-
nalübertragungswege keinesfalls in linearer Art und Weise agieren. Eine
Erkenntnis, die auch hinsichtlich der Entwicklung von Medikamenten und
der Beschreibung der Homeostasis von Organismen von wichtiger Bedeu-
tung ist.
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Part I
I N T R O D U C T I O N A N D C O N T E X T

1
I N T R O D U C T I O N
Systems Biology is a broad field, comprising a wide range of biological re-
search areas and incorporating both experimental and computational tech-
nologies [1, 2, 3, 4, 5]. While the classification of Systems Biology as an
independent field of science has been somewhat controversial, it is clear
that the term denotes a set of newly developed experimental, mathematical
and computational methods applied to solving biological problems [6]. This
points out that the rise of Systems Biology would not have been possible
without technological advancements. Rather, it actually coincides with and
is based on the invention and development of the so called ‘omics’ disci-
plines including genomics, transcriptomics, proteomics, and metabolomics.
The conceptual novelty of Systems Biology is also reflected by its lack
of a concise definition. One of many working definitions is “the search for
the syntax of biological information, that is, the study of the dynamic net-
works of interacting biological elements” [7]. Various ‘ome’ units (genome,
transcriptome, proteome, etc.) constitute such biological elements. The con-
certed interplay of their underlying biological networks forms and defines
all living systems. As a result, a complex framework arises that is subject
to precise regulation, carried out by adequate regulatory networks.
In 1992, Edmond H. Fischer and Edwin G. Krebs were awarded with
the Nobel Prize in Physiology or Medicine for their “discoveries concern-
ing reversible protein phosphorylation as a biological regulatory mecha-
nism” [8, 9]. Initially only characterized in carbohydrate metabolism [10], it
soon became clear that phosphorylation is indeed one of the most prevalent
mechanism by which the cell turns a reaction on or off [11]. Thus, together
with the transcriptional network, the phosphorylation network is consid-
ered as one of the most prominent regulatory networks: Protein kinases and
protein phosphatases mediate signals by phosphorylating and dephospho-
rylating their target (phospho–) proteins, respectively, hereby controlling a
wide range of essential cellular processes including cell division, transcrip-
tion, growth, and metabolic pathways [12, 13].
Although many of the individual players in the phosphorylation net-
works of various organisms are known, the topological landscapes of these
networks are not. The signaling context for most phosphorylation sites con-
tinues to be unidentified, i.e. there is a big gap in linking kinases and phos-
phatases to their respective substrates [14]. For instance, information about
the upstream kinases and phosphatases is available for only 13% of the
known phosphorylation sites of the yeast Saccharomyces cerevisiae [15] and
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conversely, not a single substrate is known for about half of the kinases and
phosphatases identified in the same organism.
The work presented in this thesis provides an important step towards
the understanding and interpretation of this essential regulatory network
in eukaryotes and describes the first system–wide protein phosphorylation
network in vivo. Our results constitute a major resource for further studies,
not only concerning the field of phosphoproteomics but also in a broader
Systems Biology context in order to describe the interactions of the various
biological networks in living organisms. In doing so, this work further gives
insights into the interrelationship of the phosphorylation network with the
metabolic network by analyzing the impact of protein phosphorylation on
the regulation of the metabolome.
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P R O T E I N P H O S P H O RY L AT I O N
Protein phosphorylation is one of the most common post–translational mod-
ifications (PTMs) of proteins. As depicted in Figure 1(a), it plays a key role
in eukaryotes, regulating essential cellular processes including cell division,
signal transduction, metabolism, and cell motility [12, 13]. The process of
“enzymatic protein phosphorylation” was first described in 1952 by George
Burnett and Eugene Kennedy [16]. The reversible transfer of a phosphate
group to specific amino acids is catalyzed by protein kinases while its re-
moval is catalyzed by protein phosphatases (see Figure 1(b)). In eukaryotes,
mostly serine and threonine residues are phosphorylated, and, to a lesser
extent, also tyrosine residues. Nevertheless, phosphorylation events involv-
ing histidine and aspartate residues have also been described [13].
Nowadays, it is common knowledge, that the addition of a phosphate
group to the side chain of an amino acid can have strong effects on the char-
acteristics of proteins. Particularly, the protein’s charge is changed which in
turn can induce extensive conformational modifications and for instance re-
sult in the activation or deactivation of enzymes. Also, the protein’s ability
to interact with other proteins can be influenced. Existing binding sites can
be blocked as well as new binding sites created. In consequence, protein
phosphorylation is significantly involved in protein complex assembly and
disassembly.
It has been estimated that 30 to 50 % of all cellular proteins might be
phosphorylated and thus represent possible phosphoproteins [21, 22]. The
number of human phosphorylation sites has recently been revised upwards
from 100.000 to 500.000, implying an average of about 25 potential sites per
protein [23]. In yeast, currently about 9000 phosphosites for over 3000 phos-
phoproteins are curated [24]. The availability of multiple phosphorylation
sites in the same protein (multisite phosphorylation) greatly increases the
combinatorial space of regulation and plays a significant factor in the fine–
tuned control of protein function. Furthermore, the order in which the sites
are processed seems to play a crucial role, too [13, 25].
The kinome and phosphatome represent a species‘ complete set of pro-
tein kinases and phosphatases, respectively. Protein kinases are among the
largest of protein families in eukaryotes, comprising about 2% of all eu-
karyotic genes [22, 26, 12, 27, 28]. For example, the analysis of the human
genome revealed the existence of 518 putative protein kinases [12]. In the
fruit fly, Drosophila melanogaster, 239 protein kinases have been reported
[29, 30], in yeast 123 [31]. Based on sequence similarities between their cat-
alytic domains, protein kinases can be classified into a hierarchy of groups,
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Figure 1: Reversible protein phosphorylation. (a) Schematic overview of a selection of cellular
processes known to be regulated by protein phosphorylation. Graphics taken from [17, 18,
19, 20] (b) Schematic diagram of reversible protein phosphorylation. In eukaryotes, mostly
serine, threonine, and tyrosine residues are phosphorylated. Protein kinases catalyze the
transfer of a phosphate group from ATP to an amino acid, protein phosphatases catalyze
the removal of a phosphate group.
protein phosphorylation 7
families, and subfamilies [29, 32]. Phylogenetic comparisons of different
eukaryotic kinomes showed an ancient conservation of kinase families: All
major kinase groups and most kinase families are shared among metazoans
and many of them are also conserved in yeast [29].
As a result on the substantial influence of protein phosphorylation on
most cellular processes, abnormal phosphorylation leads to many diseases,
including cancer, diabetes, and rheumatoid arthritis [33]. However, this as-
pect also makes protein kinases and phosphatases to a possible source as
drug targets. In fact, kinases have become the second most important group
of drug targets and a multitude of human clinical trials involving kinases
are carried out at present [34].
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P H O S P H O P R O T E O M I C S
The advent of proteomics [35] has revolutionized the way we study proteins.
Simultaneously, the analysis of protein phosphorylation has shifted from
targeted biochemical studies to high–throughput (HTP) studies, leading to
the subdiscipline of phosphoproteomics, dedicated to the systematic study
of the phosphoproteome (i.e., the comprehensive set of phosphoproteins in
an organism) [36, 37].
Within the proteomics discipline, mass spectrometry (MS) is the technol-
ogy of choice, and shotgun proteomics (bottom–up proteomics) is the most
popular approach used in phosphoproteomics [38, 39]. Figure 2 outlines
the standard shotgun proteomics procedure. In a first step, complex pro-
tein samples are enzymatically digested into peptides, which are then sepa-
rated by the MS pipeline. Phosphopeptides are naturally underrepresented
in digested peptide mixtures. In order to compensate for this, in phospho-
proteomics, protein digestion is followed by the enrichment of phospho-
peptides, usually by applying metal affinity chromatography like titanium
dioxide (TiO2) or immobilized metal affinity chromatography (IMAC) [40].
Implementing this approach, hundreds of phosphorylation sites have
been identified and reported [42, 43, 44, 45, 46]. Various databases like
PhosphoPep [24], Phospho.ELM [23], Phosida [47], and PhosphoSite [48]
were established to catalogue and curate these large numbers of phospho-
sites.
In recent years, analyses have changed from the simple reporting of
phosphorylation sites to more quantitative phosphoproteomic studies. This
allows obtaining precise measurements of small changes in the level of
abundance of phosphopeptides of interest, and hence gaining insights into
the dynamics of protein phosphorylation across different cellular states
[49, 50, 51, 52].
In principle, there are two main approaches for MS–based quantitative
proteomics: isotope label–based quantification and label–free quantification.
A number of excellent reviews addressing these methods have been pub-
lished, for a selection see [53, 54, 39]. Figure 3 gives a schematic overview
of both workflows, whereas the MS–landscape in Figure 4 highlights the
differences in identifying and quantifying identical peptides in different
samples.
Briefly, in isotope labeling proteomics, (Figure 3(a)) peptides are modified
metabolically (stable isotope labeling by amino acids in cell culture (SILAC)),
chemically (isotope–coded affinity tag (ICAT)), or enzymatically (proteolytic
9
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Figure 2: Standard shotgun proteomics workflow. (a) Proteins sampled from cells or tissues
are digested into peptides and if necessary enriched for peptides containing specific PTMs.
(b) Purified peptides are chromatographically separated and then ionized (for example
by electrospray ionization (ESI)) directly into the mass spectrometer. (c) In the mass spec-
trometer particular peptide ions are selected for MS2 and fragmented in a collision cell,
resulting in a MS/MS spectrum. (d) Spectra are mapped to peptides and proteins, which
can then be further analyzed via bioinformatic approaches. Taken from [41].
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18O labeling). These ‘heavy’ peptides are then run together with their na-
tive counterparts (‘light’ peptides) and are analyzed by liquid chromatogra-
phy coupled to tandem mass spectrometry (LC–MS/MS). The quantification
is based on the fact that labeled and native peptides are chemically identi-
cal and therefore should also behave identically (at least outside the mass
spectrometer). As a result, they can be recognized by their (known) mass
difference, and by comparing their signal intensities, a change in relative
abundance of the two peptides can be accurately determined.
In contrast to labeled proteomics, in label–free approaches different sam-
ples are analyzed by separate LC–MS/MS runs (Figure 3(b)). The (relative)
quantification is achieved either by aligning peptides across different sam-
ples based on their precursor ion scan of the mass spectrometer (MS1) spec-
tra and followed by a comparison of their peak intensities (comparative
LC–MS/MS), or by estimating the abundances of peptides based on their
number of identified MS2 spectra (spectral counting) and comparing the
number of such spectra between different samples.
Both labeled and label–free approaches have advantages and disadvan-
tages. In general, the former offer higher accuracy in measuring protein
abundances while label–free methodologies exhibit a greater dynamic range
and enable more comprehensive (phospho)-proteome coverage [53].
A crucial factor in comparative LC–MS/MS is the computational procedure
of matching identical peptides across different samples/MS runs. In the fol-
lowing section, I will explain some of the problems and challenges arising
while generating this type of alignment, and review some of the software
applications currently available.
12 phosphoproteomics
(a) (b)
Figure 3: Main approaches for quantitative proteomics (a) Isotope label–based proteomics.
Different samples containing light and heavy isotopes are analyzed together. The quan-
tification is based on the ratio of signal intensities of chemically identical but differently
labeled peptides. (b) Label–free proteomics. The quantitative information can be achieved
either by aligning peak intensities across different samples or by comparing spectral
counts, respectively. Both methodologies yield relative protein quantifications. Taken from
[55].
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Figure 4: Comparison of the three main quantification approaches in proteomics. Red: Isotope
label–based proteomics. Chemically identical but differently labeled peptides can be iden-
tified based on their mass shift. Blue: Comparative LC–MS/MS. Identical peptides in differ-
ent samples are identified by their specific retention time and precise m/z values. Green:
Spectral counting. Identical peptides are identified based on their MS2 annotation. Taken
from [56].
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C O M PA R AT I V E L C – M S / M S
Label–free quantification based on the comparison of precursor ion intensi-
ties depends on the accurate alignment of corresponding MS1 spectra across
the different liquid chromatography mass spectrometry (LC–MS) runs and
requires prior peak and feature detection. Typically, most software pro-
grams for comparative LC–MS/MS do implement these steps. A brief outline
of the usual data processing pipeline of label–free quantification software
is depicted in Figure 5.
LS-MS data
peak/feature detection
feature quanti!cation
feature alignment
normalization
statistical analysis
a)
b)
c)
d)
e)
Figure 5: Typcial data processing workflow of compar-
ative LC–MS/MS software. a) Raw MS1 data obtained
from the mass spectrometer is processed for fea-
ture detection, resulting in a list of features char-
acterized by their m/z and Rt values. b) Features
are quantified by the integration of their signal
intensities. c) Mass spectra of different MS runs
are aligned and identical features are matched.
d) Usually, this is followed by the normalization
of Rt and intensity values (in some algorithms
this is done at the beginning of the pipeline). e)
Statistical analysis: identification of features that
differ significantly in their abundances across the
different MS runs.
Peak detection is the process of selecting peptide–induced signals from
MS raw data. In doing so, one of the major bottlenecks is distinguishing be-
tween peptide and noise signals. Both chemical noise (molecules other than
peptides) and random (electronic) noise contribute to the overall noise rate.
Additionally, the true peptide signal is disturbed by the baseline, which is
the background signal produced by the mass spectrometer. Consequently,
noise filtering or ‘smoothing’ and baseline correction mark the beginning of
peak detection algorithms. For smoothing, most approaches are based on
signal processing techniques like Gaussian or wavelet–based filters. Base-
line correction is done by subtracting the estimated baseline signal from the
15
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peptide signals. Reference [57] summarizes some of the standard smooth-
ing filters and baseline modulation methods.
The actual peak extraction procedure (‘peak picking’) utilizes a set of
criteria like signal–to–noise (S/N) ratio, miscellaneous peak characteristics
(shape, intensity, slope, width), and the existence of local maxima [57]. Due
to the occurrence of isotopes on the one hand and different charge states on
the other hand, peptides are never represented as single peaks but as a se-
quence of isotopic peak patterns. Thus, in a last step all peaks arising from
the same peptide are grouped and converted into a single feature. Often,
only the peak representing the monoisotopic mass (i.e. the mass calculated
while taking only the most abundant isotope of each constituent atom into
account) is used for later quantification. The separation of overlapping peak
patterns constitutes a complex matter and is a likely source of error.
The quantification of features is based on the finding that the abundance
of peptides in a sample should be proportional to their MS peak intensity
[58]. Therefore, quantification is achieved by integrating the peak intensity
over chromatographic time (also referred to as area under the curve (AUC)).
Because the final goal of the analysis is to compare peptide abundances
across different samples, it is indispensable to ensure identical experimen-
tal and instrumental conditions for all the protein samples analyzed sequen-
tially.
The main task in comparative LC–MS/MS is constructing the alignment of
multiple LC–MS runs in order to compare peptide quantities across different
samples. Peaks identified in one sample are to be linked to matching peaks
in the other sample. This constitutes a nontrivial challenge, and, as stated
in [58], “given the enormous complexity of high resolution LC–MS datasets,
a perfect detailed alignment of all features seems a non–realistic goal.”
Below is a listing of challenges that algorithms have to deal with:
• drifts in Rt and m/z between different runs, caused by technical prob-
lems
• Rt and m/z drifts often differ within the set of identified peaks (mainly
non–linear shifts in Rt)
• a single peak in one run could be interpreted as multiple peaks in the
other run (inaccurate peak detection)
• peaks could be missing completely in one sample, either due to true
absence or failure of detection
• features having very similar Rt and m/z values can nevertheless repre-
sent different peptides (high–complexity peptide samples)
Though comparative LC–MS/MS is a relatively recent field, a variety of
different software solutions is available in order to master the challenge of
comparative lc–ms/ms 17
LC–MS alignment construction. All of them have in common that the quality
of the alignment built is highly dependent on the resolution of the MS data
in terms of mass accuracy and chromatographic separation. The higher the
resolution in the m/z dimension, the better peaks will be discriminated.
Well–established software applications for LC–MS alignment construction
include SuperHirn [59], OpenMS [60], msInspect [61], SpecArray [62] and
MZmine [63], among others. Recently, MaxQuant, a frequently used soft-
ware in the field of isotope–label based proteomics analysis [64], is available
with a label–free implementation, too [65].
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P R E V I O U S W O R K O N T H E R E C O N S T R U C T I O N O F
P H O S P H O RY L AT I O N N E T W O R K S
Deciphering (global) interrelationships between kinases, phosphatases and
their substrates has always been the main focus of protein phosphoryla-
tion analysis. In order to link kinases and phosphatases to their substrates,
besides MS–based phosphoproteomics other HTP techniques have been em-
ployed as well. In the following paragraphs, I outline some of the relevant
research studies of recent years. Because the work in my thesis is done
using yeast as a model organism, I will focus on findings in this system.
One of the first HTP technologies employed were in vitro phosphorylation
assays. Based on them, Ubersax et. al [66] identified about 180 targets of
yeast Cdk1. In a similar study, 24 substrates of yeast kinase Pho85 could be
determined [67].
Ptacek et al. used proteome microarrays to determine in vitro substrates
of yeast protein kinases [68]. For 87 kinases they identified about 4200 phos-
phorylation events comprising more than 1300 phosphoproteins. Most of
the targets were recognized by only one or two kinases, indicating a strong
preference of kinases for specific targets. By integrating protein protein
interaction (PPI) and transcription factor (TF) binding site data, they con-
structed the first integrated in vitro phosphorylation network in yeast.
Detection of functional connections between kinases and substrates by ap-
plying genetic screens is discussed in [69]. Comprising most of the known
kinases and phosphatases in yeast, the authors measured about 100.000 dis-
tinct pairwise genetic interactions. Their analysis revealed a significant en-
richment of positive genetic interactions between known kinase–substrate
and phosphatase–substrate pairs. Particularly strong positive genetic inter-
actions could be observed for kinase–phosphatase pairs that shared a com-
mon substrate. Therefore, the authors argued that their dataset would be
helpful in identifying unknown kinase/phosphatase substrates.
Combining affinity purification and MS, Breitkreutz et al. [70] constructed
a global kinase and phosphatase interaction network in yeast, consisting of
more than 1800 interactions between almost 900 proteins. A clustering ana-
lysis revealed many locally dense regions, suggesting new functions for
known kinases and phosphatases. Upon the incorporation of (previously
known) PPI datasets, an extended interaction network showed a signifi-
cant enrichment in kinase–kinase interactions, strongly suggestion that the
extensive kinase–kinase interaction network constitutes the proteome back-
bone.
19
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Van Wageningen et al. integrated genome–wide transcriptomic profiling
and genetic screens to study the degree of redundancy between kinases and
phosphatases in signaling networks [71]. Three different genetic buffering
relationships were identified: mixed epistasis, complete redundancy, and
quantitative redundancy. Mixed epistasis, the most frequent type of redun-
dancy detected, is exhibited by pairs of kinases and phosphatases that show
only partial functional overlaps but that are coupled by additional regula-
tory links. The authors conclude that such modules act as the molecular
mechanism for multi–process control and that they likely contribute to the
stable maintenance of paralogs during evolution.
A computational approach to determine kinase–substrate relationships is
presented in [72]. Here, the software NetworKIN combines sequence mod-
els of kinase consensus motifs with contextual information about putative
targets in order to predict in vivo kinases for identified phosphorylation
sites. Context information comprises and integrates a) experimental evi-
dence data like physical interactions and co–expression, b) genomic context
like gene fusion, gene neighborhood, and phylogenetic profiles information
as well as c) manually curated pathway databases, and d) automated liter-
ature mining. In a thoroughly investigation, the authors could show that
NetworKIN improves the accuracy of phosphorylation network prediction
by 2.5 fold compared to previous methods, making it a useful tool for the
construction of phosphorylation networks.
Recently, a database for literature–curated kinase–substrate pairs was in-
troduced [73]. KID, the Yeast Kinase Interaction Database, holds both HTP
as well as low–throughput (LTP) data, adopted from various sources. By
integrating these datasets quantitatively, a set of 517 high-confident kinase–
substrate pairs was defined and suggested to act as a gold standard in order
to assess published HTP datasets.
By now, the availability of phosphoproteome datasets in different organ-
isms provides the opportunity to study protein phosphorylation in the light
of evolution. Below I summarize some of the research studies addressing
this issue.
Boekhorst and co–workers conducted one of the first comparative ana-
lysis of protein phosphorylation based on public available phosphopro-
teomics data of distantly related species [74]. In their research they com-
pared the phosphoproteomes of six eukaryotes (Homo sapiens, Mus muscu-
lus, Drosophila melanogaster, Arabidopsis thaliana, and Danio rerio). They found
the overlap between the phosphoproteomes to be significantly enriched, in-
dicating an increased functional relevance. However, due to the incompre-
hensive nature of HTP datasets and differences in experimental procedures,
they clearly pointed out the need of additional datasets in order to improve
the power of comparative phosphoproteomics to understand protein phos-
phorylation evolution.
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In order to gain insights into the evolution of phosphorylation sites,
Landry et al. compared high quality phosphoproteomics datasets of yeast
and human [75]. Interestingly, their analysis revealed differences in the evo-
lution of phosphosites in ordered and in disordered regions, as well as of
phosphosites with known function and phosphosites that are uncharacter-
ized. Phosphosites in ordered regions exhibit a higher degree of conserva-
tion, and the same observation holds true for functional phosphosites, in-
dicating that the known rapid evolution of phosphoproteomes is possibly
due to a large set of non–functional phosphosites.
One of the first system–wide studies to quantify evolutionary changes
in phosphoproteomes across different species was conducted by Beltrao et
al. [76]. They applied in vivo MS to compare the phosphorylation status of
proteins in Saccharomyces cerevisiae, Candida albicans, and Schizosaccharomyces
pombe, and estimated the evolutionary rate at which changes in phospho-
rylation emerged. Their analysis revealed that interactions between kinases
and their substrates evolve at most two orders of magnitude slower than
those between TFs and deoxyribonucleic acid (DNA) promoter sequences.
Furthermore, the incorporation of genetic interaction data showed that ge-
netic interactions among kinases are less conserved than expected, suggest-
ing a substantial contribution of kinases to the evolution of phenotypic
diversity.
Tan et. al studied the conservation of human phosphorylation sites in
Saccharomyces cerevisiae, Drosophila melanogaster, and Caenorhabditis elegans
by means of a comparative sequence–alignment analysis [77]. They found
about 480 human phosphorylation events that exhibit an ancient conserva-
tion in their position. Additional 780 conserved phosphorylation sites could
be identified by an integrated network–alignment approach. Interestingly,
the proteins corresponding to conserved phosphosites were found to be
enriched in disease–associated genes, suggesting that this type of analy-
sis could be helpful to identify networks that are misregulated in diseases
like cancer or diabetes. Furthermore, the authors argue that conservation of
kinase–substrate interactions is to be considered equally important as sole
conservation of phosphoproteins when searching for disease–related genes.
Another approach to study the evolutionary properties of phosphoryla-
tion sites is presented in [78]. Here, annotated phosphorylation sites from
Saccharomyces cerevisiae were compared to their respective flanking regions
in closely related species of yeasts (Saccharomyces paradoxus, Saccharomyces
mikatae, and Saccharomyces bayanus). As a result, not only phosphorylation
sites but also the phosphorylation motifs recognized by the kinases are sig-
nificantly higher conserved than the surrounding sequences, indicating that
their evolution is constrained relative to the regions in which they occur.
In contrast to the work described above, the research presented in [79]
did not reveal a particular conservation in the position of most phospho-
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rylation sites analyzed. Substrates of yeast kinase Cdk1 were identified
by quantitative MS and compared to orthologous sequences of 32 fungal
species. The results indicated a conservation of phosphosites in disordered
regions but less constraints regarding the precise positions of the sites. More
precisely, the conservation appeared only to be conserved in very closely re-
lated species.
A very recent study addresses the evolution of phosphorylation networks
in the context of gene duplication [80]. The authors compared the phospho-
rylation sites of paralogous proteins in yeast to a species that diverged
from yeast prior the duplication of those genes. Their analysis revealed a
considerable divergence of paralogous phosphoproteins in terms of their se-
quence, function, localization and/or recognition by protein kinases, mean-
ing that only only 36 – 54% of regulation by phosphorylation seems to be
conserved, even if a conservation of the actual residue is known.
Part II
T H E P H O S P H O RY L AT I O N N E T W O R K O F
S A C C H A R O M Y C E S C E R E V I S I A E
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P R E FA C E
Phosphorylation networks describing the interdependences between kinases
and phosphatases and their substrates constitute highly dynamic systems.
The process of reversible protein phosphorylation affects most cellular activ-
ities including cell division, signal transduction, metabolism and cell motil-
ity. In recent years, large-scale MS studies provided growing amounts of
phosphoproteomic data, characterizing phosphoproteins and their sites of
phosphorylation in a variety of organisms. Nevertheless, for the majority of
phosphorylation sites their signaling context is unknown, and linking the
kinome and phosphatome (the complement of kinases and phosphatases,
respectively, in an organism) to the phosphoproteome remains a challeng-
ing task.
In our study, we analyzed kinase and phosphatase signaling in the yeast
Saccharomyces cerevisiae. Based on perturbed phosphoproteome data, we
identified phosphopeptides whose abundances reproducibly changed upon
the absence of a given kinase or phosphatase. Thereby we generated a net-
work describing the first system–wide in vivo protein phosphorylation net-
work of any eukaryotic organism.
For this study, I developed and carried out the computational pipeline to
compile and analyze the phosphoproteomic data in order to construct the
yeast protein phosphorylation network. The experiments that generated the
raw data were performed by Bernd Bodenmiller, ETH Zurich.
In detail, I implemented the clustering algorithm for the subsequent pro-
cessing of the LC–MS/MS alignments produced by SuperHirn [59] (for de-
tails, see Supplementary Materials). This post–alignment procedure com-
pensates errors introduced during peak detection and peak matching and
ensures high–quality LC–MS/MS alignments between the wild–type and per-
turbed phosphoproteomes.
Furthermore, I assisted in the statistical analysis of the data, both by us-
ing Corra [81] and by employing a self coded customized version of the
Bioconductor Limma package [82].
Particularly, I implemented the bioinformatics workflow for the func-
tional analysis of the data. In addition, I compiled and prepared various
phosphoproteomic, transcriptional, genomic interaction and PPI datasets in
order to compare and integrate them with our data.
Last but not least, I contributed to most of the figures. In particular fig-
ures 1–3, and figures S2–S7.
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P H O S P H O P R O T E O M I C A N A LY S I S R E V E A L S
I N T E R C O N N E C T E D S Y S T E M – W I D E R E S P O N S E S T O
P E RT U R B AT I O N S O F K I N A S E S A N D P H O S P H ATA S E S I N
Y E A S T
The original publication is included below and is followed by a selection of
the Supplementary Materials, featuring my contributions.
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Phosphoproteomic Analysis Reveals Interconnected
System-Wide Responses to Perturbations
of Kinases and Phosphatases in Yeast
Bernd Bodenmiller,1,2*† Stefanie Wanka,2,3* Claudine Kraft,4 Jörg Urban,5 David Campbell,6
Patrick G. Pedrioli,4‡ Bertran Gerrits,7§ Paola Picotti,1 Henry Lam,8 Olga Vitek,9
Mi-Youn Brusniak,6 Bernd Roschitzki,7 Chao Zhang,10 Kevan M. Shokat,10 Ralph Schlapbach,7
Alejandro Colman-Lerner,11 Garry P. Nolan,12 Alexey I. Nesvizhskii,13 Matthias Peter,4
Robbie Loewith,5 Christian von Mering,3 Ruedi Aebersold1,6,14||
(Published 21 December 2010; Volume 3 Issue 153 rs4)
The phosphorylation and dephosphorylation of proteins by kinases and phosphatases constitute an
essential regulatory network in eukaryotic cells. This network supports the flow of information from
sensors through signaling systems to effector molecules, and ultimately drives the phenotype and
function of cells, tissues, and organisms. Dysregulation of this process has severe consequences
and is one of the main factors in the emergence and progression of diseases, including cancer. Thus,
major efforts have been invested in developing specific inhibitors that modulate the activity of individ-
ual kinases or phosphatases; however, it has been difficult to assess how such pharmacological inter-
ventions would affect the cellular signaling network as a whole. Here, we used label-free, quantitative
phosphoproteomics in a systematically perturbed model organism (Saccharomyces cerevisiae) to de-
termine the relationships between 97 kinases, 27 phosphatases, and more than 1000 phosphoproteins.
We identified 8814 regulated phosphorylation events, describing the first system-wide protein phos-
phorylation network in vivo. Our results show that, at steady state, inactivation of most kinases and
phosphatases affected large parts of the phosphorylation-modulated signal transduction machinery,
and not only the immediate downstream targets. The observed cellular growth phenotype was often
well maintained despite the perturbations, arguing for considerable robustness in the system. Our
results serve to constrain future models of cellular signaling and reinforce the idea that simple linear
representations of signaling pathways might be insufficient for drug development and for describing
organismal homeostasis.
INTRODUCTION
Protein kinases, and, to a lesser extent, protein phosphatases, are attractive
drug targets (1–5); however, although their respective catalytic activities
are well characterized, their functions in vivo remain relatively poorly un-
derstood. Despite extensive in vitro (6), in silico (7), or indirect in vivo
assays (8), our knowledge of the global relationships between kinases,
phosphatases, and their substrates remains fragmented (2). Even less is
known about the more downstream, indirect consequences of kinase ac-
tivity, making rational selection of suitable candidates for therapeutic in-
terventions difficult; consequently, many promising kinase inhibitors are
ultimately retired from development (9).
One promising approach for closing this knowledge gap is the
organism-wide, quantitative assessment of all phosphorylated proteins,
comparing phosphorylation status in wild-type cells to that in cells that
have undergone systematic perturbations of their kinases or phospha-
tases. Progress in phosphoproteomics technology has brought this goal
within reach by enabling the reproducible quantification of thousands of
phosphorylation sites in a single study (10–12). Although the throughput
is not yet sufficient to systematically address all 518 protein kinases and
147 protein phosphatases in human cells (13, 14), simpler organisms, such
as yeast, can be addressed. Yeast in particular is frequently used as a model
to study human diseases (15), including cancer, mitochondrial diseases,
and even neurological disorders caused by protein misfolding (16, 17).
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Although some signaling systems, such as the apoptotic machinery, are
absent in yeast, other parts of its signaling network display substantial
similarities to those in human cells (18, 19). Of the 161 kinases and phos-
phatases in yeast, 136 are conserved in humans at more than 30% amino
acid sequence identity (table S1), and some human signaling proteins can
even replace their yeast counterparts (20). Here, we used a combination of
phosphoproteomics measurements and computational methods (11) to de-
tect and quantify the system-wide responses in the yeast phosphoproteome
upon deletion or inhibition of most of its kinases and phosphatases.
RESULTS
Experimental strategy
We developed an integrated experimental and computational strategy for
high-throughput comparative phosphoproteomic analysis in Saccharomyces
cerevisiae (Fig. 1), which consisted of the following steps. First, we sys-
tematically perturbed the kinase-substrate and phosphatase-substrate net-
works by selecting gene deletion mutants of the nonessential kinases or
phosphatases or, for some essential kinases, by generating mutants inhib-
itable by cell-permeable drugs, which are referred to as “analog-sensitive”
kinase strains (21). To minimize compensatory mutations that might accu-
mulate over time in the gene deletion strains, we freshly prepared all mu-
tant strains. To enable a statistical characterization of our observations, we
always grew, processed, and measured each perturbed strain in three inde-
pendent replicates, together with three replicates of wild-type, control
cells. Phosphopeptides were isolated from each sample (22, 23) and sub-
mitted to high-performance mass spectrometry to generate liquid chroma-
tography coupled to mass spectrometry LC-MS/MS phosphoproteome
maps. The triplicate phosphoproteome maps generated from each perturbed
or wild-type cell sample were annotated with the amino acid sequences of
the detected phosphopeptide features and were aligned with the algorithm
SuperHirn (24), which was followed by additional postprocessing (see Sup-
plementary Materials for details). The statistical significance of observed
changes in the perturbed states was then computed for each phosphopeptide
with the Corra software suite (25).
We assessed the reliability of our measurements and computational
data processing at two levels. First, we assessed the confidence of the phos-
phopeptide identifications generated by database searching, and second,
we assessed the reproducibility of detecting quantitative phosphopeptide
differences between wild-type and mutant strains. For the first check,
and to determine the reliability of our phosphopeptide identifications from
the peptide fragment ion spectra, we performed statistical analyses with
the PeptideProphet tool (26) and a decoy database strategy (27). From
these analyses, we found that a PeptideProphet probability cutoff of 0.9
corresponded to a false discovery rate (FDR) of ~0.038 (3.8%) (table S2),
which confirms that our chosen cutoff of 0.9 yielded an acceptably low
degree of incorrect peptide identifications, in particular because most
phosphopeptides were identified repeatedly in the context of this exten-
sive study.
We then used the statistical tool Corra (25), which supports an empir-
ical Bayesian alternative to the t test (28). The test improves the reliability
of conclusions in cases of large-scale testing. For each phosphopeptide
feature, the test provided a P value of the observed differences between
wild-type and mutant replicates. The P values were further corrected for
multiple testing according to the Benjamini and Hochberg procedure (29)
(see the Supplementary Materials). After this quantitative analysis step, we
chose an FDR threshold of 0.015 in conjunction with a minimum fold-
change requirement of log2 >1.5, both of which had to be met before we
would consider any phosphopeptide as reproducibly regulated. At this
threshold, nine comparisons between wild-type and lowest-impact kinase
mutants resulted in only a single or no phosphopeptide being designated
as regulated, which verified the validity of our selected criteria. On the
basis of these results, we concluded that our applied cutoffs ensured that,
despite a high sensitivity (fig. S1), only a minimal amount of noise entered
our analyses and that we achieved high reproducibility in the observed
regulatory events.
Overall, we attempted the analysis of 161 mutant strains of yeast. Of
these, 37 strains could not be analyzed because they were not viable, not
inhibitable, or otherwise not amenable to our procedure (table S1). In total,
we generated quantitative data for 116 gene deletion mutants and for an
additional 8 strains in which analog-sensitive kinases were pharmaco-
logically inhibited (table S1). Together, this corresponds to coverage of
78% of the theoretical kinase and phosphatase space in yeast and covered
Wild-type
yeast cells
Kinase or phosphatase
deletion mutants
Proteome isolation 
Protein digestion and phosphopeptide-enrichment
LC-MS/MS analysis and map creation
Fold-change (median, log2): P value:
Bioinformatics analysis
Wild-type abundance
IASPIQHEHDSGSR
P
Example:
1523.3 1240.6 1240.6
m/z
TR
-3.76 8 x 10-05
(phosphopeptide)
47.0 112.8 33.1Mutant ab. (∆Cla4)
Fig. 1. Integrated experimental and computational pipeline to determine in
vivo kinase-substrate and phosphatase-substrate relationships. Yeast ki-
nase and phosphatase genes were systematically deleted one by one
and the phosphoproteomes were systematically compared between mu-
tant and wild-type strains. To achieve this, for each mutant strain and
wild-type, we grew and processed three independent biological replicates
by proteome isolation, protein digestion with trypsin, phosphopeptide en-
richment by applying a TiO2 resin, and quantification and identification of
the phosphopeptides with LC-MS/MS. Observed phosphopeptide ion
features were aligned, quantified, and tested for statistical significance.
For the example phosphopeptide shown, IAS*PIQHEHDSGSR, the result-
ing matrix gives the intensity values measured in the wild-type and mutant
samples, as well as the corresponding log2 fold change (here −3.76) with
its associated significance. Abbreviations for the amino acids are as fol-
lows: A, Ala; D, Asp; E, Glu; G, Gly; H, His; I, Ile; P, Pro; Q, Gln; R, Arg;
and S, Ser.
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77% of those enzymes that show sequence conservation with human en-
zymes (table S1). A matrix and a network generated from these data related
the observed changes in the abundance of a phosphopeptide (measured in
triplicate) to the corresponding kinase or phosphatase deletion (Fig. 2 and
fig. S2). The matrix contains 8814 reproducible changes in peptide abun-
dance that mapped to 1026 phosphoproteins that were clustered according
to the coregulation of the phosphopeptides (tables S3 and S4). Of note, an
additional 7550 phosphopeptides were consistently identified but did not ex-
hibit a substantial change in abundance under any of the perturbations tested.
Finally, the cellular abundance distribu-
tion of detected phosphoproteins (regulated
and unregulated) was roughly similar to that
of the total yeast proteome; however, the
complete phosphoproteome was still not
covered (fig. S3), because under our chosen
growth conditions, many phosphorylation
sites would not be phosphorylated, and be-
cause our experimental pipeline had several
biases, among them that only tryptic pep-
tides with a mass/charge ratio (m/z) suitable
for LC-MS/MS analysis (30) could be iden-
tified. Nevertheless, the observed phospho-
rylation sites covered a reasonably large
fraction of the phosphoproteome, and there-
fore an existing bias should not impair our
conclusions (31).
Direct versus indirect
phosphorylation events
Because kinases and phosphatases are com-
ponents of complex, interconnected signal-
ing networks, we fully expected to observe
a number of indirect, downstream responses,
that is, phosphopeptides whose abundance
would change despite their not being a di-
rect molecular target of the kinase or phos-
phatase in question. Indeed, we found that
such events seemed to strongly outnumber
direct kinase-substrate interactions, as argued
by the following observations. First, we de-
termined for each kinase or phosphatase the
number of phosphopeptides whose responses
showed the expected directionality (that is,
reductions in abundance in the case of ki-
nase deletions and increases in abundance in
the case of phosphatase deletions). In gener-
al, the number of phosphopeptides that re-
sponded in the expected directionality was
roughly similar to that of phosphopeptides
that responded with “inverted” directionality
(Fig. 2 and fig. S4). Exceptions to this find-
ing were analog-sensitive kinases that were
inhibited over the short term; for example,
in the case of Cdc28, about 76% of the phos-
phopeptides were regulated in the expected
directionality. No difference in the direction
of regulation was observed between non-
essential kinases or phosphatases (fig. S4).
Second, we conservatively assumed that phos-
phopeptides that changed in abundance in
only a single deletion strain might be direct molecular targets of the kinase
or phosphatase in question. By this measure, we found that, at most, 32%
of the observed regulatory events might have been direct for kinases (that
is, that the events mapped to just a single kinase), whereas in the case of
phosphatases this number was 53%. The data sets generated by the short-
term inhibition of the analog-sensitive kinases showed a higher fraction of
potential direct targets (44%) than did the permanent deletion strains.
Third, we tested the overlap of our data with various previously
established reference protein-protein interactions in yeast (32–35), such
∆Ctk1
(PK)
∆Snf1
(PK)
∆Ssn3
(PK)
∆Psr1
(PP)
∆Sit4
(PP)
[...]
(124 perturbations total)
∆Tpk3
(PK)
[...]
 (8814 observed changes 
in phosphopeptide
 abundance)
n.d.
+ 1.56
n.d.
- 6.97
- 5.69
+ 2.94
- 6.03n.d.
- 1.00
- 1.62+ 1.84
- 1.71
...
Peptide abundance
change (log2-ratio)
K.IETES*TTIPNDSDR
K.SVQKQDEDPLS*PR
R.AST*AVESLDNHPPK
K.HNMSTQADNS*DDEELQK
...EPTTVSYEIAGNS*PNAER
R.YLMQPLQEMS*PK
+ 2.07
- 1.81- 0.56+ 0.07
+ 0.32
- 3.85- 3.62- 3.21- 1.92
Directionality as expected; full response (= on/off)
Directionality inverted; full response (= on/off)
Directionality as expected; partial response (= fold-change)
Directionality inverted; partial response (= fold-change)
(All events)
 474
 3’834
77’851
 335 423
79’352
 4’171
542
False discovery rate 0.015; fold-change >= 1.5 (abs[log2])Significant events:
Number of events:
(Kinase deletion: decrease of peptide;
 phosphatase deletion: increase of peptide)
(Evidence for indirect effect, that is not
 compatible with direct molecular target)
Directionality of response as expected Directionality inverted
Fig. 2. Matrix of kinases and phosphatases analyzed in this study and their effects on the phospho-
proteome. Overall, 124 kinases and phosphatases were interrogated through our experimental and
computational pipeline. Each row (y axis) corresponds to a regulated phosphopeptide and each col-
umn (x axis) summarizes the responders of a given kinase or phosphatase. Phosphopeptides with a
directionality as expected (that is, kinase deletion resulted in a decrease in peptide abundance,
whereas phosphatase deletion resulted in an increase in peptide abundance) are shown in graded
blue, and phosphopeptides with an inverted directionality (evidence for indirect effect, not compatible
with direct molecular target) are displayed in graded gold, according to the observed fold change for
each peptide. Phosphopeptides observed but not regulated or not detected are displayed in gray. At
the bottom, the total numbers of events observed in this study are listed. “Full response” corresponds
to phosphopeptides that appeared or vanished when wild-type and mutant strains were compared,
and “partial response” corresponds to phosphopeptides that showed a statistically significant change
in abundance, but were detected in both wild-type and mutant samples. Abbreviations for the amino
acids are as follows: A, Ala; D, Asp; E, Glu; F, Phe; G, Gly; H, His; I, Ile; K, Lys; L, Leu; N, Asn; P, Pro; Q,
Gln; R, Arg; S, Ser; T, Thr; and V, Val.
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as the STRING database (tables S5 and S6). We observed that the
overlap of our data with these direct interactions was small (table S5).
This is consistent with the long-held notion that kinase-substrate inter-
actions are too weak and transient to be detectable by typical affinity
purification–based protein interaction screens. Reassuringly, however,
first, the overlap of the heavily studied kinase Cdc28 with our data set
on the level of regulated phosphoproteins was high, showing a 43% over-
lap with the study of Ubersax et al. (36) and a 76% overlap with the study
of Holt et al. (10) (on the phosphorylation site level, the overlap was
46%). Second, all other phosphorylation events that did overlap showed
substantial enrichments for the expected directionality. Likewise, we ob-
served substantial enrichment of confirmed interactions, in particular for
those phosphopeptides that responded only in a single perturbation (table
S7). This indicates that our data included a sizeable fraction of direct
enzyme-target interactions; however, from all three tests, we can conclude
that indeed a large majority of our observed events were indirect conse-
quences of the deletion. Not a single kinase showed exclusively direct
effects, indicating that a focusedmodulation of a pathway (branch) without
system-wide adaptations might not be possible with a single drug.
Changed extents of phosphorylation versus changed
protein abundance
As is the case in prolonged pharmacological intervention, our genetic
kinase-deletion approach gave the cells ample time to accommodate
(and potentially compensate for) the loss of kinase activity. This should
not only have led to downstream, indirect consequences on the phos-
phoproteome, but could have also entailed subsequent changes in gene
expression and the amounts of proteins produced. To assess the extent
of this effect, we measured not only abundance changes in the phos-
phoproteome but also abundance changes of the proteins themselves,
by observing unphosphorylated peptides in a subset of 16 kinase dele-
tion strains. The kinases selected for this test ranged from those that had
a small effect on the phosphoproteome to those that had a large effect.
The data indicated that for a total of 467 regulated phosphopeptides that
matched to 118 proteins covered in this analysis, 79% of the proteins re-
mained unchanged in abundance, and, in a single case, the directionality
of the phosphopeptide regulation was opposite to the protein abundance
change (figs. S5 and S6). In 21% of the cases in which a phosphopeptide
was regulated, we also observed a change in protein abundance in the
same direction.
We also performed additional orthogonal, but more indirect, analyses
based on the coregulation or antiregulation of phosphorylation sites on
the same protein, which we found in more than half of the phosphopro-
teins. We reasoned that a synchronous change with a similar amplitude
and directionality of such phosphopeptides would indicate an abundance
change of the corresponding protein. In contrast, a discordant abundance
change of the phosphopeptides from such proteins would indicate a
change in phosphorylation site occupancy. These data (fig. S7) can be
summarized as follows: For about 25% of the observed events, only a
single regulated phosphopeptide was detected on the entire length of the
phosphoprotein, impeding this type of analysis. The remainder of events
fell into three classes: In 49% of the remaining cases, at least two phos-
phopeptides originating from the same protein were observed to be regu-
lated, and these exhibited identical directionality. In contrast, in 5% of
events, the changes were of opposing directionality; the latter pattern was
not consistent with a simple protein abundance change. Of note, in a large
part of the data, that is, in 46% of cases, a phosphopeptide that had
substantially changed in abundance was detected with at least one other
phosphopeptide on the same protein, but the other phosphopeptides were
not observed to be regulated. The latter two categories indicate that for
most events detected in this study, changes in the abundance of a phos-
phopeptide could not be explained by changes in protein abundance alone.
Effect of a given kinase or phosphatase
on the phosphoproteome
The number of phosphopeptides that were affected by the deletion of a
given kinase or phosphatase varied considerably (Fig. 2). Therefore, we
(i) quantified the impact of each kinase or phosphatase on the phospho-
proteome under the growth conditions tested, (ii) assessed whether the
kinases and phosphatases were associated with different biological pro-
cesses according to their effect on the phosphoproteome, and (iii) de-
termined which biological processes were affected by each kinase and
phosphatase.
We first computed the fraction of phosphopeptides that were affected
by a given kinase or phosphatase relative to the total number of phospho-
peptides that were affected by the kinases and phosphatases (Fig. 3A and
table S8). We observed that the deletion of 22% of the kinases and phos-
phatases that we tested resulted in fewer than 10 perturbed phosphopep-
tides each; therefore, we considered these deletions to have had minimal
effects on the fraction of the phosphoproteome detected in this study.
These included kinases important in cellular stress response mechanisms,
such as Mrk1 (37) and Gcn2 (38). In contrast, for 78% of the kinase and
phosphatase deletion strains, distinct changes in the phosphoproteome
could be detected. The kinases with the largest effects on the phosphopro-
teome were Ctk1 (39), a kinase with key roles in the regulation of tran-
scription and translation, and Psk2, which is involved in sugar flux and
translational regulation (40). These data show that the loss of most kinases
or phosphatases indeed perturbed large parts of the signaling network.
We next determined the distribution of biological processes repre-
sented by the phosphoproteins affected by the lower-impact (bottom half)
and higher-impact (top half) kinases and phosphatases, respectively. We
found that the enzymes with the smallest effect showed a strong enrich-
ment in processes associated with mitogen-activated protein kinase (MAPK)
cascade signaling [“MAPKKK (MAPK kinase kinase) cascade,” P = 3.9−10;
“response to pheromone,” P = 4.2−6], whereas the enzymes with the largest
effects showed a strong enrichment in processes related to the mitotic cell
cycle (“interphase of mitotic cell cycle,” P = 3.1−9; “mitotic cell cycle,” P =
1.4−6) (tables S9 and S10). These data showed that under the tested con-
ditions, even stress- or mating-related kinases showed a measurable impact
on the phosphoproteome, albeit lower than that of growth- and cell cycle–
related kinases or phosphatases. Lastly, we also computed those biological
processes that were enriched among the responders of each individual ki-
nase or phosphatase. We found that 575 biological processes were enriched
(Fig. 3B and table S11), an average of five processes for each active kinase
or phosphatase. The most frequently enriched functions were “endocytosis”
(39 times) and “cell morphogenesis” (38 times). Together, these data il-
lustrate that the effects of most kinases and phosphatases on the signal trans-
duction network, and thereby on controlled biological processes, were
broad, perhaps broader than expected (2).
Correlation with yeast phenotypes
We next tested the phenotypic consequences of deletion of kinases and
phosphatases, which are relevant in particular with regard to effects (side
effects) of potential drugs that inhibit kinases or phosphatases. For each
deletion strain, we assessed changes in growth speed (41) and morpholog-
ical features (table S8) (42). Despite 97 of the deletion strains showing
reproducible responses in the phosphorylation network, only 9 mutants
showed a strong effect on growth speed, and the total was 23 if strong
changes in morphological features were also included (Fig. 3A). Con-
versely, 11 of the 27 kinases and phosphatases that had an undetectable,
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1: Positive regulation of MAP kinase activity
2: Nuclear translocation of MAPK during osmolarity sensing
3: Activation of MAPK activity during osmolarity sensing
4: Protein import into nucleus, translocation
5: Response to abiotic stimulus 
6: Hyperosmotic response 
Enrichment
significance
(P value [log])
Perturbations:
∆  kinase / ∆  phosphatase
Outcomes:
Biological processes enriched among responders
Outcome: annotations of responding peptides
are enriched in osmosensing-related terms
Example: kinases known or predicted
to function in osmoregulation
0-20 -10
1 2 3 4 5 6
YJL128C (PBS2)
YMR291W
YPL026C (SKS1)
Kinase
Essential kinase
Phosphatase
Perturbations, ranked by impact
High-impact kinases or phosphatases
Low-impact kinases/phosphatases
... ...
... ...
A
B
Interphase of mitotic cell cycle
G1/S transition of mitotic cell cycle
Mitotic cell cycle
Bud32
Sit4
Pph21
MAPKKK cascade
Osmosensory signaling pathway
MAPKKK cascade during osmolarity sensing
Prr1
Mek1
Rck2
High impact
Low impact
No impact
Highest
impact
Fig. 3. (A) Phosphoproteome-wide impact of each kinase and phos-
phatase. For all kinases and phosphatases, we computed the fraction
of phosphopeptides affected relative to the total number of phospho-
peptides affected by all kinases and phosphatases. The kinases and
phosphatases were then ranked accordingly. Blue circles represent
kinases, light blue circles represent essential kinases, and golden cir-
cles represent phosphatases. A large golden triangle indicates a strong
growth or morphological phenotype of a given mutant, whereas a small
blue triangle represents a weak growth or morphological phenotype of a
given mutant. Right side: examples of kinases that showed either a low
or a high effect on the phosphoproteome regions, together with their
known cellular functions. (B) For each kinase and phosphatase, the
biological processes enriched among their regulated phosphoproteins
were computed. Each column corresponds to a biological process,
whereas each row corresponds to a given kinase or phosphatase (ki-
nases are depicted in blue, essential kinases in light blue, and phospha-
tases in gold). The color scale denotes the statistical significance of the
observed enrichment. Magnified inset: an example for three clustered
kinases, for which a related set of processes is observed enriched among
their substrates.
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or only minimal, effect on the section of the phosphoproteome measured
in this study showed a phenotype, among them, the kinase Elm1 (43),
which showed a strong morphological phenotype. However, many strong
morphological phenotypes were indeed observed in mutants that showed a
strong change in the phosphoproteome, but the results were nevertheless
surprising because they indicated that strong phenotypes were not neces-
sarily reflected in the status of the phosphoproteome, as exemplified by
Elm1 and other enzymes. Perhaps, in some cases, compensatory effects (vis-
ible at the level of the phosphoproteome) were precisely what prevented
the occurrence of strong phenotypic consequences, as exemplified by the
lack of correlation between the growth phenotypes and the changes in the
phosphoproteome. This observation is particularly relevant because, first,
cancer cells might display in some regards increased compensatory power,
and second, kinase inhibitors that are specific for a target in vivo might not
necessarily result in a cellular phenotype.
DISCUSSION
Our study delineates the responses of the system-wide cellular phosphoryl-
ation network upon systematic inactivation of individual kinases or phos-
phatases. Because the phosphorylation network is one of the main cellular
backbones for the processing of information and the implementation of cel-
lular responses, it is highly dynamic. Our measured behavior is only a single
snapshot of a large number of possible outcomes, which were constrained
by the growth and experimental conditions that we chose.
The first surprising observation that we made was that 7550 phospho-
peptides were consistently identified but did not show a substantial amount
of regulation. This may be due to, first, our cutoffs being conservative; thus,
many putative regulatory events may not have been reproducible or strong
enough to be deemed substantial. Second, 22% of the kinase and phospha-
tase mutants could not be analyzed, mainly because the corresponding
genes are essential for cellular viability. Perhaps their essentiality is at least
partly due to a generally higher impact on the phosphoproteome, as indi-
cated recently (10), or because their substrates need to be phosphorylated
constitutively. Third, in yeast, a large number of paralogous kinase isoforms
exist (for example, Tpk1, Tpk2, and Tpk3). Given this, it is reasonable to
expect some overlap or redundancy in substrates, which could lead to a
considerable number of phosphorylation sites that would appear unregulated
as long as only one of the paralogous duplicates was deleted. Fourth, the
yeast populations that we analyzed consisted in a strict sense of many mixed
subpopulations (for example, cells in different cell cycle states), and it can
be assumed that an identical phosphorylation site can become phosphoryl-
ated by different kinases during the cell cycle. Therefore, analyzing dele-
tions of single kinases or phosphatases would only manifest in slight, if any,
regulation for such sites; for example, a cell cycle phase–specific regulation
is masked by all cells that are not in that particular phase at any given time
point. Fifth, we also analyzed whether the regulated and nonregulated phos-
phopeptides fell into different protein abundance classes (for example, the
nonregulated are of low abundance and therefore regulation is more difficult
to observe), but this was not the case. Overall, it is likely that all five pos-
sible explanations contribute to the observed result.
Another finding of this study was the unexpectedly strong dominance
of indirect effects (as opposed to direct molecular target effects), which
were often without a resulting strong cellular phenotype. To some extent,
this observation fits with a view of signaling networks having to be highly
flexible and redundant to respond to an ever-changing environment while
maintaining stable cellular states (44). This constrains the architecture of
the system, as described by the “law of requisite variety” (45, 46), a fun-
damental law in systems control theory. It states that stable systems have
to encode a number of control states that is higher than or equal to the
number of states to be controlled. Considering that for each cell the space
of “environmental states” is enormous, consequently, also the cellular “con-
trol variable space” must have an equal or greater size. The combinatorial
possibilities of the phosphoproteome seem to ideally fulfill this demand (44).
An alternative explanation for this observation might also be found in
the theory of Neutral Evolution (47). It is possible that only a small num-
ber of the observed phosphorylation events are actually relevant for the
function and survival of the cell, whereas most phosphorylation events
would simply have no effect, or at least have no negative effect, on the cell.
As a result, such phosphorylation sites would not be counterselected during
evolution. The data generated in this study do not, by themselves, support or
refute this hypothesis. Finally, the low correlation between phenotype and
the degree of change in the phosphoproteome may have been affected by
the growth conditions chosen here, the lack of sensitivity of the phenotypic
assays, or the possibility that the phosphoproteomics data were not sampled
deeply enough to find such correlations.
In addition to revealing insights into the architecture of cellular signal-
ing, our data set also describes the proteome-wide functional states of yeast
cells; this might be useful for determining diagnostic markers for stress
conditions, functional states of key pathways, or the activity of a given ki-
nase or phosphatase. These markers could be used in conjunction with tar-
geted proteomics approaches to not only study basic biological processes
but also determine how a given pharmacological intervention would affect
the cellular signaling network.
With targeted proteomics methods, not only can the cellular informa-
tion flux under many conditions be observed, at high throughput, but this
approach also enables us to understand for all phosphorylation sites wheth-
er the observed change is a “true” regulation event or simply as a result of a
change in protein abundance (48–50) because both the phosphopeptide and
several proteotypic peptides corresponding to the protein could be rela-
tively or absolutely quantified, thus determining the phosphorylation site
occupancy and regulation. Overall, our data provide global starting points,
and constraints, toward understanding the complexity of phosphorylation
regulation in yeast and other organisms. In the future, the results should
be complemented by similar data for specific cellular conditions, time courses,
or small-molecule interventions, thereby sharpening—step by step—our
view of the events in the phosphorylation network. The ensuing insights
in general design rules and motifs in cellular information processing will
be essential for our ability to develop kinase-based drugs in an informed way.
MATERIALS AND METHODS
The generated LC-MS/MS phosphoproteome maps (table S2), an over-
view of the generated data (table S12), and the statistical methods used
for their analysis are explained in detail in the Supplementary Materials.
We have made available all kinase/phosphatase-responder relations in a
user-friendly way in the recently described PhosphoPep database (30, 51)
(http://www.phosphopep.org). All yeast strains used here can be supplied
upon request in a 96-well plate format (table S13).
SUPPLEMENTARY MATERIALS
www.sciencesignaling.org/cgi/content/full/3/153/rs4/DC1
Materials and Methods
Fig. S1. Power of the analysis approach.
Fig. S2. Topological properties of the protein phosphorylation network.
Fig. S3. Abundance distribution of responder phosphoproteins (proteins that contain
“regulated” phosphopeptides).
Fig. S4. Ratio of phosphopeptides that are reduced or increased in abundance.
Fig. S5. Regulation of phosphopeptides versus regulation of protein abundance.
Fig. S6. Regulation of phosphopeptides versus regulation of protein abundance.
Fig. S7. Regulation of phosphopeptides that map to the same protein.
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Table S1. List of enzymes.
Table S2. False discovery rate of peptide identification and specificity of phosphopeptide
enrichment for each analyzed phosphorylation pattern.
Table S3. Information on phosphopeptides and phosphoproteins.
Table S4. Significant coregulation of kinases and phosphatases.
Table S5. Overlap of data from this study with other data sets.
Table S6. Confirmed STRING interactions.
Table S7. Overlap of possible direct targets with other data sets.
Table S8. Effects of each kinase and phosphatase on the phosphoproteome.
Table S9. Enrichment of biological processes among the low-impact kinases (bottom half).
Table S10. Enrichment of biological processes among the high-impact kinases (top half).
Table S11. GO terms.
Table S12. Overview of the entire data set.
Table S13. Information on yeast strains.
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Global impact of kinases and phosphatases on the phosphoproteome 
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Computation of the biological processes enriched in the inactive and active kinases and 
phosphatases 
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Computation of the biological processes enriched among all responding proteins for a 
given kinase or phosphatase 
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Determination of morphological phenotypes 
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Fig. S2. Topological properties of the protein phosphorylation network. The network shown, 
which contains 1,088 nodes and 6,509 unique edges, is a summary view of the connectivity 
observed in our dataset. Kinases are shown in red, phosphatases in green, and responder 
proteins in light blue. Lines indicate substantial regulatory events. Inset: degree distribution of 
network connectivity. The x-axis shows the degree of connectivity of the network and the y-
axis shows the cumulative frequency of the appearance of a given degree. The degree of a 
node is the number of edges connected to that node. The cumulative degree distribution was 
indicative of a scale-free topology. The average path length of the network is 3.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. S3. Abundance distribution of responder phosphoproteins (proteins that contain 
“regulated” phosphopeptides). A comparison of the yeast proteome abundance distribution 
(blue) and the abundance of the regulated phosphoproteins as observed in this study (red, 
significance threshold FDR  0.015 and requiring at least a log2 1.5-fold regulation or a full 
on or off response). The protein abundances were taken from Ghaemmaghami et al. (26). 
Proteins with more than 20,000 copies per cell are not displayed (the distribution of proteins 
with more than 20,000 copies per cell is similar between the analyzed phosphoprotein sets and 
the yeast proteome). The x-axis displays the protein copy number per cell, the y-axis the 
percentage of protein counts per copies per cell bin (with a bin size of 100) normalized by all 
of the proteins from the regulated phosphoprotein set or the data set of Ghaemmaghami et al. 
(26). The observations made for the responder phosphoproteins also held true if only the non-
regulated phosphopeptides were analyzed, if the protein abundances were estimated by 
spectral counting as determined by Weiss et al. (27), or both. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. S4. Ratio of phosphopeptides that are reduced or increased in abundance. The y-axis 
shows the ratio [log2(number of increased phosphopeptides / number of decreased 
phosphopeptides)] and on the x-axis, the kinases and phosphatases are ordered according to 
the extent of their effect on the phosphoproteome (0 = lowest effect; 124 = highest effect, as 
calculated from the dataset in this study). The blue squares show the ratios for the kinases, the 
red squares show the ratios for the phosphatases, and the green squares show the ratios for the 
essential kinases. The higher ratios observed for the kinases and phosphatases with low 
activities were probably noise, because of the fewer regulated phosphopeptides observed. For 
this plot, relative regulation (“fold-changers”) and complete disappearance (“on/off-
responders”, “vanishers”) were not distinguished. 
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Fig. S5. Regulation of phosphopeptides versus regulation of protein abundance. Each dot 
corresponds to a measured phosphopeptide. The x-axis shows the fold-change (on a log2 
scale) of the phosphopeptide and the y-axis shows the median change observed for all of the 
non-phosphorylated peptides that map to those particular proteins (both shown on a log2 
scale). The color code illustrates whether the observed fold-change was significant in one or 
both of the measurements. Ɣ denotes significant regulation detected in both phosphorylated 
and nonphosphorylated peptides; Ɣ denotes significant regulation only for the phosphorylated 
peptide detected; Ɣ denotes significant regulation only for the nonphosphorylated peptide 
detected; and Ɣ denotes no significant regulation of any peptide detected. 
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A D D I T I O N A L R E S U LT S A N D D I S C U S S I O N
As discussed in [83], our analysis revealed, among other things, two in-
triguing observations: a) a surprisingly large number of detected phospho-
peptides that never exhibited a significant change in abundance upon the
knockout of any given kinase or phosphatase, and b) a high prevalence
of indirect effects, as evidenced by the large number of peptides peptides
whose abundance changes had a directionality opposite to the expectation.
In our work we discussed possible reasons for these findings: i) conserva-
tive cutoffs might have prevented the detection of a subset of events, ii)
a number of essential kinase and phosphatase mutants could not be ana-
lyzed, iii) paralogous kinases and phosphatases possibly have redundant
functions and consequently may have masked each other, and last but not
least iv) the experimental set-up itself may have been too restricted.
However, it is worth mentioning that the characteristics discovered in
the yeast phosphorylation network meet the requirements for a comprehen-
sive regulatory cellular signaling network: interconnectedness and dynamic
flexibility are high, while all the same a stable cellular state is maintained
against most of our perturbations [83, 84, 85, 86].
These observed network traits are associated with the concept of bio-
logical robustness, one of the fundamental properties of all biological sys-
tems [87, 88]. The network’s interconnectivity and non–linearity in terms of
its large number of connections between kinases, phosphatases and phos-
phoproteins (which are often kinases themselves) form the basis for this
robustness: first, most kinases and/or phosphatases have an extensive im-
pact on the phosphoproteome, affecting a wide range of biological pro-
cesses [83] and second, the network comprises a large number of indirect
effects. Furthermore, as mentioned above, phosphopeptides failing to ap-
pear as regulated could indicate a functional redundancy in the network
where similar kinases and phosphatases can replace each other. Due to
the network size and its interconnectivity, one could also imagine that
the (de)phosphorylation of a peptide is backed up by alternative network
pathways not functionally related to the particular perturbed kinase or
phosphatase. Either mechanism contributes to the network’s robustness by
buffering perturbations [87, 88]. This also substantiates the observation that
in most cases, no strong cellular phenotypes were detectable in our single
knockout mutants [83].
As described above, a certain degree of indirectness in the phosphoryla-
tion network was to be expected. Nevertheless, the lack of sufficient direct
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kinase or phosphatase targets naturally complicated the analysis of our
data.
For instance, we grouped potential direct molecular phosphopeptide tar-
gets according to their responsible kinase and scanned each set of phos-
phopeptides for overrepresented patterns using the motif–x software [89].
Then, we compared these patterns to known consensus recognition sites
of the respective kinase [90]. However, none of the kinase phosphorylation
site motifs could be recovered. In a second step, we restricted the set of pos-
sible direct kinase targets to phosphopeptides that showed a ‘full response’
(vanisher peptides). This resulted in too little phosphopeptides per kinase,
preventing statistically significant conclusions. For this reason, we finally
clustered the peptides according to whole kinase families (see Figure 8(a))
instead to single kinases. Figure 6 shows the results for consensus recogni-
tion sites of three kinase families.
Except for the sequence logo derived from possible direct phosphopep-
tide targets of the CAMKL kinase family, none of the logos revealed any
evidence for a specific kinase recognition signal. In addition, there were no
apparent differences in the expressiveness of sequence logos derived from
direct and indirect target sets. Furthermore, the direct target sequence logo
of the CAMKL family could not be identified in the set of known consensus
phosphorylation site motifs of kinases in this family. These negative results
are most likely due to the limited number of direct targets in our dataset,
and the analysis strongly supports our finding of a high number of indirect
effects in our dataset.
The clustering of kinases while using different measures of similarities
was another important aspect in our study. For instance, we analyzed all
kinases with regard to their effect on the phosphoproteome and searched
for common properties between kinases showing similar phosphorylation
‘footprints’. In doing so, the similarity between pairs of kinases was deter-
mined using different measurements.
One approach was to simply count the number of phosphopeptides which
are affected by both kinases. Figure 7 relates this ‘shared–substrate’ similar-
ity between kinase pairs to the type of genetic interaction they exhibit. As
can be seen, there is a weak but significant correlation: the more phospho-
peptides two kinases share, the more likely they also interact genetically,
suggesting that kinases that act on the same peptides are also functionally
related. Notably, this result is consistent with the findings presented in [69].
Comparing kinase similarity to other properties like the number of PPI
shared by the kinases, or the number of gene ontology (GO)–terms shared,
did not yield significant results (data not shown).
A more sophisticated similarity measure for kinases is the correlation
coefficient between the fold changes of the phosphopeptides that are af-
fected by the given kinases. For example, we performed a clustering ana-
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lysis based on the Spearman correlation of the kinases’ phosphosite fold
change vectors and reviewed the clusters obtained for a) reflecting the ki-
nase family tree [29] (Figure 8(a)) and b) being consistent with functional
annotations of the kinases, for example regarding their GO annotations [92].
In both cases no significant enrichment could be found.
Similarity between kinases can also be defined based on characteristics
other than their measurable effects on the phosphoproteome. For instance,
pairs of kinases working together in pathways or functional units should
also exhibit similarities in terms of their cellular and morphological pheno-
types. Just as before, we used correlation analysis to determine the similar-
ity of kinases with respect to their cellular phenotypic profiles (see Table S8
in Supplementary Methods).
By invoking both the similarities concerning the phosphoproteomic phe-
notype and the cellular phenotype we carried out a bi–clustering analysis in
order to test whether kinases that have similar phosphoproteome footprints
also tend to have similar phenotypic consequences on the cell. Furthermore,
we included a third source of information by mapping all kinases to their
respective kinase superfamily. The result is shown in Figure 8(b).
As can be seen, there is no obvious relationship between similar phospho-
proteomic phenotypes and similar cellular phenotypes. Although some of
the kinase pairs cluster together in both phenotypic dimensions (red edges),
the majority of the pairs displays an independent behavior and did not sup-
port our hypothesis that kinases that share similar effects on substrates also
tend to have similar morphological effects.
Besides the clustering of kinases, we also clustered all regulated phos-
phopeptides according to their kinase or phosphatase regulation profiles.
On the one hand we screened for functional uniformity of the clusters, on
the other hand for peptides of a cluster being enriched in similar kinase
binding motifs. Again, the results were largely uninformative.
Bearing in mind that a number of kinases and phosphatases could not be
analyzed for technical reasons and the existence of intrinsic technical short-
comings within the experimental setup, we expected that our data might
not be representative of the whole regulated phosphoproteome. Neverthe-
less, the restricted overlap of our data with known kinase–substrate interac-
tions as listed in various PPI databases [94, 95] was dissatisfying. However,
to some extent this could be explained by the transient type of interac-
tion between kinases and phosphatases and their substrates, which com-
mon PPI databases likely fail to specify. Furthermore, PhosphoGrid [15],
the only database focusing on kinase/phosphatase – substrate interactions,
currently includes a rather small portion of the phosphoregulome.
Another important aspect must be taken into account with regard to a)
the indirect and incomplete nature of the data and b) the amount of non–
regulated phosphopeptides: In order to be considered as a possible direct
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target of a kinase, a phosphopeptide would have to show either a decrease
in abundance or a complete absence in the knockout sample of that kinase.
This necessarily requires the successful detection of the phosphopeptide in
the corresponding wild–type samples (to which the mutant samples are
compared to). Otherwise, the peptide only appears to be phosphorylated
in the mutant and may consequently be considered as an inverse responder.
In our dataset, a total of 102 wild–type samples (34 batches of wild–type
cells with 3 replicates each) were measured. In contrast, 372 mutant sam-
ples, more than 3.5 times more, were processed. This indicates on the one
hand a notable undersampling of the wild type relative to the mutants
and moreover, it means that some of the wild–type batches were compared
to several deletion strains. In theory, one would expect different perturbed
phosphoproteome maps aligned to the same wild–type samples to offer the
same wild–type phosphopeptides. However, close scrutiny revealed that
the number of identified peptides varies within a range of 30%, an incon-
sistency which most likely prevented the identification of direct targets in
many cases and may sometimes even have favored the inverse conclusion.
Another test to reveal deficiencies concerning the wild–type reference
sets is to look for kinases and phosphatases that are represented in the
data by their own phosphopeptides. A kinase or phosphatase that had been
knocked out (i.e. genetically deleted) should not be detectable at all in the
corresponding mutant sample. Therefore, possible self–phosphopeptides
should disappear and be reported as ‘vanisher’ peptides. Such peptides
should act as a control set. We checked our dataset and found 58 kinases
that were indeed detected at least once as phosphopeptides. However, only
for 7 of them (12 %) the expected vanisher events were observed, indicat-
ing an under–reporting of about 90% of this most obvious class of vanisher
events. On the positive side, only a single peptide was wrongly called as
present (i.e., a false positive) in a sample where the corresponding kinase
gene had been deleted.
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Figure 6: Consensus phosphorylation site motifs. Full responder phosphopeptides with ex-
pected directionality were grouped according to their kinases‘ families and scanned for
overrepresented consensus recognition sites. For a negative control, the analysis was re-
peated for strong indirect targets, i.e. full responders with inverted directionality. (a) Ob-
tained sequence logo for kinase family HAL, both for the set of direct and indirect targets.
(b) Sequence logo for kinase family CAMKL. (c) Sequence logo for kinase family CDK.
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Figure 7: Similarity of kinase pairs versus genetic interactions. Each diamond represents a pair
of kinases. Pairs that show a positive genetic interaction are plotted in blue, pairs with
negative genetic interaction are plotted in red, and pairs that are not known to interact
genetically are plotted in grey. Black rectangles represent the median number of shared
phosphopeptides. Y–axis: number of phosphopeptides shared between two kinases, in log
space. The genetic interaction data was taken from [91].
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Figure 8: Bi–clustering analysis of kinases (a) Dendrogram of the yeast protein kinase su-
perfamilies. Taken from [93]. (b) Clustering network obtained from the simultaneous
clustering of kinases based on both their phosphosite response similarity and their mor-
phological similarity. Kinases are represented as nodes in the network and are colored
according to the their superfamily membership. Edge colors: i) red: corresponding kinases
are grouped together with respect to both dimensions, ii) green: corresponding kinases
only cluster with respect to the similarity of their phosphoproteomic phenotypes, iii) blue:
corresponding kinases only cluster with respect to the similarity of their morphological
phenotypes.
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F U RT H E R P E R S P E C T I V E S
To overcome the inconsistencies mentioned above, we intend to merge all
wild–type samples simultaneously in order to create a global ‘super’–refer-
ence map. This will allow us to aggregate all phosphopeptide information
contained in the wild types (‘artificial deep sampling’) and ensures that all
mutants are compared to the same list of wild–type phosphopeptides.
Furthermore, we plan to use different LC–MS/MS alignment software pro-
grams like MaxQuant [64] and OpenMS [60] in order to compensate for
the various strengths and weaknesses of the individual programs. The ul-
timate goal will be to generate a ‘gold standard’ of phosphopeptides that
were identified as regulated while using different comparative alignment
software programs.
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I N T R O D U C T I O N
10.1 metabolomics
Metabolites are small molecules that take part in or are produced during
various metabolic processes. They do not only comprise a very diverse spec-
trum of chemical compounds including lipids, carbohydrates, and amino
acids, but are also present in a wide range of concentrations. The complete
set of all small molecules in a defined system (e.g. a cell or tissue) forms
the metabolome [96, 97]. Estimates of metabolome sizes differ greatly; for
example, predictions for the plant kingdom range from 200.000 to 1.000.000
metabolites [98]. As for the human metabolome, currently about 8000 cu-
rated metabolites are known but estimates go up to 30.000 and more [99].
For yeast, a recent study raised the number of described metabolites to
about 950 [100].
In a manner analogous to transcriptomics and proteomics, metabolomics
describes the global study of the metabolome from a Systems Biology ap-
proach. Other terms often used in this context are metabonomics, metabolic
profiling, and metabolic fingerprinting. Metabolomics continues to be a
rapidly developing field and terminologies evolve constantly, resulting in
ongoing debates within the scientific community about the respective defi-
nitions (which also often overlap) [97, 101]. However, in recent years meta-
bolomics has emerged as the term used most often [102, 103].
Like with other ‘omics’–fields technological developments have been (and
are) the basic requirements for system–wide studies of the metabolome.
Primarily the use of two HTP procedures, namely nuclear magnetic reso-
nance (NMR) and MS, has enabled the quantification of large numbers of
metabolites in a non–targeted manner [104]. NMR has the advantage of
being a noninvasive platform with relatively low requirements in terms
of sample preparation. While having an excellent quantitative precision
the limiting step of NMR is its sensitivity, allowing only the detection of
metabolites with medium to high abundances. In contrast, the detection
ability of MS techniques covers a broad range of compound concentrations.
While separation–based techniques like LC–MS and gas chromatography
mass spectrometry (GC–MS) predominated in the beginning, recently (direct)
flow injection electrospray mass spectrometry (FIE–MS) has been established,
offering a more ‘global’ coverage of the metabolome [104, 103, 105, 106].
Despite substantial technical advances, two main challenges persist: first,
it is still not feasible to identify all metabolites in a sample, and second, the
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quantification of detected compounds is limited even further. Most studies
barely achieve an identification rate of 25% [97, 107].
System–wide metabolic studies assist in understanding metabolism in
general, for instance by predicting novel metabolic pathways and by provid-
ing input for metabolic network construction [108, 109, 110]. In functional
genomics, comparative metabolomics is employed for elucidating enzyme
functions or in identifying natural substrates of enzymes [104, 111].
Scientifically, applications for metabolomics are versatile. One prominent
and significant field is medical sciences. For example, the discovery of new
biomarkers plays an important role in clinical diagnosis. The number of
diagnostic assays using metabolic markers is increasing, amongst others
signature studies for breast cancer [112], diabetes [113], and Alzheimer’s
disease [114] have been reported over the past years. Furthermore, another
important field of application is pharmacology. Metabolomic studies are
particularly suitable for toxicology and pharmacogenomics [115, 103]. Ulti-
mately, the goal is to employ metabolomics as a tool to pursue and establish
personalized medicine [116, 117].
10.2 regulation of the metabolome
The metabolome represents a fairly downstream component of the ‘omics’
cascade [118]. Consequently, mechanisms controlling the upper–ome levels
such as the transcriptional and the phosphorylation regulatory networks
have a strong influence on the metabolic network, transmitted through the
enzymes that are catalyzing the metabolic reactions. This allows for tight
regulation, and as a matter of fact, transcriptional and PTMs are important
factors in metabolic control (see Figure 9). Also referred to as hierarchi-
cal, these types of control affect the quantity of active enzymes whereas
metabolic regulation targets the enzymes’ kinetic activities by means of the
presence of substrates, products, and modifiers [119, 120].
Transcriptional regulation of the metabolism has been a main focus of
study for many years. With the emergence of transcriptomics, genome–
wide screens could be performed in order to analyze the comprehensive ef-
fect of changes in abundance of particular enzyme transcripts on metabolic
networks in a variety of organisms [121, 119, 122, 123].
In contrast, the global impact of PTMs on metabolic control is less well
understood. Concerning protein acetylation, two recent reports suggest a
more relevant role than previously thought [124, 125]. However, the key
player in post–translational regulation appears to be the process of revers-
ible protein phosphorylation [126, 127]. While we know of some specific ex-
amples of metabolic enzymes regulated by protein phosphorylation, to the
best of my knowledge, no system–wide studies have been published thus
far. Even though great progress has been made towards cataloguing and
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Figure 9: The ‘omics’ cascade. The hierarchically coordinated ‘omics’ cascade comprises
complex datasets that interact in highly concerted actions. The metabolome is one of the
endpoints of the cascade and thus perhaps the closest to the phenotype. Adapted from
[118].
mapping phosphorylation sites, the “function of specific phosphorylation
events has rarely been demonstrated and quantified, leaving a major chal-
lenge for the near feature” [126], and it “remains to be established whether
those modifications actually have regulatory significance for protein func-
tion or not” [128].
Nonetheless, metabolic regulation by protein phosphorylation and reg-
ulation by transcription are closely connected. For example, many TFs are
phosphorylated in order to perform transcriptional initiation. Consequently,
as illustrated in Figure 10, the phosphorylation network and the transcrip-
tional network are highly intertwined, and a direct (and isolated) analysis
of the functional role of protein phosphorylation on the metabolome is thus
hardly possible.
Below I provide some insight into the first system–wide study on the
impact of reversible protein phosphorylation on metabolic regulation in
yeast. This project, conducted in close collaboration with Juliane Schulz
from the Uwe Sauer group, ETH Zurich, is a work in progress.
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Figure 10: Interconnectedness of the phosphorylation network, transcription factor network, and
metabolic network. Reversible protein phosphorylation controls both the TF network and the
metabolic network, the latter being coordinated via transcriptional control, too. In contrast,
via feedback loops, metabolic levels also may influence the regulatory networks.
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I N T E G R AT I N G T H E P H O S P H O P R O T E O M E A N D T H E
M E TA B O L O M E
11.1 project description
As highlighted in the previous section, little is known about the control of
metabolism by protein phosphorylation on a global scale. One approach to
address this is to analyze the set of proteins that execute this very type of
PTM: protein kinases and protein phosphatases. Their systematic silencing
coupled to subsequent quantitative metabolomics analysis yields metabo-
lites whose abundances are affected (either directly or indirectly) by the
activity of a given kinase or phosphatase. Consequently, these metabolites
are potential candidates for regulation via protein phosphorylation.
However, exactly how these metabolites are linked to the kinase and phos-
phatase regulatory network remains to be understood. Does their abun-
dance depend on the phosphorylation of distinct metabolic enzymes? More
precisely, can the behavior of particular metabolites be associated with in-
dividual phosphosites? Or could these variations in metabolite concentra-
tion perhaps be a result of changes in the transcriptional level of enzymes,
caused by phosphorylation–based activation or inactivation of TFs?
The availability of datasets from kinase and/or phosphatase perturba-
tion experiments both on the phosphoproteome [83] and on the transcrip-
tome [71] level provides an opportunity to address these questions. The
integrated analysis of the datasets can help to shed light on the complex
relationships between the three ‘–omics’ levels and to elucidate regulation
of the metabolome by protein phosphorylation.
Implementing the experimental approach mentioned in the first para-
graph, the group of Uwe Sauer at ETHZ generated 122 perturbed metabo-
lomes by performing FIE–MS [106] on the same knockout mutant strains that
were used in the genome–wide kinase and phosphatase knockout phospho-
proteome screens (91 kinases, 27 phosphatases) in the yeast Saccharomyces
cerevisiae described before [83]. Significantly and reproducibly regulated
ions were detected by comparing the abundance of mutant metabolomes
to those of wild–type metabolomes [129].
The data obtained – in combination with the phosphoproteomic data
described in chapter 7 – enables to address the following questions:
• To what extent does the phosphorylation network regulate the metab-
olomic network?
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• Which are the specific kinases and phosphatases involved in metabolic
regulation?
• Which metabolic enzymes and metabolic pathways are regulated by
protein phosphorylation?
• Can we find metabolite–phosphosite pairs that show a correlated be-
havior in their abundance changes upon each knockout of the same
set of kinases and phosphatases?
11.2 results and discussion
In total, 1710 distinct ions could be quantified. Ions exceeding a log2 fold
change of 0.8 (q-value 6 0.001, FDR–based multiple testing corrected) were
defined as regulated, resulting in a total of 662 ions (39%). The number of
kinases and phosphatases affecting a given ion ranged from 1 to 81, with
an average number of five. Only four ions had a regulatory link to more
than 70 kinases or phosphatases. About 415 of all ions could be annotated
and assigned to chemical compounds (24.3%).
Of the 91 kinases and 27 phosphatases tested, 78 and 26, respectively,
showed an effect on the metabolome, that is they appeared to regulate at
least one ion. On average, a kinase or phosphatase regulated 34 ions; six
kinases (Vps34, Pho85, Vps15, Ime2, Snf1, Ctk1) and one phosphatase (Ptc4)
affected more than 100 ions.
In order to find pairs of metabolites and phosphorylation sites that re-
sponded similarly to the absence of a set of kinases and phosphatases, we
calculated the correlation (both Pearson and Spearman rank correlation) be-
tween the phosphosite and the metabolite abundance fold changes. In do-
ing so, phosphosite and metabolite both had to be showing an effect in at
least five shared kinase or phosphatase perturbations. To increase the num-
ber of possible pairs we also considered fold changes (for both metabolites
and phosphosites) that fell below the original regulation cutoffs (phospho-
site: | log2 FC | > 1.5, p-value 6 0.015, metabolite: | log2 FC | > 0.8, q-value
6 0.001).
Figure 11 compares the number of actually observed significantly corre-
lated metabolite–phosphosite pairs (red line, correlation p-value 6 0.01) to
the expected number of significant pairs (box plots, based on 1000 random-
izations), plotted as a function of the significance cutoff of the correspond-
ing metabolite and phosphosite fold changes (data p-value, x–axis). The in-
dividual plots vary in the required minimum number of kinases and/or
phosphatases that each phosphosite–metabolite pair had to share in order
to be considered for the correlation analysis. (Figure 11(a): 5, Figure 11(b):
10, Figure 11(c): 15, Figure 11(d): 20).
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Figure 11: Number of observed significantly correlated metabolite–phosphosite pairs versus the
expected number of significant pairs. The number of expected pairs was estimated by calcu-
lating the correlations for metabolite–phosphosite pairs with randomized fold changes
and repeating this procedure for 1000 times. The fold change randomization was done
by shuffling the links between phosphosites and kinases/phosphatases in the phospho-
proteome dataset. The metabolomics data was kept unchanged. The plots differ in the
requested minimum number of shared kinases/phosphatases. (a): minimum of 5 shared
kinases/phosphatases. (b): minimum of 10 shared kinases/phosphatases. (c): minimum of
15 shared kinases/phosphatases. (d): minimum of 20 shared kinases/phosphatases.
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In all plots, the number of significantly correlated phosphosite–metabolite
pairs (y–axis, log space) is clearly above the random expectation, which is
encouraging for our analysis. Relaxing the individual fold change cutoffs
(x–axis) is likewise justified: pairs whose correlation was calculated based
on fold changes that were not necessarily considered to be significantly reg-
ulated (x–axis, data p-value > 0.015) individually, also clearly outnumber
the expected number of pairs. This outcome suggests to expand the cutoffs
for further analyses, too.
Across the whole range of data p-value cutoffs, except for the first one
of 0.01, the ratio of the number of observed significant data pairs to the
number of expected significant data pairs shows only very little variation.
In contrast, more stringent conditions in terms of the minimum number
of shared kinases and phosphatases between metabolites and phosphosites
lead to a slight increase of the ratios. However, at the same time the number
of outliers increases, too. (Figures 11 (a) to (d)). Therefore, since an analysis
with a minimum requirement of five shared kinases and phosphatases best
separates from random with respect to the significant data p-values 6 0.05,
this number seems to be a reasonable choice for future analyses.
Figures 12 to 18 illustrate examples of ion–phosphosite pairs showing
significant negative or positive correlations between their abundance fold
changes. For each data p-value threshold (ranging from 0.01 to 0.4 and
incremented by steps of 0.025) both Pearson correlation and Spearman rank
correlation were calculated.
Figure 12 features ion ‘1306’, which could be mapped to UDP–N–acetyl–
D–glucosamine (KEGG [130] compound C00043 [131]), a compound involved
in amino sugar and nucleotide sugar metabolism (KEGG pathway sce00520
[132]). The abundance changes of this molecule clearly (anti–)correlate with
the abundance changes of a triple–serine–phosphorylated peptide (amino
acids 956, 959, and 965) of Hbt1, a protein known to be a substrate of the
Hub1p ubiquitin–like protein ([133], and see Figure 12(a), and Table 12(b)
for correlation values).
Of the three correlated residues of Hbt1, only phosphosites 956 and 959
are currently curated in PhosphoGRID [15], but neither of them is function-
ally annotated. Equally little is known about the function of Hbt1 itself.
However, our correlation analysis links the protein to the metabolic net-
work and suggests a functional relationship between Hbt1 and UDP–N–
acetyl–D–glucosamine. This observation is supported by the STRING database
[94]. As shown in figure 12(c), STRING indicates a direct PPI between Hbt1
and Mcr1, as well as between Hbt1 and Hxk1, two enzymes (mitochondrial
NADH–Cytochrome b5 reductase, EC 1.6.2.2, and hexokinase isoenzyme 1, EC
2.7.1.1, respectively) known to participate in our pathway of interest ([132]).
Figure 13 depicts another example for an anti–correlation observed be-
tween the abundance fold changes of a metabolite and a phosphopeptide.
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(c)
Figure 12: Correlation analysis between phosphosites 956, 959, 965 of Hbt1 and UDP–N–acetyl–
D–glucosamine. (a) Fold change plot of metabolite and phosphopeptide abundances. For
each shared kinase/phosphatase (x–axis) the corresponding fold changes (log2, y-axis)
in ion abundance (green) and in phosphopeptide abundance (blue) are plotted. Kinas-
es/phosphatases tagged in the same color were considered together for calculating the
fold change correlations at a given data p-value cutoff. (b) Correlation values relative to
different data p-values. At a given data p-value, all fold changes with a less or equal data
p-value were take into account for the correlation calculations. (c) STRING network show-
ing direct interactions between Hbt1 and metabolic enzymes Mcr1 and Hxk1.
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Here, the ion involved is annotated to the metabolite uracil (KEGG com-
pound C00106 [134]). In contrast, the correlated di–phosphorylated pep-
tide (serine 222 and threonine 225) belongs to a yet uncharacterized pro-
tein, YHR097C. The strong and significant anti–correlation found (see Ta-
ble 13(b) for correlation coefficients and p-values) indicates a connection
of YHR097C to metabolism. Again, the STRING database supports this as-
sumption and states an interaction with both aldehyde dehydrogenase (Ald4,
EC 1.2.1.3) and glutamate decarboxylase (Gad1, EC 4.1.1.15) as depicted in
Figure 13(c). Remarkably, the two enzymes are participating in β–alanine
metabolism (KEGG pathway sce00410 [135]), the very pathway which syn-
thesizes uracil, and thus encourage our hypothesis of an association of
YHR097C to metabolism.
The impact of TFs on metabolomic regulation triggered by protein phos-
phorylation is exemplified in Figure 14. Here, a highly significant correla-
tion between a double–phosphorylated peptide (residues 322 and 326) of
Not3, a subunit of the Ccr4–Not TF complex [136], and ion ‘141’, a small
molecule annotated as (S)–Malate (KEGG compound C00149 [137]) and par-
ticipating in methane metabolism (KEGG pathway sce00680 [138]), is illus-
trated (Figure 14(a)). Though no direct interactions with enzymes involved
in methane metabolism are known, the STRING database connects Not3 to
the methane pathway protein network via the enzyme Pdc1 (pyruvate decar-
boxylase, EC 4.1.1.1, see Figure 14(c)), confirming the relationship between
Not3 and methane metabolism identified in our correlation analysis.
As mentioned in the beginning of this section, most of the ions quanti-
fied have not been annotated yet. To bypass this limitation, we employed
STITCH, a database for known interactions between proteins and chemi-
cal compounds [139]. Using the information provided by STITCH, we were
able to locate and map some of the unidentified ions to known metabolites
based on their m/z values.
In doing so, ion ‘205’ (m/z 157.051) could be assigned to 7,8–dihydropteroate
(KEGG compound C00921 [140]), a small molecule synthesized during fo-
late biosynthesis (KEGG pathway sce00790 [141]). The corresponding reac-
tion is catalyzed by the enzyme dihydropteroate synthase (Fol1, EC 2.5.1.15).
In our analysis, we found the two molecules indeed to be interrelated: the
metabolite’s abundance fold changes show a significant anti–correlation
to the fold changes of tyrosine residue 33 of the protein (see Figure 15),
strongly supporting our annotation of the metabolite.
Another example of mapping unidentified ions to pathways is shown
in Figures 16 to 18. Using STITCH, ion ‘1612’ (Figure 16) was identified
as metabolite acetyl–CoA (KEGG compound C00024 [142]), ion ‘1559’ as
acetoacetyl–CoA (KEGG compound C00332 [143], Figure 17), and ion ‘1510’
as coenzyme A (KEGG compound C00010 [144], Figure 18). The three mole-
cules are participating in neighboring and interlinked metabolic pathways,
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(c)
Figure 13: Correlation analysis between phosphosites 222, 225 of uncharacterized protein
YHR097C and uracil (a) Fold change plot of metabolite and phosphopeptide abundances.
For details, see 12(a). (b) Corresponding correlation values. (c) STRING network showing
direct interactions of YHR097C with Ald4 and Gad1, two metabolic enzymes that partici-
pate in β–alanine metabolism, just like the metabolite of interest, uracil, does.
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among others in the fatty acid biosynthesis (KEGG pathway sce00061 [145])
and fatty acid metabolism (KEGG pathway sce00071 [146]). The multifunc-
tional enzyme acetyl–CoA carboxylase (Acc1, EC 6.4.1.2) plays a prominent
role in these pathways and is the key enzyme of fatty acid biosynthesis by
catalyzing the carboxylation of acetyl–CoA in order to produce malonyl–CoA
[147].
The functional relationship between Acc1 and the three compounds is
also visible in our analysis. All three metabolites show a sufficient correla-
tion in their abundance fold changes to serine residue 1159 of Acc1. Acetyl–
CoA and coenzyme A are positively correlated, whereas acetoacetyl–CoA is
negatively correlated to serine 1159. It should be noted, however, that the
correlations are only significant when calculated based on extended data
p-values (for correlation values see Tables 16(b), 17(b), and 18(b)).
Some details of the regulation of Acc1 are known. For instance, the en-
zyme is deactivated through phosphorylation by the AMP–activated kinase
Snf1. In contrast, the dephosphorylation by phosphatase Sit4 leads to the
activation of Acc1 [148, 149].
Since Acc1 was not detected as a target of Snf1 in the phosphoproteome
dataset, a likely association between acetyl–CoA, the substrate of Acc1, and
Snf1 could not be verified in our correlation analysis. Nevertheless, the pos-
itive correlation between Acc1 and acetyl–CoA reflects the molecular back-
ground, as Acc1 is only active upon dephosphorylation. Interestingly, Sit4
(YDL047W), the phosphatase which is responsible for the activation of Acc1,
is among the perturbations that were considered for the correlation analysis.
Its knockout yields a positive fold change of the abundance of serine 1159
of Acc1, an outcome that is consistent with the fact that Acc1 constitutes as
a direct target of Sit4.
Acetoacetyl–CoA is synthesized from acetyl–CoA in a reversible reaction.
During this process, coenzyme A is released as well, and acts as an inhibitor
of the reaction ([150, 151]). The negative correlation of acetoacetyl–CoA with
Acc1 could be explained in light of the relations between the metabolites
themselves. On the other hand, Acc1 is a multifunctional enzyme and also
involved in other pathways, as are the various metabolites. These factors
as well as the still not fully understood complex regulation of Acc1 [148]
impede more definitive conclusions.
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0.01 0.731 0.006908 0.8042 0.002746
0.025 0.6988 0.000425 0.7221 0.0003251
0.05 0.6433 0.0002951 0.6374 0.0004693
0.075 0.6523 0.0001259 0.6488 0.0001985
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0.175 0.5054 0.0008792 0.5266 0.0005786
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(c)
Figure 14: Correlation analysis between the TF Not3 and (S)–Malate (a) Fold change plot of
metabolite and phosphopeptide abundances. For details, see 12(a). (b) Corresponding
correlation values. (c) STRING network showing an indirect interactions of Not3 to the
methane pathway protein network via enzyme Pdc1.
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Figure 15: Correlation analysis between phosphosite residue 33 of Fol1 and ion ‘205’, annotated as
7,8–dihydropteroate using STITCH (a) Fold change plot of metabolite and phosphopeptide
abundances. For details, see 12(a). (b) Corresponding correlation values.
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(b)
data p-value
cutoff
Pearson
correlation
Pearson
p-value
Spearman
correlation
Spearman
p-value
0.01 0.4022 0.4293 0.1449 0.7841
0.025 0.5113 0.2408 0.4685 0.289
0.05 0.4493 0.1428 0.4799 0.1144
0.075 0.4862 0.06609 0.5344 0.04014
0.1 0.4815 0.04304 0.5142 0.02903
0.125 0.4834 0.03081 0.5258 0.01727
0.15 0.4585 0.03659 0.48 0.02764
0.175 0.4135 0.03993 0.4947 0.01194
0.2 0.3833 0.04014 0.4858 0.007551
0.225 0.3945 0.02547 0.4696 0.006692
0.25 0.3902 0.02252 0.4469 0.00805
0.275 0.4131 0.01106 0.496 0.001797
0.325 0.41 0.008596 0.4689 0.002275
0.35 0.4221 0.004811 0.4897 0.0008582
0.375 0.4121 0.004428 0.4436 0.002015
0.4 0.3784 0.008732 0.3854 0.007465
Figure 16: Correlation analysis between residue 1159 of Acc1 and ion ‘1612’, annotated as acetyl–
CoA using STITCH (a) Fold change plot of metabolite and phosphopeptide abundances.
For details, see 12(a). (b) Corresponding correlation values.
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data p-value
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Pearson
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Pearson
p-value
Spearman
correlation
Spearman
p-value
0.01 -0.5713 0.1391 -0.5509 0.157
0.05 -0.6254 0.02965 -0.5499 0.06398
0.075 -0.6649 0.01315 -0.575 0.03982
0.1 -0.6466 0.006791 -0.518 0.03983
0.125 -0.5325 0.01892 -0.4581 0.04856
0.15 -0.5131 0.01461 -0.4637 0.02973
0.175 -0.5095 0.01098 -0.4497 0.02748
0.2 -0.5237 0.005056 -0.4546 0.01721
0.225 -0.4221 0.02257 -0.3577 0.05678
0.25 -0.4253 0.01915 -0.3549 0.05432
0.275 -0.4406 0.01161 -0.3621 0.04172
0.3 -0.4396 0.01047 -0.3714 0.03334
0.325 -0.3751 0.02417 -0.3394 0.04284
0.35 -0.3745 0.02241 -0.3252 0.04954
0.375 -0.3718 0.01534 -0.2965 0.05655
0.4 -0.3283 0.02591 -0.2247 0.1333
Figure 17: Correlation analysis between residue 1159 of Acc1 and ion ‘1559’, annotated as
acetoacetyl–CoA using STITCH (a) Fold change plot of metabolite and phosphopeptide
abundances. For details, see 12(a). (b) Corresponding correlation values.
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(b)
data p-value
cutoff
Pearson
correlation
Pearson
p-value
Spearman
correlation
Spearman
p-value
0.01 0.4821 0.1583 0.6261 0.05278
0.025 0.5095 0.1094 0.6651 0.02553
0.05 0.4436 0.09766 0.5416 0.03706
0.075 0.4581 0.06443 0.5138 0.03488
0.1 0.5025 0.02395 0.5182 0.01924
0.125 0.486 0.02184 0.5061 0.01626
0.15 0.472 0.01989 0.4658 0.02181
0.175 0.4353 0.01437 0.4375 0.01383
0.2 0.4446 0.006594 0.4648 0.00429
0.225 0.4093 0.009662 0.4103 0.009485
0.25 0.3974 0.01111 0.3912 0.01255
0.275 0.3729 0.01377 0.349 0.0218
0.3 0.3499 0.01712 0.316 0.03243
0.325 0.3437 0.0156 0.2974 0.03799
0.35 0.352 0.01049 0.3058 0.02746
0.375 0.3392 0.0113 0.2768 0.04074
0.4 0.3418 0.009923 0.2758 0.03963
Figure 18: Correlation analysis between residue 1159 of Acc1 and ion ‘1510’, annotated as coen-
zyme A using STITCH (a) Fold change plot of metabolite and phosphopeptide abundances.
For details, see 12(a). (b) Corresponding correlation values.
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11.3 conclusion and perspectives
Our preliminary results illustrate the potential of an integrated analysis of
perturbed metabolome and phosphoproteome data in order to elucidate the
role of protein phosphorylation on metabolome regulation.
The examples presented show the usefulness of our approach in sev-
eral aspects. First, the correlation analysis can contribute significantly to
the functional annotation of proteins. So far, both Hbt1 and YHR097C had
not been linked to metabolic pathways before. The strong correlations to
metabolites we could identify in our analysis suggest such metabolic as-
sociations, which are indeed supported by findings and predictions in the
STRING database. Secondly, besides protein annotation, our analysis can
also be employed for ion annotation. Combined with a database providing
context information such as STITCH, it is possible to locate the ion based
on its m/z value and its relationship (in our case correlation) to a protein.
Thirdly, our analysis can reveal phosphosites that act as indicator sites of
protein function, like enzyme activity or transcriptional control activity.
It is worth mentioning that our analysis was implemented in an unbiased
fashion, meaning that we considered the kinase and phosphatase knockouts
as anonymous perturbations and did not employ knowledge about known
events of kinase/phosphatase regulation. Despite this, the results appear
reasonable and meaningful, further validating our analysis.
Besides applications already mentioned, our correlation analysis could
also be helpful for the identification of functional phosphosites that were
unidentified so far. For example, a strong correlation to an ion may indicate
a functional role of a phosphosite whether or not it was reliably quantified
initially. Consequently, our analysis could act as a filter in order to detect
functional phosphosites previously unknown to be connected to a given
kinase or phosphatase.
Part IV
A P P E N D I X

A
A N I N V I V O G E N O M E - W I D E S T U D Y O F O R G A N
G R O W T H R E G U L AT I O N
The following preliminary manuscript describes a genome–wide in vivo
RNA interference (RNAi) screen in order to identify new growth regulators
in the fruitfly Drosophila melanogaster. I implemented the full bioinformatic
pipeline in order to analyze the HTP data. Furthermore, I compiled and
prepared data from a number of other RNAi screens in order to compare
their results to our data.
The provisional manuscript is attached below.
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Summary 
A major problem concerning organ development is how tissue growth is achieved, and how its regulation is 
coordinated with other biological processes such as cell growth, cell division, and differentiation. Various 
high-throughput RNAi screens focusing on cell growth and proliferation have relied on cultured cells. In 
order to learn more about organ growth we used the wing of Drosophila melanogaster as a model system 
to uncover new growth regulators. We could thus study growth control in an entire, intact organ. Hence we 
conducted a genome-wide in vivo RNAi screen in the wing system with a coverage of 11’250 genes (83% 
of Drosophila protein coding genes). 21’014 transgenic RNAi lines were assayed in two differently 
sensitized tester backgrounds exhibiting small or large wings due to insufficient or excessive levels of Hh 
signaling, respectively. The Hedgehog (Hh)- and Decapentaplegic (Dpp)/TGFβ-signaling pathways are 
central to growth control in wing imaginal discs but it is unclear how they impinge on growth and if/how 
they define disc size. We have identified known as well as novel growth regulators. 2’669 genes (23% of 
all tested genes, 19.6% of all Drosophila protein-coding genes) revealed a wing growth phenotype upon 
RNAi in at least one of the two conditions tested, including genes with an established function in wing disc 
growth. Our in vivo screen therefore provides a comprehensive catalogue of growth regulatory genes, 
revealing many novel components of growth that have not been so far recognized in cell culture screens. 
A large number of our candidate genes have mammalian orthologs. We show that CG6854 acts as a 
positive growth regulator during wing disc development while CG14542 are required to restrict growth, 
illustrating the potential of this screen to uncover novel growth regulators important for the control of cell 
proliferation and organ size in humans. 
 
 2 
Introduction 
Tissue growth and its orchestration with morphogenetic processes are central to the development of 
multicellular organisms. The size of an organ or appendage is determined by the number and size of the 
cells it contains (Reis and Edgar, 2004; Cook and Tyers, 2007). Pro-growth processes such as cell 
proliferation (cell division) are counteracted by specific inhibitors, or by cell death. The final size of an 
organ is determined by extracellular and intracellular mechanisms that induce and terminate growth. 
These mechanisms remain largely elusive as concurrent with growth, different gene expression programs 
need to be implemented to ensure proper patterning and differentiation of the organ. 
The ideal system to study growth regulation is a tissue that contains mitotically active and differentiating 
cells amenable to genetic manipulation in vivo, but which is largely dispensable for the viability of the 
organism. Drosophila wing imaginal discs, anlagen of the adult wings, satisfy these criteria. During the first 
larval day a  50-cell wing primordium starts to proliferate and increases thousand-fold in size by the end of 
larval development (five days later), prior to undergoing metamorphosis into adult wing cuticle. This growth 
is influenced (i) by extrinsic parameters, including nutrients, oxygen, temperature and hormone signaling 
(Britten and Edgar, 1998; Kawamura et al., 1999; Leopold and Perrimon, 2007), and (ii) by organ-
autonomous, intrinsic factors (Bryant and Simpson, 1984; Neto-Silva et al., 2009). Morphogen-operated 
pathways that regulate wing patterning are emerging as key players in the intrinsic control of growth. For 
example, the Hh signaling cascade is crucial for patterning the A/P (antero-posterior) wing axis and for 
controlling wing growth (Tabata and Takei, 2004; Crozatier, 2004). The key growth effector of Hh signaling 
is dpp, whose expression is activated at the A/P border (Affolter and Basler, 2007). Dpp exerts its pro-
growth activity, primarily by repressing the growth-antagonist brinker (Campbell and Tomlinson, 1999; 
Jazwinska et al., 1999; Minami et al., 1999; Marty et al., 2000; Cook et al., 2004; Martin et al., 2004; 
Schwank et al., 2008). Disrupted Hh signaling causes many diseases ranging from developmental 
abnormalities to an increasing list of cancers (Wetmore, 2003; Rubin and de Sauvage, 2006). In addition 
to morphogens, mechanical forces in the disc may also affect growth processes (Hufnagel et al., 2007; 
Aegerter-Wilmsen et al., 2007). Due to their genetic amenability imaginal discs have served to uncover 
many aspects of growth cues, and their networks form the basis of our still incomplete understanding of 
growth control at the organ level. 
Traditional forward genetic methods, such as mutagen-based loss-of-function screens, have revealed a 
number of core components of growth regulatory pathways. More recently, high-throughput screening 
approaches using RNAi in cell culture-based assays have provided further exciting insights (DRSC 
http://flyrnai.org; DasGupta and Gonsalves, 2008; Mathey-Prevot and Perrimon, 2007; Fuchs and Boutros, 
2006; Lents and Baldassare, 2006). However, a more powerful approach would be to investigate the 
consequences of loss of function of growth-relevant genes in the context of the entire animal or whole 
organ. 
One way to accomplish this are reverse-genetic approaches like “gene-knockouts” by homologous 
recombination (Rong et al., 2002); however due to their laboriousness these techniques have not been 
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employed for large-scale studies. Moreover, global loss of gene function often causes lethality of 
homozygous mutant animals. While this difficulty can be circumvented by mosaic analyses (Garcia-Bellido 
and Dapena, 1974, Tyler et al., 2006) this approach is extremely time-consuming.  
An alternative is RNA interference that has become the standard methodology to investigate the loss or 
reduction of gene function in a high-throughput manner. Numerous screens were performed in cell culture 
with the aim to catalog genes involved in diverse processes, ranging from cell cycle control to lipid droplet 
formation (Boutros et al., 2004; Björklund et al., 2006; Guo et al., 2008; Steinbrink and Boutros, 2008). The 
generation of a genome-wide transgenic RNAi library by the VDRC (Vienna Drosophila RNAi Center; 
Dietzl et al., 2007) enabled the performance of such screens in a whole organ or organism. By using this 
library we achieved a systematic and unbiased in vivo loss-of-function screen to uncover growth regulators 
of an entire, intact organ - the Drosophila wing. Drosophila's low gene redundancy further simplifies a 
functional screening approach to identify novel regulators of growth. Advantageous to previous cell based 
approaches, performing a screen in an intact organ should reveal more components relevant for tissue 
growth. We could assay 11’250 genes (83% of all Drosophila protein coding genes), which are 
represented by 21’014 transgenic “UAS-hairpin” lines (1.8 lines per gene on average). 2’669 genes (23% 
of all tested genes, 19.6% of Drosophila protein-coding genes) revealed a wing size phenotype upon 
RNAi, including known genes with an established function in wing disc growth. In addition to wing size 
changes, phenotypes relating to vein patterning and epithelial morphology could be distinguished. Our 
approach is accompanied by a careful bioinformatic analysis of the data. Genes that scored positively in 
our screen have a significantly enriched set of human orthologs, validating the use of the Drosophila wing 
epithelium, which resembles epithelia of higher metazoans, as a system to discover regulators important in 
tumorigenesis and mammalian organs growth. 
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Results and Discussion 
Establishment of two sensitized systems to identify growth regulators in vivo 
Successful in vivo screening approaches require a sensitive, robust, and easily identifiable phenotype. To 
achieve this and to maximize the recovery of growth regulators we created two sensitized tester systems 
with larger or smaller wings by increasing or decreasing, respectively, the levels of Hh signaling. We 
employed two transgenes expressing different forms of Cubitus interruptus (Ci): Cirep or Ciact. Ci is the 
transcriptional effector of Hh signaling (Slusarski et al., 1995; reviewed in Huangfu and Anderson, 2006) 
and is proteolytically truncated in cells that do not receive the Hh signal. The full length form is favored 
upon Hh signaling and is a transcriptional activator. Importantly, dpp is activated by Hh signaling and 
repressed in absence of Hh. Dpp signaling in turn largely accounts for wing growth (Affolter and Basler, 
2007). In our screen system the Cirep transgene encodes a constitutively truncated repressor (Methot and 
Basler, 1999), while Ciact lacks phosphorylation sites necessary for the proteolytic cleavage and is thus 
always in the active, full length form irrespective of the presence of Hh (Methot and Basler, 2000). 
Consequently, these transgenes caused either small wings (nub-Gal4, UAS-cirep), or large wings (nub-
Gal4, UAS-ciact) (Fig. 1; Fig. 2B-B’; Material and Methods). Since Hh/Dpp signaling acts predominantly 
along the A/P axis the Ciact tester wings are significantly enlarged along the A/P axis, and less pronounced 
along the PD (proximo-distal) axis. In addition to being suited for detecting suppressors of their respective 
phenotypes (i.e. enlarging the small wings or reducing wing over-size), both wing phenotypes could also 
be enhanced. Therefore in each of the setups it is possible to identify both positive and negative regulators 
of growth. This system is hence not only able to identify potent regulators of wing size, but should also 
reveal more subtle effectors. This is particularly important in cases of functional redundancy or moderate 
RNAi-mediated knockdown causing hypomorphic phenotypes. The phenotypes of the tester lines were 
robust and showed only limited variability. 
We expressed the VDRC RNAi transgenes in the primordial wing pouch by nubbin-Gal4 (nub-Gal4; Fig. 1). 
The pouch of the wing imaginal disc develops into the wing proper. As a consequence, effects on 
primordial wing growth could be observed in the adult wing. The nub-Gal4 driver is active from the 2nd 
larval stage onwards in the wing pouch, during the exponential growth phase until early pupal stages 
(Calleja et al., 1996; Ng et al., 1996; Cifuentes and Garcia-Bellido, 1997).  
 
Validation of the screening setup 
Our tester system is based on modulating the levels of Hh signaling. Ci is one of the most downstream 
components in this cascade, and the transcriptional output of Cirep or Ciact should be independent of the Hh 
signaling input. Nevertheless, the endogenous Hh-regulated Ci may contribute to the readout – an ideal 
situation since our screen could potentially uncover also novel Hh signaling components. This was indeed 
the case since depletion of positive Hh signaling components that act functionally upstream of Ci, like 
Smoothened (Smo) or Hh itself, caused a size reduction of Cirep and Ciact wings predominantly along the 
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A/P axis due to the pronounced activity of Hh/Dpp signaling along this axis (Fig. 2C,C’; not shown). A ciRNAi 
hairpin, which targets both transgenes as well as the endogenous transcript, caused size reduction of 
large tester wings (Fig. 2D), however, no further size reduction in the small tester wings (Fig. 2D’). This 
was not unexpected since the size increase due to the removal of transgenic Cirep would be counteracted 
by the loss of endogenous Ci activator. To further validate the screening setup we tested the effect of 
knocking down a number of genes known to act in signaling pathways other than the Hh pathway that are 
important during wing disc development. Dpp is a key regulator of wing growth, and in our tester conditions 
dpp expression levels were up- or downregulated upon Ciact and Cirep, respectively. As expected, RNAi 
mediated depletion of transcripts encoding Dpp signaling components such as mad, med, put, tkv or brk, 
modified the ciact and cirep phenotypes in agreement with their sign of action in the Dpp pathway (Fig. S1 C-
G’). In sum, of the well-established components of Hh (27 genes) and Dpp (15 genes) signaling addressed 
by RNAi we found 16 and 14 genes, respectively, with the expected phenotype (Fig. 2, Fig. S2, Tab. S1). 
Among the 24 Hh signaling pathway genes, 4 were lethal before eclosure, 1 resulted in an unexpected 
phenotype, and 3 showed no phenotype upon RNAi, including 2 genes encoding Hh secretory 
components (ski, disp), where a strong phenotype would not be expected in the Ciact condition. Based on 
RNAi phenotypes obtained from a control gene set (Fig. S1) we estimate that 81.4% of genes show the 
expected phenotype upon RNAi, whereas 11.6% are false negative. We found 7 % false positive genes 
which is likely based on off-target effects and/or mutagenic effects caused by a hairpin-transgene 
insertion. 
We also tested Hh-independent growth regulatory pathways, such as components of Insulin- and Hippo-
signaling. Depletion of pten, a negative regulator of Insulin signaling, caused enlarged wings in both tester 
conditions without any effect on vein patterning (Fig. 2E,E’). Similarly, targeting merlin, expanded and 
warts also caused increased wing sizes in both tester conditions (Fig. 2F,F’; Fig. S1H-I’); These 
components normally inhibit Hippo signaling, which has emerged as an important repressor of cell 
proliferation and promoter of apoptosis in differentiating epithelial cells (reviewed in Saucedo and Edgar, 
2007; Reddy and Irvine, 2008). In summary, our assay system has the potential to uncover, by RNAi 
mediated depletion, both positive and negative regulators of growth. 
 
Screen results: the yield of the wing size screen 
We screened a total of 11’606 genes (21’014 lines), which represent a coverage of approximately 83% of 
all predicted 14’306 protein-coding genes in Drosophila. RNAi of 3’677 genes (5067 RNAi lines) caused 
alterations of at least one tester phenotype (Fig. 3A). We eliminated 73 precarious genes from our analysis 
(Suppl. Info). We categorized our positive gene set (3’677 genes) into different phenotypic classes (Fig. 
3B), whereas Tab. S2 details the genes associated with distinct phenotypes and distinguishes between 
the two different tester conditions. The hierarchy used for phenotype categorization is described in the 
Suppl. Info. 
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We scored 2’596 genes to affect wing size in at least one tester condition (Fig. 3B; Tab. S2). The main 
class consists of growth activators (1’728 genes), which reduced tester wing sizes upon RNAi mostly in a 
proportional (allometric) manner (Fig. 4D-D’’). RNAi of 412 genes resulted in a round wing phenotype (Fig. 
4E,F). Roundish wings can either result from growth defects predominantly along the wing proximo-distal 
axis (Fig. 4F), or from aberrant cell orientation as observed in mutants with misoriented cell divisions like 
dachsous (Strutt, 2005), and even in the context of overgrowth, as seen in strong Hh/Dpp expressing 
wings (Fig. 4E). From the plain, roundish wings we distinguished an other roundish class for its additional 
dusky and convex-bent wing epithelia based on altered wing hair densities (Fig. 4F’). A last apparently 
small-wing class characterized by lack of wing tissue comprises 86 genes which showed wings marginal 
notches to different extents (Fig. 4D’’’). In addition to small-wing phenotypes we also found growth 
repressors (370 genes), as revealed by wing enlargement upon RNAi (Fig. 4E,E’). 
In addition to growth phenotypes we also observed altered wing morphologies, consisting of three main 
classes: (i) wings with blistered or wrinkled cuticle (115 genes; Figure 4G), (ii) wings with a singed 
appearance (72 genes; Fig. 4G’), and (iii) wings which did not properly unfold (25 genes; Fig. 4G’’’; Suppl. 
Info). Blistered or wrinkled cuticles were frequently associated with a size phenotype (Fig. 4D’’). 
Furthermore, venation- (Fig. 4H) and wing hair defects (Fig. 4H’), including supernumerary or aberrantly 
spaced trichomes, were also mostly associated with size-phenotypes. This is concurrent with the acitivities 
of several signaling pathways during wing development to provide not only growth-, but also patterning 
cues. 
Finally, we observed lethality phenotypes upon RNAi, including necrotic or apoptotic wings (88 genes), 
and lethality at pupal or larval stages (909 genes; Suppl. Info). One cause for the small size of the Cirep 
tester wing is apoptosis, as Caspase-3 is hyperactivated in such wing primordia (Fig.S 2B,B’, compare to 
A,A’). Cirep tester were therefore sensitive to detect pro-apoptotic genes, whereas Ciact wings remained 
unaltered since they do not display apoptosis. Unlike several cell-culture growth screens we identified well 
established pro-apoptotic genes: RNAi of hid and rpr led to a gain of Cirep wing size, and a decrease of 
apoptosis (Fig.S 2C,C’,D). Because the proliferative input of Hh/Dpp signaling is still reduced in these 
conditions, Cirep wing size restoration was not complete. 
 
Enrichment of gene functions required for tissue growth 
As part of an initial assessment of our screen results we determined the classes of our positive gene set 
by using GeneOntology (GO) terms (Ashburner et al., 2000). GO terms provide a controlled vocabulary to 
describe gene and gene product attributes for any organism. Each ontology represents a key concept in 
molecular biology: the molecular function of gene products, their role in multi-step biological processes and 
their localization to cellular compartments. A gene product can therefore be annotated to several GO 
terms. For our analysis we defined a gene as unknown if it was not associated to any GO term or only to 
the ontology Cellular Component, or if its GO term(s) were only inferred from electronic annotation (GO 
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evidence code EA), and not based on “wet lab” experiments. According to this, our screen uncovered 
1’349 unknown genes. 
 
We asked by double-sided statistical tests whether distinct GO terms, i.e. genes with related functions, 
were significantly over- or underrepresented in our screen hits (Tab. S_). In the phenotype classes 
affecting wing size (L,S) we found significant enrichment of several terms expected to be linked to tissue 
growth, such as cell proliferation, cell cycle, growth and cell death. Furthermore we found an enrichment in 
cell-cell-signaling, cytoskeleton organization and anatomical structure morphogenesis, consistent with a 
mitotically active, multicellular tissue. Central cellular processes linked to transcription were strongly 
enriched in the growth phenotype class. However, there was a striking underrepresentation of genes 
annotated for ribosome/translation. Not unexpectedly, such genes scored mainly in the lethal phenotype 
class and were significant enriched here. In sum, the analysis of the GO terms validates our screening 
approach, since we have an enrichment of genes whose GO annotation suggests a role in organ growth. 
Bioinformatic analysis of GO annotations showed that less than __ of the genes we identified had 
previously annotated with biological functions consistent with a function in growth. For the majority of our 
hit genes our data provide a novel functional link to growth regulation. 
In the morphology class of wing blisters we found a prevalence of the GO term anatomical structure 
morphogenesis. A phenotypical hallmark of this class were wings inflated with lymph. Importantly, in the 
blister class _ genes (_%) have human orthologs. A well known example is if (inflated), which encodes an 
integrin normally required for cell adhesion-dependent apposition of dorsal and ventral wing blades. 
Integrin signaling has a strong biological relevance since its disruption is a prerequisite for tumor 
metastasis (reviewed in Yilmaz and Christofori, 2009). if mutant wings have a defective venation causing 
dehydration and blistering. ifRNAi caused strong blistering of the wings in both tester systems, 
phenocopying the mutant alleles. In addition, we also observed wing size reduction along the D/V axis. In 
our RNAi screen we found further yet unknown genes to be required for D/V apposition, and are detailed in 
the Suppl. Info. 
 
Regulators of Drosophila wing morphogenesis are enriched for human orthologs 
The genes identified in our screen are significantly enriched in human orthologs (1’949 genes; 49%) - 13% 
more than expected -, potentially indicating a conserved role of these genes for tissue growth also in 
humans. Among these 50 genes are associated with diseases including cancer (Tab. S3). 6% (225 genes) 
have no human ortholog, but are conserved in mouse, worm or yeast. 45% (1’805 genes) were fly specific 
(Drosophila and Anopheles) with an enrichment of unknown genes (902, including 747 Drosophila-only 
genes) and of genes annotated in chitin metabolism. Among the 1’349 unknown genes were 378 genes 
with human orthologs with an enrichment for GO terms associated with transcriptional regulation. This 
group includes CG6854 and CG16975 which are detailled below. 
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CG6854 is a novel regulator of tissue growth 
We found CG6854 as a novel positive regulator of wing growth. Based on two VDRC RNAi lines 
CG6854RNAi strongly reduced the size of the large wing tester below that of wild-type wings (Fig. 5B). The 
ciact wing became roundish-shaped as a result of wing size reduction predominantly along the proximo-
distal axis. A third RNAi line (NIG-Fly) caused a similar phenotype (not shown). CG6854RNAi expression in 
otherwise wild-type animals led to wings that were reduced along their PD axes, however, with normal 
development of the hinge region (Fig. 5C). Additionally, development of marginal wing bristles was 
disturbed (Fig. 5B,C): long triple-row bristles, specific for the A compartment, appear also on the posterior 
margin, and the most distal point lacks wing hairs, reminiscent of mild notches. Expression of CG6854RNAi 
in the eye primordium also caused a severe size reduction (Fig. 5D). CG6854RNAi expressing clones were 
indistinguishable from wild-type clones in late 3rd instar wing imaginal discs, but nevertheless gave rise to 
adult wing phenotypes initially described (Fig. S_). To find out the spatio-temporal requirement of CG6854 
we activated CG6854RNAi during different larval stages in cell clones and analyzed them in adult wings. To 
visualize adult clones we co-expressed forkedRNAi (Fig. S_). We found that CG6854 is predominantly 
required in the wing marginal region and more distal wing pouch regions (Fig. S_), but not in the proximal 
wing pouch or wing hinge region (Fig. S_). 
We also observed wing size reduction in a background with hyperactivated Hh/Dpp signaling generated by 
constitutive activity of Smoothened, which causes wing size expansion and ectopic anterior veins (Fig. 5F): 
CG6854RNAi reduced wing extension along the PD axis, but did not alter the Hh-dependent vein defects. In 
a nub::lgs17E- or nub::fringe- background, where reduced Wg- or Notch-signaling, respectively, cause PD 
axis reduction based on tissue loss from the wing margins (“notches”), CG6854RNAi enhanced the wing 
margin defect (Fig. 5G,H, and not shown). A cell culture-based RNAi study had suggested CG6854 could 
play a positive role in Dpp signaling (Xu et al., 2007). We were curious if this function could account for the 
phenotypes we had observed. In disagreement with a positive role in Dpp signaling, CG6854 knockdown 
did not up-regulate brk-lacZ expression (Fig. 5I), which is normally a hallmark of decreased Dpp signaling 
(Jazwinska et al., 1999; Minami et al., 1999). Moreover, reporters of Hh/Dpp signaling, like hh-lacZ, ptc-
lacZ, dpp-lacZ, pMAD or Sal, were not affected (not shown). The wing margin phenotype suggests an 
interference with signaling pathways required at the distal wing pouch region. However, protein expression 
at the D/V border required for proximo-distal signaling and growth, like that of Wg and its targets Sens and 
Vg, or the Notch-signaling target Cut were not affected in wing primordia expressing CG6854RNAi (not 
shown). Solely the Notch-signaling reporter m8-lacZ was infrequently and slightly reduced (not shown). 
Wing size reduction upon CG6854 depletion is not due to elevated apoptosis, since the level of activated 
terminal Caspase-3 expression was comparable to control discs (Fig. 5J). In agreement with this finding, 
the decreased growth phenotype in the wing and the eye could not be ameliorated by co-expression of 
apoptosis antagonists (not shown). Normal phospho-Histone H3 levels in the wing primordium suggest 
that cell division (M-phase) was not affected upon CG6854RNAi (Fig. 5K). Transition from G1- to S-phase is 
another important checkpoint during the cell cycle: we found that EdU incorporation during DNA replication 
(S-phase) was significantly reduced in wing imaginal discs expressing CG6854RNAi (Fig. 5L). Consistent 
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with this, hh>CG6854RNAi expression in the P-compartment of imaginal wing discs did cause a 
compartmental difference of trichome distances in adult wings (not shown). Co-overexpression of cell 
cycle components CycD/Cdk4 which curb the G1/S transition could ameliorate the nub>CG6854RNAi wing 
phenotype (Fig. 5S), whereas overexpression of String (G2-M transition) had nearly no effect (not shown). 
Activation of Hippo signaling which normally causes tissue overgrowth by repression of apoptosis and 
enhanced mitoses was not able to enlarge the size of CG6854RNAi-expressing wings (Fig. 5O-R).  Curbing 
mitotic cycles could therefore not rescue or ameliorate the wing size deficit observed in wings whick lack 
CG6854 function. Wing size reduction upon CG6854RNAi is therefore based on impaired cell size, and is 
independent of mitosis and apoptosis. 
CG6854 is conserved from yeast to humans, and encodes three isoforms implicated in transcriptional 
regulation (Fig. S7): one protein A-isoform with MADF/BESS DNA binding domains, and two highly similar 
B- and C-isoforms which encode a domain similar to a CTPase. All CG6854 RNAi lines targeted the B/C-
isoforms. Overexpression of the CDS encoding the longest C-isoform did not cause any phenotype in the 
wild-type wing, but could rescue the wing RNAi phenotype completely (data not shown). We showed that 
the putative CTPase form of CG6854 is required for cellular growth, and is specifically required for 
proximo-distal wing growth. It was previously suggested that Notch signaling cannot solely be integrated 
by the activity of its nuclear transducer Su(H), but must involve other transcriptional regulators (Cooper, 
2000).  Based on the Notch-reporter analysis CG6854 might act as a co-regulator of some aspects of 
Notch signaling. 
 
CG16975/sfmbt is a transcriptional repressor of Wg signaling 
We found sfmbt in our wing size RNAi screen based on the phenotype “convex-roundish-dusky” which 
resembled a Wg-signaling gain-of-function. Sfmbt remained undetected in cell-based RNAi screens 
focusing on growth or Wg signaling. The effect of two RNAi lines from the VDRC could be recapitulated by 
our three costum-made, oligo-nucleotide-based RNAi lines. Overexpression of sfmbt-CDS rescued the 
sfmbt RNAi phentoype. RNAi of sfmbt shows genetic interaction with Wg signaling and caused ectopic 
activation of Wg-target gene expression (Fig. 6). Because Ubx is ectopically activated by sfmbt RNAi in the 
wing primordium (Fig. 6; sfmbt mutant: Hox gene silencing by Sfmbt: Klymenko et al., 2006), we 
expressed ubx RNAi (TRIP and VDRC lines) to see whether the observed phenotype is due to ectopic 
Ubx. However, knockdown of ubx only partially restored the sfmbt RNAi wing phenotypes (not shown), 
indicating that ectopic Wg target expression can be disentangled from ectopic Ubx function. Sfmbt is the 
Drosophila ortholog of a Polycomb-protein-component of a chromatin-regulating complex which conveys 
transcriptional repression to SUMOylated proteins (Stielow et al., 2008). SUMOylation was previously 
found to regulate LEF1/TCF, a nuclear effector of mammalian Wnt signaling (Sachdev et al., 2001; 
Yamamoto et al., 2003). Wnt/Wg signaling is also regulated by another chromatin-regulating complex: the 
HDAC activity of the NuRD/Hyrax/Paf1 complex, which mediates transcriptional repression, different from 
the SUMO complex. hyrax was previously shown to act as a positive regulator of Wg- and Hh-signaling in 
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the wing primordium (Mosimann et al., 2006, 2007). dSfmbt and Scm interact synergistically to maintain 
Polycomb target gene repression (Grimm et al., 2009: Abd-B and En are ectopically expressed only if both 
Sfmbt and Scm are lost; Oktaba et al., 2008: en is misexpressed in many dSfmbt mutant clones; Dll 
expression is lost in Scm single mutant clone (our sfmb RNAi experiments: Abd-A-lacZ and Abd-B-lacZ: no 
ectopic expression). 
 
Comparison of the in vivo wing growth screen to cell culture based RNAi screens 
Exclusiveness & overlap (GO enrichments and depletions): wing screen vs. cell culture growth 
screens (9 Drosophila +/- 1 Human) 
In recent years many large scale RNAi studies have been undertaken in vitro – in cultured Drosophila cell 
lines - to analyse cell cycle, cell growth and cell survival (reviewed in Cully and Leevers, 2006; Pollard, 
2003). Since our screen addressed some of the same processes but in an in vivo context we were 
interested in systematically comparing our results (Fig. S5, blue circle) with a selection of nine RNAi 
screens focused on cell-cycle/-growth associated phenotypes, which were based on FACS- and imaging-
supported cell culture RNAi assays (Venn-Diagram Fig. S5, red circle; Björklund et al., 2006; Boutros et 
al., 2004; Bettencourt-Dias et al., 2004, Kiger et al., 2003; Eggert et al., 2004; Echard et al., 2007; 
Goshima et al., 2007; Yu et al., 2007; Lu et al., 2007). Clearly, the comparison is somewhat arbitrary since 
it is based on screens with different read-outs and with different “cut-offs” for genes defined as hits, 
influencing the degree of overlap. In any case, from our total positive gene set (3’979, including off targets) 
we found 471 genes in common with the growth-based culture screens (939 genes). The overlap included 
mostly known genes, and only 6.7% (32) unknown genes. In contrast, the fraction uniquely found in our 
screen is highly enriched for unknown genes (37.5% or 1’317 genes). Notably, most genes of this unique 
wing fraction were conserved during evolution up to higher vertebrates. We were interested to see if we 
could further distinguish the ‘uniquely-wing’ from ‘uniquely-culture’ based gene sets. 
 
Genes only found in our screen are enriched for GO terms linked to lipid metabolism, whereas culture 
based screens show no such enrichment (Tab. S4). One example to explain this finding might be Hh 
signaling itself, because the activity of Hh depends on a direct dual lipidation, and our tester systems are 
sensitive to factors which modulate the strength of the Hh signal. Since the Hh protein is lipidated by a 
palmitoyl and cholesterol moiety, depleting factors involved in lipid/cholesterol absorption likely affect the 
ciact tester. An example of a gene we identified in this class was NPC1b. NPC1bRNAi significantly reduced 
the large wing but not in the small wing tester. So far, no mutant phenotype is available for NPC1. The 
NPC1 family of proteins plays crucial roles in the intestinal absorption and intracellular trafficking of sterols. 
Another significantly enriched functional class concerns carbohydrate metabolism. The functions of many 
extracellular proteins, including those of HSPGs, rely on sugar modifications. ECM molecules often have 
auxiliary functions in signaling and are likely functionally redundant, therefore knockdown of such 
components does not always lead to a strong phenotype, if at all. This is particularly the case in cell 
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culture RNAi screens based on autocrine signaling, since ECM components are required for cell-to-cell 
signaling, e.g. for the establishment of morphogen gradients. Likewise, a RNAi phenotype of well known 
carbohydrate ECM components such as boi, botv, iHog, dally or dlp which scored positive in our in vivo 
screen (Tab. S1, Tab. S2), remained largely undetected in most in cell culture screen. Components of the 
chitin metabolism also belong to the carboyhydrate metabolism class. Two examples of genes involved in 
chitin metabolism are CG5883RNAi and CG7017RNAi caused wrinkled wing epithelia as well as reduced wing 
sizes. No mutant phenotype has so far been reported for these genes, however, CG5883 RNAi led to 
impaired secretory activity of S2 cells (Bard et al., 2007). A chitin-based extracellular matrix not only 
stabilizes the exoskeleton but might also play a role in growth (Kawamura at el., 1996). Likewise, the 
secreted ZP (Zona pellucida) proteins Miniature and Dusky link the ECM with the cytoskeleton and are 
required for proper wing growth (Roch et al., 2003). A third, highly enriched GO term of genes only found 
in our screen is transmembrane transporter/receptor activity. Although not statistically enriched, our screen 
detected more frequently genes encoding components of the cytoskeleton. For example, RNAi against 
genes encoding intracellular adaptors of the cytoskeleton like wasp, zyxin or chi reduced the tester wing 
sizes, but did not score in cell culture based screens. 
 
Of emerging biological interest are kinases and phosphatases. They are complementary regulators of 
protein activity and comprise a relatively large protein class within the proteome. Phosophorylation is a 
fundamental strategy used by eukaryotic organisms to regulate a host of biological functions, including 
DNA replication, cell cycle progression, energy metabolism, and cell growth and differentiation. Many 
human tumors carry genetic alterations in at least one phosphatase or kinase gene (Futreal et al., 2005; 
Greenman et al., 2007). 236 kinases and 84 phosphatases are predicted in the Drosophila protein set 
(kinase.com; Morrison et al., 2000). 200 kinases and 78 phosphatases were represented in the RNAi 
library. Our screen identified 76 kinases and 26 phosphatases as regulating growth. Kinases are central to 
Hh signaling. For example, Pka-C1 negatively or positively influences Hh signaling, depending on the dose 
(Zhou et al., 2006). RNAi against Pka-C1 reduced size in both wing conditions. Our screen results share 
56 kinases and 16 phosphatases with different culture based RNAi screens mentioned above, including 
one focusing only on kinases (Bettencourt-Dias et al., 2004), supporting the notion that kinases can also 
be involved in the crosstalk of different signaling pathways (Cully et al., 2006; Katz et al., 2007). 21 
kinases and 19 phosphatases were found only by our wing screen. 
 
We scored the highly conserved gene CG3534, which encodes a putative carbohydrate kinase, as a 
growth repressor: CG3534RNAi caused variable enlargement of small cirep wings, although predominantly 
along their PD axes, and blistering of large ciact wings. No mutant allele or RNAi phenotype had previously 
been reported for this kinase. A further promising example is the tumor suppressor ASPP, which regulates 
C-terminal Src kinase activity (Langton et al., 2007): ASPPRNAi caused enlarged wings in both of our tester 
conditions. It has not been described in cell culture RNAi screens. A similar phenotype (enlargement in 
ciact wings) was also seen for CG3216, an unknown gene which encodes a putative GPCR-coupled 
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kinase. In cultured fly cells its depletion led to aberrant mitosis (Bettencourt-Dias et al., 2004); no 
phenotype based on a mutant allele is currently reported. Consistent with our observations that it is a 
putative growth repressor CG3216 is homologous to the human Atrial natriuretic peptide receptor, which 
inhibits cell proliferation (Kong et al., 2008). As a positive growth regulator we found lal/AuroraB kinase, 
whose knock-down caused wing size reduction in the ciact condition (pupal death in cirep wings). No mutant 
allele is available so far; however, RNAi in cultured cells caused cell number decrease in the G1 phase 
and a cell number increase in the G2 phase of the cell cycle (Björklund et al., 2006), supporting the 
aberrant cytokinesis phenotypes observed in previous RNAi studies (Lange et al., 2002; Giet and Glover, 
2001). We found mts (microtubule star), which encodes the PP2A subunit of a phosphatase complex, as a 
suppressor of the large ciact tester wing. PP2A is required for cell polarity/adhesion, ommatidial 
differentiation, mitotic spindle organisation and cell proliferation (Dombradi et al., 1990; Kiger et al., 2003; 
Eggert et al., 2004). RNAi in Drosophila tissue culture revealed a positive function in Hh signaling 
(Nybakken et al., 2005; G.H. and K.B., unpubl.), supported in vivo by a smo mutant modifier screen 
(Casso et al., 2008).  
 
Pooling all results of the cell-based RNAi screens and comparing this with our screen generates a set of 
__ genes that potentially regulate cell growth / imaginal disc growth (Fig. S5). This leaves __ genes 
uniquely identified in our screen. The overlap, however, among the cell-culture screens (__ genes) or the 
total overlap together with our in vivo screen (__ genes) is not very extensive, and unknown genes are 
underrepresented: we addressed only 83% of the genome as compared to culture based screens, which 
addressed altogether the entire genome. The occurrence of false negative results might be higher in our 
wing screen based on the nature of the RNAi source: i) P-element transgenes are affected by genomic 
position effects, ii) a gene was often addressed only by one RNAi line, and iii) on average 300 nucleotides 
of the coding region was used for VDRC siRNA design, whereas RNAi of cell culture screens often 
targeted larger parts and at least 2 independent regions of the coding sequence (www.flyrnai.org, 
www.genomernai.org). In culture based screens, cellular growth on one hand, and signaling cascades on 
the other hand have been addressed by functional readouts primarily based on the analysis of individual 
cells. The mostly cell autonomous read-outs did not allow the detection of components normally required 
for a multicellular tissue to interact at the cellular level and to grow. Genes may also encode proteins 
whose function are required at the interface of two or more pathways or whose function are only needed 
for organ growth. In contrast, our in vivo screen targets tissue growth and patterning at the same time.  
 
Why an in in vivo screen is superior: cell-to-cell signaling is central to intact organ growth 
One important advantage of our in vivo growth screen over cell-based screens is the detection of tumor 
suppressor gene functions. An example how a TSG’s function is coupled to tissue growth regulators is the 
ubiquitin ligase Hyperplastic discs (Hyd), which negatively regulates hh and dpp expression by 
independent mechanisms and also impacts on the stability of Ci (Lee et al., 2002). We scored hydRNAi as 
giving severely blistered wings in the ciact condition (Fig. S1 J). Furthermore, components of the Insulin- or 
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Hippo (Hpo) signaling pathways, which were readily detected in both of our wing conditions, remained 
largely undetected in cell culture-based RNAi screens. Discovered initially in Drosophila, the Hpo pathway 
has emerged as an important conserved signaling pathway that controls organ size during development by 
restricting cell growth and proliferation and by promoting apoptosis (Harvey et al., 2003). Abnormal activity 
the Hpo pathway has been implicated in human cancer (Harvey and Tapon, 2007). Of the 10 established 
components of this pathway we found 7 (ex, mer, ds, d, ft, sav and wts (Fig. 2, Fig. S1, Tab. S1). RNAi 
against growth restricting components of the pathway varied in effects: depletion of mer, warts and 
expanded caused enlargement of wings in both testers; in contrast, targeting the atypical cadherins 
encoded by fat and dachsous caused enlargement only in the small wing tester. In the large-wing tester 
depletion of these gene functions caused predominantly epithelial blistering and more folds, or necrosis, 
respectively. Of note, our screen set-up did not allow us to test for overgrowth effects observed in systemic 
TSG mutants that are based on a developmental extension of the larval period (Bilder, 2004), since nub-
Gal4 is not active in the entire animal. 
 
An important control function for the integration of different pathway activities is exerted by the ESCRT 
machinery (endosomal sorting complex required for transport), which mediates sorting of ubiquitinated 
membrane proteins, like ligand-activated receptor tyrosine kinases, into the intraluminal vesicles of 
multivesicular endosomes, thereby targeting them for lysosomal degradation in lysosomes. Clonal loss of 
dTsg101/erupted/vps23 or vps25, which encode components of the ESCRT I and II complex, lead to 
overgrowth involving the activation of the Notch- and the Jak/Stat pathways, caused by impaired 
downregulation of the Notch receptor (Moberg et al., 2005; Thompson et al., 2005).  
 
Wing growth is repressed by CG14542/vps2  
We found the highly conserved gene CG14542/vps2 to act as a negative and novel regulator of wing 
growth. CG14542RNAi caused significant enlargement in the small wing condition (Fig. 7B,C), and pupal 
lethality in the ciact as well as in the wild type background, and it also caused enlarged eyes (not shown; 
Fig. 7J, Fig. S6). Milder ubiquitous CG14542RNAi expression in the wing primordium resulted in overgrown 
wings with thickened veins (Fig. 7D,E; Fig. S6). As a similar effect is also observed upon increased 
CG14542 expression (Fig. 7R  into Supplement), it is likely that CG14542 acts in a dominant negative 
manner when over-expressed. Normal spacing of adult wing blade trichomes and elevated string mRNA 
levels in CG14542RNAi wing primordia (Fig. S6; not shown) suggest that CG14542 controls cell number, but 
not cell size. We also observed sensory organ defects indicative of reduced Wg/Notch signaling or 
elevated Hh signaling (Fig. S6). To test the hyperproliferative behavior we made use of Minute+/- clones, 
which would normally under-grow and die (Morata et al., 1975). Minute+/- clones were rescued and even 
over-grew by activating pro-growth pathways like Hh/Dpp signaling within such clones (not shown). 
Unexpectedly, Minute+/- clones could not be rescued by CG14542RNAi within such clones, and were even 
more rapidly lost from the wing primordium (not shown). When clones of CG14542RNAi were generated in 
the wild-type background, we observed roundish-shaped clones with pyknotic, dying cells indicating cell 
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death. Terminal caspase-3 activation, a prerequisite for apoptosis, was highly activated in CG14542RNAi 
clones (Fig. 7K,K’, close-up of a pouch clone). Clones died when they are located within the wing pouch, 
but they round up and overgrow outside of the pouch (Fig. 7L). We found several pro-growth signaling 
pathways activated in clones inside (dying) and clones outside (overgrowing) of the wing pouch: pMad, the 
nuclear transducer of Dpp signaling and its target gene sal (Fig. 7N, Fig. S6A, and not shown), Wg (Fig. 
7O), and Upd, a Notch target gene which encodes the ligand of Jak/Stat signaling (not shown). Consistent 
with the upregulation of these pro-growth cues, global over-expression of CG14542RNAi led to enhanced 
phospho-Histone expression (Fig. 7P). However, signaling pathways upregulated in the clonal condition 
were mostly unaltered in wings globally expressing CG14542RNAi, and pMad domains were distorted, likely 
due to the strong folding of the overgrown wing disc (Fig. S6B; Ptc, Upd: not shown). Among all tested 
markers we only found Wg epression altered. The ring of Wg expression that coincides with the most 
proximal wing and the most distal hinge region was extended (Fig. 7Q-Q’’), and nkd, a Wg target, was 
upregulated as assessed by quantitative RT-PCR (not shown). Strong and expanded Wg expression was 
already apparent during early L3 stages, where normally ring expression is only faintly occurring in a slim 
ring. Of note, 30A-Gal4 driven expression of CG14542RNAi in the ring domain could recapitulate the 
overgrowth effect (not shown). In contrast, Wg expression at the D/V border was not altered, and Vg 
expression, which requires Wg D/V expression, was also normal (not shown). Initiation of Wg ring 
expression normally requires the confrontation of Vg-positive (pouch) versus Vg negative (hinge) tissue, 
whereas el and noc repress Wg ring expression (Weihe et al., 2004). (wg transcription / wg-lacZ 
affected?). 
 
We associate the overgrowth effect of global CG14542 knockdown, which is predominantly enhanced 
along the distal-proximal direction (Fig. 7P,Q,Q’), with elevated Wg ring expression at the interface of the 
wing pouch/hinge region. Ablation of Wg ring expression in spade mutants causes reduced wing size 
predominantly along the PD direction (Tiong and Nash, 1990; Couso et al., 1994). The cause for 
deregulated proximo-distal growth in the global knockdown likely differs from local overgrowth and 
upregulation of several growth factors in the clonal scenario. In the latter case, regions outside the pouch 
are competent for overgrowth, whereas potentially overgrowing clones within the pouch are counteracted 
by simultaneous autonomous activation of apoptosis. Understanding the cause for the selective 
competence of potentially overgrowing tissue requires further investigation. CG14542 plays a putative role 
in protein transport in the ESCRT III subcomplex of the ESCRT/Vps machinery based on electronic 
annotation. Previously, a CG14542 MENE mutant (mutant eye disc no eclosion) was reported to cause 
pupal death (Menut et al., 2007) and intracellular Notch accumulation in eye disc clones, reminiscent of 
other ESCRT components (Vaccari et al., 2009). However, the previous studies were limited to clonal 
assays due to systemic lethality. In contrast, we could show an additional and, likely, alternative way for 
CG14542/Vps2 to elicit overgrowth upon RNAi in a non-clonal condition. Further, the protein interaction 
database STRING reveals an interaction with Chmp1/CG4108, which we also scored as a negative growth 
regulator in our screen (Fig. S7). Similar to the depletion of CG14542, Chmp1RNAi enhanced the cirep wing 
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size. No mutant phenotype is known of Chmp1, and neither CG14542 nor Chmp1 scored positive in any 
cell culture RNAi screen focusing on cell cycle or signaling pathways. 
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Conclusion 
Our search for growth regulators exemplifies the application of functional genomics in developmental 
biology. We interrogated the genome of D. melanogaster by transgenic RNAi by performing an in vivo 
RNAi screen which allowed us to generate an extensive catalogue of genes required for tissue specific 
growth regulation. The inducible system used in our RNAi screen further allowed to detect gene functions 
which would have remained uncovered by classical mutagenesis due to early developmental lethality. The 
screen recovered most of the predicted genes required for growth and related processes. Importantly, our 
study identified novel regulators of growth and morphology of the Drosophila wing epithelium. By 
monitoring growth within an entire organ analysis of the candidates will help us to understand in future how 
growth control of a complex tissue is achieved. We identified 2’596 genes (incl. off-target prone genes) of 
as being involved in growth control, including 1’349 genes with previously unascribed function. 
Furthermore, genes with human orthologs are significantly enriched. The analysis of CG6854/CTPsyn, 
CG16975/sfmbt and CG14542/vps2 indicate how our tissue specific in vivo RNAi study complements cell 
culture-based screens which looked at individual cells and reporter-based detection of signaling activities 
uncoupled from entire organs, thereby often fail to detect certain gene function requirements. In ongoing 
and future studies on candidates from our screen we aim to uncover how morphogenetic pathways 
connect ultimately to components of the cell cycle machinery. An important additional step will be to 
determine how orthologs of the components identified here link to molecular pathways of higher 
vertebrates, and thereby further our understanding of diseases caused by deregulated growth. 
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Figure Legends 
 
Figure 1. The experimental setup of the growth RNAi screen 
Two different forms of Ci, the transcriptional mediator of Hh signaling, were used to generate the tester fly 
strains: cirep acts as a transcriptional repressor of Hh-dependent target genes, ciact is a constitutive 
activator of Hh-dependent target expression like ptc or dpp. Increase or decrease of Hh signaling in the 
wings of the two different tester strains leads to stereotyped size alterations and vein abnormalities. The 
VDRC RNAi library was assayed with a large-wing (ciact) and a small-wing (cirep) tester fly strain. nub-Gal4 
activates expression of the RNAi transgenes in the larval wing pouch, which develops into the adult wing 
(orange oval). The adult F1 progeny was scored for suppression or enhancement of tester wing sizes and 
for alterations of epithelial wing morphology. 
Figure 2. Efficient depletion of gene function required during wing development 
(A) Wild-type wing. (B) ciact tester wing. (B’) cirep tester wing. (C) smoRNAi suppress the ciact and (C’) 
enhances the cirep phenotype. (D) ciRNAi reduces ciact wings, and (D’) only slightly affects cirep wings. (E,E’) 
ptenRNAi enlarges ciact and cirep wings without altering the Hh signaling dependent patterning defects. (F,F’) 
merRNAi strongly enlarges ciact and cirep wings, accompanied by severe folding of the wing cuticle. 
Figure 3. Results overview of the RNAi screen 
(A) A total of 11’606 (11’466 genes) Drosophila protein coding genes, addressed by 21’014 (21’206) RNAi 
lines, was analyzed. RNAi of 3.979 genes led to an adult wing phenotype, including 654 off target-prone 
genes (hatched segment). (B) Main phenotype classes found in the screen are alterations of wing size 
(S/smaller wings, L/larger wings, R/roundish wings), morphology and lethality (hatched segments and grey 
numbers: off target-prone genes). 
Figure 4. Classes of predominant wing phenotypes scored in the RNAi screen 
(A) Wild-type wing. (B) ciact tester wing. (B’) cirep tester wing. (D-D’’’) Different strengths in size reduction of 
ciact tester wings upon RNAi against different genes. (E,E’) Wing size enlargement upon RNAi against two 
different genes. (F,F’) Round shaped wing phenotypes primarily based on reduction along the proximo-
distal axis. (G,G’) Wing blistering in ciact wings. The dusky wing surface (G) indicates an aberrantly dense 
trachoma formation. (G’’) Impaired wing unfolding. (H) Vein reduction in ciact. (H’) Wing trichoma defect in 
ciact accompanied by size reduction and broadened veins. 
Figure 5. CG6854 is a novel gene required for proximo-distal wing growth 
(A) Wild-type wing. (B) CG6854RNAi causes significant size reduction of ciact tester wings, predominantly 
along the PD axis. (C) CG6854RNAi causes a less strong size defect in the wild-type background. (D) Eye 
size reduction upon CG6854RNAi (left inset) in comparison to a control eye (right inset). (E,F) PD shortening 
upon CG6854RNAi is apparent in sal::smoI wings. (G,H) CG6854RNAi does not cause further PD shortening 
or enhancement of notches in sal::lgs17E wings. (I) brk reporter gene expression is upregulated upon 
CG6854RNAi (left inset). (J) m8 reporter expression is lost in the posterior wing discs compartment upon 
expression of CG6854RNAi by hh-Gal4 in the posterior wing compartment. (K) pHis expression is reduced 
by CG6854RNAi expression in the wing pouch (left inset, compare to non-pouch regions with normal pHis 
expression). 
Figure 6. sfmbt is a repressor of Wg signaling 
 
Figure 7. CG14542 is a novel tumor suppressor 
(A) Wild-type wing. (B,C) CG14542RNAi causes enlargement of cirep tester wings. (D) Ubiquitous expression 
of CG14542RNAi leads to allometrical overgrowth of wild-type wings, and furthermore to blistering and 
broadened veins at higher expressivity (E). (F) Enlargement of the eye upon CG14542RNAi. (G) Broadened 
L3 vein (upper inset) and (H) loss of chemosensory bristles (upper inset) upon CG14542RNAi. (I,I’) 
Campaniform sensillae are supernumerous along LV3 (I) and ectopic along the anterior wing margin (I’). 
(J) CG14542RNAi expression in the entire wing primordium results in a strongly overgrown L3 wing disc. (K) 
CG14542RNAi expression in wing clones causes pyknotic cells. (K,K’) Close up of a wing pouch clone 
shows caspase activation in CG14542RNAi expressing cells. (L) Clones round up and overgrow outside of 
the wing pouch, whereas clones grow normally within and outside the wing pouch in control wing discs 
(M). (N) Upregulation of pMad and (O) Wg in CG14542RNAi expressing clones. (P) Phospho-Histone 
expression is enhanced upon CG14542RNAi expression in the entire wing primordium, as compared to 
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control wing discs of the same stage (P’). (Q) Expression of Wg is expanded in the inner ring of the wing 
primordium. (Q’’) Wg expression in a wild-type wing primordium. (R) Overexpression of CG14542 cds 
causes a likely dominant-negative effect, resulting in wing notches and slightly thickened veins.  
Supplementary Figures 
Figure S1. Efficient knockdown of known genes required for wing growth 
(A) Wild-type wing. (B) ciact tester wing. (B’) cirep tester wing. (C-F’) Knockdown of genes required for Dpp 
signaling like mad (C,C’), med (D,D’), put (E,E’) and tkv (F,F’) cause wing size reduction of both tester 
conditions. (G-J) RNAi of known tumor suppressor-like genes like brk (G,G’), warts (H,H’), ex (I,I’) lead to 
enlarged wing sizes in both tester conditions. (J) hydRNAi causes strong blistering in the ciact condition. 
Figure S2. RNAi of pro-apoptotic genes 
(A) Wild-type wing. (B) Expression of activated caspase in a wild-type wing primordium. (B) cirep tester 
wing. (B’) Caspase activation is strongly enhanced in a cirep tester wing primordium. (C) hidRNAi or (D) 
rprRNAi can partially restore wing size. (C’) Caspase activation is suppressed in imaginal discs upon 
expression of hidRNAi. (B-D) nub-Gal4 was used for transgene expression. 
Figure S3. Enrichment/depletion analysis of wing RNAi screen hits 
Enrichment/depletion of (A) all hits and phenotypes and (B) phenotype-subclasses “larger” and “smaller”. 
Figure S4. ric8a is required for proper dorso-ventral wing adhesion 
(A) Wild-type wing. (A’) ciact tester wing. (B,B’) The primary screen phenotype of ric8a knockdown in the 
wing primordium. (C-F’) Knockdown of ric8a by three independent oligo-based RNAi transgenes. (E,E’) A 
mutant oligo does not cause a phenotype. (G,H) Expression of ric8aRNAi in the dorsal wing primordium 
suppresses the Myc-dependent down-bending of the dorsal wing blade, and even reduces wing size, but 
enhances the failure of the dorsal and ventral wing blade apposition. (H’) Accumulation of cells between 
the dorsal and ventral wing blade. 
Figure S5. Comparison of the wing RNAi screen with cell culture RNAi screens  
Blue circle: all hits from our wing RNAi screen. Red circle: the cell culture RNAi screen family „cell 
cycle/cell growth“ (including hits of 9 RNAi screens). Green circle: screen family „signaling pathways“ 
(including hits of 10 RNAi screens). 
Figure S6. Supplementary data to CG14542 
Chemosensory bristles normally associated with L1 at the dorsal wing blade margin were lost upon RNAi 
(Fig. 7H). Three campaniform sensillae which normally form along L3 appear supernumary along L3 and 
L1 (Fig. 7I,I’). CG14542RNAi expression in the notum also led to loss of thoracic sensory bristles (not 
shown). 
(A) pMad expression is upregulated and ectopically activated in CG14542RNAi expressing clones. (B) pMad 
expression domains are distorted in a CG14542RNAi expressing wing primordium. 
Figure S7. Protein interactions of Ric8a, CG15652 and CG6854 
Protein networks are based on STRING. 
 
Figure S_. CG11286 is required for Notch/Wg signaling 
(A) Wild-type wing. (B) ciact tester wing. (C) cirep tester wing. (D-F) CG11296RNAi causes notched wings and 
broadened veins in the wild-type and the tester wings. (G-I) The wing margin notch phenotype is strongly 
enhanced in a sal::lgs17E background. (J,J’) Expression of the Notch signaling target genes m8 (J) and cut 
(J’) is lost upon expression of CG11296RNAi in the posterior wing primordium by hh-Gal4, whereas gene 
expression in the anterior (control) compartment devoid of RNAi is not affected. Such wing primordia result 
in adult wings where a comprehensive notch removed most of the posterior compartment (K). (L-M’’) 
Expression of Cut (L-L’’) and Sens (M-M’’) require CG11286 in a cell-autonomous way.  
 
 
Supplementary Tables 
Table S1. RNAi wing phenotypes of known components and signaling pathways 
Table S2. Genes and their wing phenotypes in the two tester conditions 
A color code at the end of each list denotes the strength of the phenotype. 
(A) Genes that scored in the S class (tester wing size smaller) 
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(B) Genes that scored in the L class (tester wing size enlarged) 
(C) Genes that scored in the R class (tester wing rounded) 
(D) Genes that a bivalent RNAi phenotype (both tester systems suppressed) 
(E) Genes of the ambiguous class (different RNAi lines of a gene led to opposite wing size phenotypes) 
(F) Genes that scored in the M class (tester wing sizes are not altered, but display an altered morphology, 
for example blistered wing epithelia) 
(G) Genes that scored in the death class, including the lethal class (larval or pupal death in both tester 
conditions), the partial lethal class (larval or pupal death in only one tester condition), and the necrotic 
class (predominant necrosis in both tester wing conditions) 
Table S3. Wing RNAi hits with human disease orthologs 
Table S4. GOstat enrichments (biological process, molecular function) 
Comparison of the wing RNAi gene set with the hits of the cell culture RNAi screen family „cell cycle/cell 
growth“ (including hits of 9 RNAi screens). 
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Material and Methods 
In vivo knockdown of gene function by RNAi 
The library of transgenic UAS-RNAi fly lines was provided by the Vienna Drosophila RNAi Center (VDRC, 
Vienna; www.vdrc.at; Dietzl et al., 2007). „Hairpin RNA“ expression was based on the Gal4/UAS system 
(Brand and Perrimon, 1993). 21’206 VDRC RNAi lines were available to carry out our screen, which we 
could map to 11.466 genes (Flybase release ___ of the Drosophila melanogaster genome), including ___ 
“manually mapped” genes which could not be mapped by computational means. At present there are 
14.306 putative protein-coding genes in Drosophila melanogaster (i) FlyBase annotated: 14’141 genes 
and ii) 165 „hand-mapped“ genes, which have only an FBgn identifier, but no CG number and no 
cytological map position. 
Tester fly lines for the modifier screen: two conditions for RNA interference 
For the screen we generated two genetically modified tester strains that are based on Hh-signaling either 
below or above the normal level (Figure 1). Genotype of the tester fly lines: (i) small wing tester: nub-
Gal4/CyO^UAS-cirep/Tm6b; (ii) large wing tester: nub-Gal4, UAS-ciact/CyO. Sensitivity of cells to levels of 
Hh, and consequently Dpp, is reflected by the extent of the intervein regions, the vein pattern and by the 
wing growth. To create two opposing levels of Hh-signaling, we manipulated endogenous functions of Ci 
(Cubitus interruptus), the transcriptional effector of Hh signaling (Slusarski et al., 1995), by misexpression 
of Ci-transgenes in wild-type wing primordia. The overexpression of Cicell (= Cirep), a dominant repressor 
form of Ci (Methot and Basler, 1999), prevents Hh signaling. Consequently, Dpp signaling is impaired, 
which eventually results in small-wing phenotypes with anterior vein fusions and partial vein loss. The 
expression of Cipka4 in the other tester strain (= Ciact) results in constitutive transcriptional activation of Hh 
target genes including dpp (Methot and Basler, 2000). Consequently, Dpp signaling is hyperactivated, 
causing a large-wing phenotype. Here, wing veins are mostly affected in the anterior compartment, with 
enlargement of intervein regions L2/L3. In summary, due to moderate Ci-transgene activities each wing 
condition lent itself to size-modification into both directions, i.e. size enhancement or reduction. A pilot 
screen preceding the actual large-scale screen tested 160 UAS-RNAi lines in combination with several 
wing- and semi-wing-specific Gal4-driver lines, including scalloped-Gal4, MS1096-Gal4 or vestigial-Gal4 
(BDSC, Bloomington Drosophila Stock Center). We eventually chose nubbin-Gal4 (a gift from the lab of G. 
Morata; Calleja et al., 1996), since it combined appropriate activity, specificity and less general lethality 
than other Gal4 sources.  
Fly crossing scheme for the RNAi screen 
2-3 female virgin flies of each of the two tester strains were crossed to 1-2 males per UAS-RNAi fly line 
(21’206 RNAi fly lines in total) and kept at 26°C. Standard size plastic food tubes with yeast and nipagin 
were used for the fly crosses. 
Wing phenotype analysis upon RNAi knockdown 
14 days after setting up the crosses, the F1 generation was analyzed for phenotypical alterations of the 
wings with a standard stereomicroscope. RNAi based alterations of tester wing phenotypes (i.e., wing size 
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or morphology) were compared with unaltered tester wing phenotypes and scored in a semiquantitative 
and descriptive way (Table S2). Adult wings were flat mounted in Euparal and were photographed with a 
Zeiss camera adjusted to a Zeiss microscope (Zeiss AxioCam, Zeiss Axioplan). If not noted otherwise, flat 
mounted adult wings were 5x magnified. Tester phenotype controls during the screen: crosses of 
heterozygous RNAi lines or X-linked RNAi lines allowed us to analyze also flies with tester-only genotypes 
as internal controls within the same F1 generation. In addition, tester-only control fly crosses were included 
in each batch of experimental crosses of the same date.  
Molecular characterization of RNAi lines 
Genomic DNA of VDRC RNAi flies were tested for the presence of their predicted hairpin-insert by 
standard DNA sequencing analysis of the PCR product obtained after PCR amplification of the inverted 
repeat sequence. Genomic DNA was obtained from one male fly of the respective RNAi fly line based on a 
standard protocol of the Berkeley Drosophila Genome Project website (www.fruitfly.org). 
Secondary confirmation of the primary RNAi phenotype 
For genes which showed a wing phenotype in the primary RNAi screen we used transgenic RNAi lines 
from NIG-Fly (www.shigen.nig.ac.jp/fly/nigfly) or custom made UAS-RNAi lines based on the 
oligonucleotide method of Haley et al., 2008. 
Quantitative RT-PCR 
To test whether gene expression is downregulated upon UAS-hairpin expression, total RNA was isolated 
from third larval instar wing imaginal discs (Nucleospin RNA II kit, Machery-Nagel) which expressed a 
particular UAS-RNAi transgene under the control of c765-Gal4 at 29°C (c765-Gal4 is active throughout the 
imaginal disc; Nellen et al., 1996). Subsequent cDNA synthesis was performed by the Transcriptor High 
Fidelity cDNA Synthesis Kit (Roche). Quantitative real time PCR reactions were performed in triplicates 
and analyzed by the SYBR Green kit and the ABI Prism 7900HT System of Applied Biosystems. Gene 
expression of actin-5c, TBP, gapdh-α and cyp1 was used as standards to normalize RNA expression 
levels in the RNAi conditions. 
Inverse PCR (i-PCR) 
To localize the genomic integration site of the hairpin transgene of certain RNAi lines i-PCR was carried 
out according to a standard protocol of the Berkeley Drosophila Genome Project website (www.fruitfly.org). 
As a note of caution we like to mention RNAi results which are most likely based on endogenous gene 
activation by nearby inserted hairpin transgenes: (i) we scored the RNAi phenotype of the VDRC line 
40852 (gr23a) as a Hedgehog signaling gain-of-function phenotype, which strongly resembled moonrat, an 
allele causing ectopic activation of Hh signaling (Felsenfeld and Kennison, 1995). We localized the gr23a 
hairpin transgene in the upstream regulatory region of hh, thereby indicating the likely cause of hh 
overexpression (several new but phenotypically silent insertions of the same hairpin construct corroborate 
this finding); (ii) we scored the RNAi phenotype of the VDRC line 26508 (CG4674) as a Notch signaling 
loss-of-function-like phenotype (including missing tissue along the wing margin and thickened, terminally 
delta-like broadened veins). iPCR revealed the integration of the hairpin element upstream of the fringe 
coding region.  
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CDS-overexpression in flies 
For gain-of-function studies coding regions of respective genes were overexpressed based on the site 
specific ΦC31-integration system (Bischof et al., 2007). 
Transgene induction and RNAi phenotype analysis 
To analyze reporter gene activities (lacZ/bGal) of third instar larval wing imaginal discs we crossed UAS-
RNAi males to virgin females of the following genotypes: 
m8-lacZ/CyO^hh-Gal4/Tm6b (m8-lacZ: gift from G. Halder) 
brkX47-lacZ; ap-Gal4/CyO (brkX47-lacZ: Campbell and Tomlinson, 1999) 
wg-lacZ/CyO (Kassis, 1990) 
For clonal analyses UAS-RNAi transgenes were crossed to virgin females of the genotype yw hsflp; +/+; 
act5c>CD2>Gal4, UAS-GFP. Larvae from this cross were heat-shocked 48 hrs AEL at 37°C for 15 min. 
Immunohistochemistry and antibodies 
Immunostaining of late third instar larval wing discs were performed as per a standard protocol. The 
following primary antibodies were used: mouse anti-bGal (1:2000, Promega), guinea pig anti-Senseless 
(1:800, gift from H. Bellen), mouse anti-Wingless (1:1000, DSHB), rabbit anti-phospho Histone 3 (1:400, 
Upstate), mouse anti-Cut (1:20, gift from S. Bray), rabbit anti-cleaved Caspase3 (1:400, Cell Signaling), 
rabbit anti-Spalt (1:50, gift from ), rabbit anti phosho-Mad (1:800, gift from E. Laufer). Secondary 
antibodies (Molecular Probes, 1:400): goat antibodies Alexa Fluor 594 and 499. 
Bioinformatic analyses 
Definition of off targets: VDRC RNAi Lines which scored positive in the wing growth screen were 
analyzed with respect to their putative off targets based on the VDRC web page. To be as stringent as 
possible, while not needlessly eliminating real growth regulators, we defined an RNA line as being off-
target prone based on the following criteria: s19 ≤ 0.96 AND/OR CAN ≥ 5 AND/OR on-target. 
GO term enrichment analyses: 
Gene Ontology (GO) enrichment analysis is based on GoStat with a Benjamini and Hochberg correction 
using the online GoToolbox application. p < 0.05 was considered to indicate statistical significance. 
Prediction of orthologous genes: 
Orthologs were retrieved from InParanoid. 
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SMALLER_GO enrichment_Biological Process_overrepresented
p-value Enrichment value
GO:0007448 0.005414623 5.690703736 anterior/posterior pattern formation, imaginal disc
GO:0007478 0.030916795 5.685217391 leg disc morphogenesis
GO:0035156 0.031183016 5.660914582 fusion cell fate specification
GO:0007228 0.005524144 5.652885444 positive regulation of hh target transcription factor activity
GO:0045880 0.005524144 5.652885444 positive regulation of smoothened signaling pathway
GO:0008284 0.005524144 5.652885444 positive regulation of cell proliferation
GO:0035217 0.005524144 5.652885444 labial disc development
GO:0048099 0.005524144 5.652885444 anterior/posterior lineage restriction, imaginal disc
GO:0046672 0.005524144 5.652885444 positive regulation of compound eye retinal cell programmed cell death
GO:0021954 0.005524144 5.652885444 central nervous system neuron development
GO:0007386 0.005524144 5.652885444 compartment specification
GO:0035019 0.031271706 5.652885444 somatic stem cell maintenance
GO:0045850 0.031271706 5.652885444 positive regulation of nurse cell apoptosis
GO:0016340 0.031271706 5.652885444 calcium-dependent cell-matrix adhesion
GO:0009186 0.031271706 5.652885444 deoxyribonucleoside diphosphate metabolic process
GO:0035191 0.031271706 5.652885444 nuclear axial expansion
GO:0035157 0.031271706 5.652885444 negative regulation of fusion cell fate specification
GO:0007032 0.031271706 5.652885444 endosome organization and biogenesis
GO:0042069 0.031271706 5.652885444 regulation of catecholamine metabolic process
GO:0035207 0.031271706 5.652885444 negative regulation of hemocyte proliferation
GO:0021960 0.031271706 5.652885444 anterior commissure morphogenesis
GO:0048100 1.39E-06 5.087596899 wing disc anterior/posterior pattern formation
GO:0030708 0.000180205 4.84533038 germarium-derived female germ-line cyst encapsulation
GO:0007487 0.00088048 4.71073787 analia development
GO:0051090 0.00088048 4.71073787 regulation of transcription factor activity
GO:0045887 0.004187672 4.522308355 positive regulation of synaptic growth at neuromuscular junction
GO:0009608 0.004187672 4.522308355 response to symbiont
GO:0046622 0.004187672 4.522308355 positive regulation of organ growth
GO:0001746 0.000612376 4.239664083 Bolwig's organ morphogenesis
GO:0035171 0.000612376 4.239664083 lamellocyte differentiation
GO:0015014 0.019171137 4.239664083 heparan sulfate proteoglycan biosynthetic process, polysaccharide chain biosynthetic process
GO:0035263 0.019171137 4.239664083 genital disc sexually dimorphic development
GO:0016572 0.019171137 4.239664083 histone phosphorylation
GO:0048076 0.019171137 4.239664083 regulation of compound eye pigmentation
GO:0007483 0.019171137 4.239664083 genital disc morphogenesis
GO:0007418 0.019171137 4.239664083 ventral midline development
GO:0007076 3.46E-06 4.145449325 mitotic chromosome condensation
GO:0030307 9.33E-05 4.111189414 positive regulation of cell growth
GO:0045705 0.002631168 4.037775317 negative regulation of salivary gland boundary specification
GO:0045500 0.002631168 4.037775317 sevenless signaling pathway = EGFR signaling pathway
GO:0035224 0.002631168 4.037775317 genital disc anterior/posterior pattern formation
GO:0007425 0.002631168 4.037775317 epithelial cell fate determination, open tracheal system
GO:0008362 0.000388644 3.957019811 chitin-based embryonic cuticle biosynthetic process
GO:0008101 0.000388644 3.957019811 decapentaplegic receptor signaling pathway
GO:0030713 5.95E-05 3.913536076 ovarian follicle cell stalk formation
GO:0048190 0.000236331 3.768590296 wing disc dorsal/ventral pattern formation
GO:0007307 0.000236331 3.768590296 eggshell chorion gene amplification
GO:0045747 0.010802056 3.768590296 positive regulation of Notch signaling pathway
GO:0046534 0.010802056 3.768590296 positive regulation of photoreceptor cell differentiation
GO:0007458 0.010802056 3.768590296 progression of morphogenetic furrow during compound eye morphogenesis
GO:0006379 0.000905567 3.597290737 mRNA cleavage
GO:0035110 0.005843861 3.55326087 leg morphogenesis
GO:0035288 0.005995823 3.533053402 anterior head segmentation
GO:0035214 0.038605768 3.488080073 eye-antennal disc development
GO:0048863 2.64E-06 3.391731266 stem cell differentiation
GO:0030718 2.76E-05 3.391731266 germ-line stem cell maintenance
GO:0035080 0.041646334 3.391731266 heat shock-mediated polytene chromosome puffing
GO:0007523 0.041646334 3.391731266 larval visceral muscle development
GO:0045498 0.041646334 3.391731266 sex comb development
GO:0007473 0.041646334 3.391731266 wing disc proximal/distal pattern formation
GO:0051642 0.041646334 3.391731266 centrosome localization
GO:0007157 0.001842497 3.297516509 heterophilic cell adhesion
GO:0030720 0.001842497 3.297516509 oocyte localization during germarium-derived egg chamber formation
GO:0051297 0.02142646 3.241729649 centrosome organization and biogenesis
GO:0046328 0.011364542 3.151515152 regulation of JNK cascade
GO:0007549 0.011538391 3.140491913 dosage compensation
GO:0048070 0.011538391 3.140491913 regulation of pigmentation during development
Table S1    RNAi wing phenotypes of control genes
Hh signaling (24 genes addressed by VDRC RNAi lines)
Gene symbol CG Line ci-rep ci-act
boi CG7894 42248 < 0 Phenotype codes:
boi CG7894 29592 0 0
boi CG7894 29593 0 0 < - <<< wing size reduction
boi CG7894 869 0 0 >->> wing size enlargement
boi CG7894 3060 0 0 PD pupal death
botv CG15110 37185 0 <-<< and PD nec necrosis
botv CG15110 37186 0 << and PD bli wing blisters
ci CG2125 51479 0 << cr crinkled wings
CkI alpha CG2028 13664 PD nd round round shaped wing
dally CG4974 14136 0 < 0 no alteration of tester wing
dbr CG11317 9293 << << nd not determined
dbr CG11317 9292 0 0
dbr CG11317 18070 < <<
dbr CG11317 18071 0 <
disp CG2019 10004 nd 0
dlp CG32146 10298 < <
dlp CG32146 10299 0 0
fu CG6551 27662 <<, nec tips <
fu CG6551 27663 < <
hh CG4637 1402 PD <
hh CG4637 43255 < <
hh CG4637 1403 PD PD
iHog CG9211 1001 << PD
iHog CG9211 29897 < (variable) 0
iHog CG9211 29898 0 0
nejire CG15319 3787 < <<<, most PD
Pka-C1 CG4379 6993 PD PD
skpA CG16983 46605 << <<<, cr, nec
skpA CG16983 46607 << PD
skpA CG16983 32789 PD PD
skpA CG16983 32790 PD PD
slmb CG3412 34273 < <
slmb CG3412 34274 < <
smo CG11561 9542 < <
tws CG6235 34340 0 <, cr
ski CG11495 6459 0 0
Su(fu) CG6054 35055 0 0
mts CG7109 41924 << <<
mts CG7109 35171 0 0
mts CG7109 35172 0 0
smw CG10084 38334 << <<<
smw CG10084 38336 < <
roadkill CG12537 45759 <<< nd
roadkill CG12537 45761 <<(<) <<
roadkill CG12537 28800 << PD
roadkill CG12537 28798 << PD 16 genes expected phenotype
 cullin 3  CG11861 16331 0 PD 1 gene false positive (slimb)
combgap CG8367 2965 PD PD 3 genes false negative (disp, ski, Su(fu))
combgap CG8367 2966 LD LD 4 genes larval or pupal lethality
Dpp signaling (15 genes addressed by VDRC RNAi lines)
Gene symbol CG Line ci-rep ci-act
brk CG9653 2919 >> >
dad CG5201 42840 <<< <<<
dally CG4974 14136 0 <
dlp CG32146 10298 < <
dlp CG32146 10299 0 0
hth CG17117 12763 0 >, round
hth CG17117 12764 0 > and PD
lack, smurf CG4943 24681 > >
lack, smurf CG4943 24680 0 0
mad CG12399 12635 <<< <<<
med CG1775 19688 < round
med CG1775 19689 << <<
put CG7904 848 nd <, nec
put CG7904 849 < <<
put CG7904 37279 0 <<
sax CG1891 9434 < <
sax CG1891 42456 < <
sax CG1891 9433 0 bli
mtv CG5580 41845 0 round, >
shn CG7734 3226 < 0
tkv CG14026 862 < <<, nec, bli
tkv CG14026 3059 0 <, round
ttv CG10117 4871 << <
ubx CG10388 37823 haltere >> 0 14 genes expected phenotype
ubx CG10388 37825 haltere > 0 1 gene false positive
Hippo signaling (10 genes addressed by VDRC RNAi lines)
Gene symbol CG Line ci-rep ci-act
ex CG4114 22994 >> >, bli
fat CG3352 9396 > PD; bli
dachsous CG17941 4312  nd nd
dachsous CG17941 4313 > bli
dachsous CG17941 36219 > PD; bli
sav CG33193 46445 bli bli, rond
sav CG33193 24801 0 round
sav CG33193 24802 > nec spindle
sav CG33193 46446 0 0
wts CG12072 9928 > >>, bli
dachs CG31610 12555 << 0
dachs CG31610 12556 << <
fj CG10917 6774 0 0
mer CG14228 7161 > >
mer CG14228 7162 0 PD 7 genes expected phenotype
hippo CG11228 7823 0 0 1 genes false positive
yorkie CG4005 40497 <<< nd 2 genes false negative (hippo, fj)
Total genes (excl. 4 lethal cases): 43 genes
Expected phenotype:   35 genes (81.4%)
False positive:               3 genes (7%)
False negative:              5 genes (11.6%)
Total lines (excl. lines of 4 lethal cases): 80 lines
Expected phenotype:    60 lines  (75%)      
False positive:               4 lines (5%)           
False negative:            16 lines (20%)        
Table S2      a) SMALLER class
1905 Genes (2277 Lines): wing size reduction in at least one tester condition
Genes are listed 1.by CG number > 2.by TF-ID number
CG Gene Symbol RNAi Line ci-rep ci-act
CG10001 AR-2 1327 0 < Phenotype codes:
CG10002 fkh 37063 << PD
CG10009 Noa36 17954 <<< PD < mild wing size reduction
CG10009 Noa36 19485 <<< <<, dus, cr, PD << significant wing size reduction (below wt)
CG10033 for 38319 << <<, dus <<< vestigial wings
CG10033 for 38320 < <, dus bli blistered, fluid filled, vesicular wings
CG10035 CG10035 7524 0 < wr wrinkled wings
CG10037 vvl 47182 << PD dus dusky wings (wing hairs aberrant: density a/o length)
CG10052 Rx 44716 nd < sin singed (dark, spindled) wing
CG10055 CG10055 17973 << PD nex not exfolded wings
CG10064 CG10064 38322 0 << N, N* notches incl. thicker veins (N* slight notches)
CG10084 swm 38334 << <<< bif bifid or bifurcated wings
CG10084 swm 38336 < < nec predominant necrotic wings
CG10107 CG10107 18005 <<< PD PD (LD) pupal (or larval) death
CG10109 L 38339 0 <, wr, bli 0 no alteration of tester phenotype
CG10110 cpsf 18009 <<< nd nd not determined
CG10117 ttv 4871 << <
CG10118 ple 3308 PD <<
CG10122 RpI1 12688 0 <<<
CG10125 zpg 33277 < PD
CG10126 CG10126 44103 < 0
CG10144 CG10144 18019 << sin
CG10146 AttA 50320 << <<<
CG10152 beat-IV 1410 < PD
CG10154 CG10154 31188 nd <
CG10158 CG10158 18026 << <<, wr
CG10158 CG10158 47389 nd sin
CG10174 CG10174 31195 << <<
CG10200 CG10200 47613 0 <, wr
CG10209 CG10209 28153 PD sin
CG10209 CG10209 29042 < nd
CG10212 SMC2 10711 << nd
CG10222 CG10222 18038 < sin
CG10223 Top2 30625 << <<<
CG10226 CG10226 5055 nd <
CG10228 l(2)k08015 38366 << <, wr
CG10230 Rpn9 31206 << PD
CG10231 Pde11 18041 <<< nd
CG1024 CG1024 18599 << nd
CG10244 Cad96Ca 1091 0 <<
CG10244 Cad96Ca 49398 0 <
CG10253 CG10253 3321 0 <<
CG10267 CG10267 22836 <<< nd
CG10272 CG10272 16001 <<< nd
CG10275 CG10275 36247 << PD
CG10279 Rm62 46908 << 0
CG10281 TfIIFalpha 51209 <, dus <<<, bli, dus
CG10281 TfIIFalpha 51211 < <<<, bli, dus
CG10293 how 13756 <<< nd
CG10311 CG10311 37503 << PD
CG10320 CG10320 8837 nd <<<
CG10324 CG10324 31226 <<< PD
CG10332 CG10332 49651 <<< <<<
CG10335 Pbgs 40612 < nd
CG1034 bcd 12743 0 <
CG10348 CG10348 39663 0 <
CG10354 CG10354 27254 0 <<, wr
CG10374 Lsd-1 30884 <<< PD
CG10374 Lsd-1 30885 << nd
CG10377 Hrb27C 16040 <<< PD
CG10385 msl-1 9239 < <
CG10393 amos 11796 << nec
CG10414 CG10414 16047 <<< PD
CG10414 CG10414 47391 0 <, wr, nec
CG10415 TfIIEalpha 12591 nec <<
CG10449 Catsup 7183 <<< nd
CG10463 CG10463 31248 0 <
CG10463 CG10463 31249 <<, nec sin
CG10466 CG10466 23367 <<< PD
CG10479 CG10479 45098 0 <<
CG1048 zen2 10406 < nd
CG10480 Bj1 38388 0 <<<
CG10493 CG10493 45363 << PD
CG10528 fs(2)ltoPP43 16068 << PD
CG10539 S6k 18126 < <
CG10542 CG10542 15620 nd <
CG1057 MED31 27284 < 0
CG1057 MED31 27285 nd <, nec
CG10582 Sin 52094 << nd
CG10583 Sse 45091 < nd
CG10583 Sse 45092 << <<, wr
CG10603 mRpL13 31285 0 <, wr, PD
CG1064 Snr1 12645 << nd
CG10648 CG10648 51701 << PD
CG1065 Scsalpha 27298 <<< 0
CG10688 CG10688 39715 << nd
CG10688 CG10688 39716 << PD
CG10689 CG10689 31325 <<< PD
CG10691 l(2)37Cc 12358 << PD
CG10701 Moe 37917 <, bif <<
CG10711 CG10711 16846 << nd
CG10724 CG10724 22850 < PD
FBgn0004656 CG2252 fs(1)h ENSP00000263377
FBgn0041092 CG13109 tai ENSP00000267974
FBgn0027091 CG8431 Aats-cys ENSP00000369897
FBgn0038827 CG17269 Fancd2 ENSP00000287647
FBgn0086904 CG8759 Nacalpha ENSP00000349212
FBgn0014879 CG4299 Set ENSP00000361777
FBgn0000251 CG1759 cad ENSP00000370408
FBgn0024326 CG9738 Mkk4 ENSP00000262445
FBgn0003444 CG11561 smo ENSP00000249373
FBgn0039120 CG10198 Nup98 ENSP00000316032
FBgn0011829 CG14396 Ret ENSP00000344798
FBgn0026317 CG6147 Tsc1 ENSP00000298552
FBgn0032497 CG6043 CG6043 ENSP00000327563
FBgn0011661 CG10701 Moe ENSP00000353408
FBgn0086384 CG14228 Mer ENSP00000335652
FBgn0034802 CG3800 CG3800 ENSP00000303844
FBgn0034585 CG4030 CG4030 ENSP00000262477
FBgn0004227 CG4211 nonA ENSP00000349748
FBgn0000319 CG9012 Chc ENSP00000269122
FBgn0030855 CG5800 CG5800 ENSP00000314348
FBgn0020245 CG10117 ttv ENSP00000367446
FBgn0015624 CG15319 nej ENSP00000263253
FBgn0000117 CG11579 arm ENSP00000344456
FBgn0015031 CG14028 cype ENSP00000297564
FBgn0005198 CG6975 gig ENSP00000219476
FBgn0038197 CG3143 foxo ENSP00000339527
FBgn0005658 CG7018 Ets65A ENSP00000295727
FBgn0004647 CG3936 N ENSP00000277541
FBgn0003205 CG9375 Ras85D ENSP00000256078
FBgn0004924 CG6146 Top1 ENSP00000354522
FBgn0010389 CG7223 htl ENSP00000309878,ENSP00000311337
FBgn0004419 CG4916 me31B ENSP00000264018
FBgn0023097 CG5206 bon ENSP00000340507
FBgn0000242 CG6500 Bx ENSP00000338207
FBgn0001233 CG1242 Hsp83 ENSP00000335153
FBgn0004864 CG1594 hop ENSP00000371067
FBgn0036685 CG6664 CG6664 ENSP00000263102
FBgn0037657 CG11990 hyx ENSP00000356406
FBgn0003079 CG2845 phl ENSP00000288602
FBgn0011655 CG1775 Med ENSP00000341551
FBgn0000472 CG10798 dm ENSP00000367207
FBgn0016694 CG17888 Pdp1 ENSP00000226067
FBgn0001942 CG9075 eIF-4a ENSP00000326381
FBgn0026441 CG4913 ear ENSP00000252674,ENSP00000369695
FBgn0034975 CG11290 enok ENSP00000265713
FBgn0033842 CG5970 CG5970 ENSP00000304704
FBgn0001123 CG2835 G-salpha60A ENSP00000302237
FBgn0026379 CG5671 Pten ENSP00000361021
FBgn0039559 CG4976 Mes-4 ENSP00000348031 
FBgn0004656 CG2252 fs(1)h ENSP00000263377
FBgn0041092 CG13109 tai ENSP00000267974
FBgn0027091 CG8431 Aats-cys ENSP00000369897
FBgn0038827 CG17269 Fancd2 ENSP00000287647
FBgn0086904 CG8759 N calpha ENSP00000349212
FBgn0014879 CG4299 Set ENSP00000361777
FBgn0000251 CG1759 cad ENSP00000370408
FBgn0024326 CG9738 Mkk4 ENSP00000262445
FBgn0003444 CG11561 smo ENSP00000249373
FBgn0039120 CG10198 Nup98 ENSP00000316032
FBgn0011829 CG14396 Ret ENSP00000344798
FBgn0026317 CG6147 Tsc1 ENSP00000298552
FBgn0032497 CG6043 CG6043 ENSP00000327563
FBgn0011661 CG10701 Moe ENSP00000353408
FBgn0086384 CG14228 Mer ENSP00000335652
FBgn0034802 CG3800 CG3800 ENSP00000303844
FBgn0034585 CG4030 CG4030 ENSP00000262477
FBgn0004227 CG4211 nonA ENSP00000349748
FBgn0000319 CG9012 Chc ENSP00000269122
FBgn0030855 CG5800 CG5800 ENSP00000314348
FBgn0020245 CG10117 ttv ENSP00000367446
FBgn0015624 CG15319 nej ENSP00000263253
FBgn0000117 CG11579 arm ENSP00000344456
FBgn0015031 CG14028 cype ENSP00000297564
FBgn0005198 CG6975 ig ENSP00000219476
FBgn0038197 CG3143 foxo ENSP00000339527
FBgn0005658 CG7018 Ets65A ENSP00000295727
FBgn0004647 CG3936 N ENSP00000277541
FBgn0003205 CG9375 Ras85D ENSP00000256078
FBgn0004924 CG6146 Top1 ENSP00000354522
FBgn0010389 CG7223 htl ENSP00000309878,ENSP00000311337
FBgn0004419 CG4916 me31B ENSP00000264018
FBgn0023097 CG5206 bon ENSP00000340507
FBgn0000242 CG6500 Bx ENSP00000338207
FBgn0001233 CG1242 Hsp83 ENSP00000335153
FBgn0004864 CG1594 hop ENSP00000371067
FBgn0036685 CG6664 CG6664 ENSP00000263102
FBgn0037657 CG11990 hyx ENSP00000356406
FBgn0003079 CG2845 phl ENSP00000288602
FBgn0011655 CG1775 Med ENSP00000341551
FBgn0000472 CG10798 dm ENSP00000367207
FBgn0016694 CG17888 Pdp1 ENSP00000226067
FBgn0001942 CG9075 eIF-4a ENSP00000326381
FBgn0026441 CG4913 ear ENSP00000252674,ENSP00000369695
FBgn0034975 CG11290 enok ENSP00000265713
FBgn0033842 CG5970 CG5970 ENSP00000304704
FBgn0001123 CG2835 G-salpha60A ENSP00000302237
FBgn0026379 CG5671 Pten ENSP00000361021
FBgn0039559 CG4976 Mes-4 ENSP00000348031 
Table S3  Positive wing RNAi hits with human disease orthologs
GO-ID p-value GO-Term
GO:0006811 0.00043179 ion transport
GO:0022900 0.00526259 electron transport chain
GO:0044262 0.00592389 cellular carbohydrate metabolic process
GO:0042773 0.00631355 ATP synthesis coupled electron transport
GO:0030001 0.00748698 metal ion transport
GO:0019752 0.01157004 carboxylic acid metabolic process
GO:0006030 0.02253184 chitin metabolic process
GO:0006631 0.02701386 fatty acid metabolic process
GO:0006066 0.03750415 alcohol metabolic process
GO:0006629 0.0378727 lipid metabolic process
GO:0005975 0.03864249 carbohydrate metabolic process
GO:0048066 0.03882044 pigmentation during development
GO:0006839 0.03882044 mitochondrial transport
GO:0019725 0.0415997 cellular homeostasis
Table S4        GO stats enrichments (Biological Process, Molecular Function)
GO-ID p-value GO-Term
GO:0016491 3.59E-05 oxidoreductase activity
GO:0022891 0.00034535 substrate-specific transmembrane transporter activity
GO:0043169 0.00049788 cation binding
GO:0046872 0.00062499 metal ion binding
GO:0005102 0.00084179 receptor binding
GO:0015267 0.00365837 channel activity
GO:0043565 0.00369695 sequence-specific DNA binding
GO:0003700 0.00404025 transcription factor activity
GO:0005506 0.01058971 iron ion binding
GO:0009055 0.01063731 electron carrier activity
GO:0008270 0.01604291 zinc ion binding
GO:0005215 0.01615857 transporter activity
GO:0022857 0.01964121 transmembrane transporter activity
GO:0005214 0.01989252 structural constituent of chitin-based cuticle
GO:0001584 0.02228613 rhodopsin-like receptor activity
GO:0048037 0.03194851 cofactor binding
GO:0004497 0.03732956 monooxygenase activity
GO:0015276 0.04368422 ligand-gated ion channel activity
GO:0030247 0.04368422 polysaccharide binding
GO:0008324 0.04373319 cation transmembrane transporter activity
GO:0005261 0.04866047 cation channel activity
GO-ID p-value GO-Term
GO:0006468 0.00029105 protein amino acid phosphorylation
GO:0006796 0.00141617 phosphate metabolic process
GO:0006464 0.00219547 protein modification process
GO:0048066 0.01199176 pigmentation during development
GO:0046843 0.01411882 dorsal appendage formation
GO:0006888 0.02515345 ER to Golgi vesicle-mediated transport
GO:0051225 0.04156771 spindle assembly
GO:0007143 0.04354042 female meiosis
GO-ID p-value GO-Term
GO:0016773 0.00010095 phosphotransferase activity, alcohol group as acceptor
GO:0016301 0.00015296 kinase activity
GO:0016740 0.00070012 transferase activity
GO:0004674 0.00121754 protein serine/threonine kinase activity
GO:0005102 0.00303437 receptor binding
GO:0004683 0.02696999 calmodulin-dependent protein kinase activity
GO:0017076 0.03405156 purine nucleotide binding
wing-only gene set
culture growth screens-only gene set
B
P
B
P
M
F
M
F
B
C H A R A C T E R I Z AT I O N O F T H E R A PA M Y C I N - S E N S I T I V E
P H O S P H O P R O T E O M E R E V E A L S T H AT S C H 9 I S A
C E N T R A L C O O R D I N AT O R O F P R O T E I N S Y N T H E S I S
For this work I processed the LC–MS/MS data generated using the clustering
algorithm for LC–MS/MS alignments described in chapter 7.
The original publication is included below.
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Characterization of the rapamycin-
sensitive phosphoproteome reveals
that Sch9 is a central coordinator
of protein synthesis
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The target of rapamycin complex 1 (TORC1) is an essential multiprotein complex conserved from yeast to
humans. Under favorable growth conditions, and in the absence of the macrolide rapamycin, TORC1 is active, and
influences virtually all aspects of cell growth. Although two direct effectors of yeast TORC1 have been reported
(Tap42, a regulator of PP2A phosphatases and Sch9, an AGC family kinase), the signaling pathways that couple
TORC1 to its distal effectors were not well understood. To elucidate these pathways we developed and employed
a quantitative, label-free mass spectrometry approach. Analyses of the rapamycin-sensitive phosphoproteomes in
various genetic backgrounds revealed both documented and novel TORC1 effectors and allowed us to partition
phosphorylation events between Tap42 and Sch9. Follow-up detailed characterization shows that Sch9 regulates
RNA polymerases I and III, the latter via Maf1, in addition to translation initiation and the expression of
ribosomal protein and ribosome biogenesis genes. This demonstrates that Sch9 is a master regulator of protein
synthesis.
[Keywords: Maf1; Sch9; TOR; phosphoproteomics; rapamycin; ribosome biogenesis]
Supplemental material is available at http://www.genesdev.org.
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The target of rapamycin complex 1 (TORC1) and TORC2
are large essential multiprotein assemblies structurally
and functionally conserved throughout eukaryotic evo-
lution. At their structural core are the TOR proteins,
which are large Ser/Thr kinases belonging to the phos-
phatidylinositol kinase-like kinase family (Wullschleger
et al. 2006). It is generally believed that TORC1 is active
when sufficient nutrients are present and noxious stres-
sors are absent (DH Kim et al. 2002; Urban et al. 2007).
TORC1 also appears to monitor intracellular cues: Treat-
ment with cycloheximide, a translation elongation in-
hibitor, causes a potent increase in TORC1 activity
(Beugnet et al. 2003; Urban et al. 2007).
Rapamycin has been an invaluable tool to study path-
ways downstream from TORC1. This hydrophobic mac-
rolide easily crosses cell membranes to rapidly and
specifically inhibit TORC1. Application of rapamycin to
yeast cells demonstrated that TORC1 signals promote
cell growth through both the stimulation of anabolic
processes, such as protein synthesis and ribosome bio-
genesis, and the inhibition of catabolic processes, such as
autophagy, and stress-responsive transcription programs.
For a comprehensive review on TORC1 signaling in yeast,
see De Virgilio and Loewith (2006).
The molecular pathways linking TORC1 to its distal
readouts are presently only partially characterized. At
least two direct effectors downstream from TORC1 have
been described: Tap42 and Sch9 (Di Como and Arndt
1996; Jiang and Broach 1999; Urban et al. 2007). Tap42
binds and regulates PP2A and PP2A-like protein phos-
phatases (Nanahoshi et al. 1998). Tap42 also interacts
with and is directly phosphorylated by TORC1 (Jiang and
Broach 1999). Genetic evidence clearly shows that Tap42
mediates TORC1 signals to a number of distal readouts.
This is based on the observation that tap42-11, a temperature-
sensitive allele of TAP42, confers semidominant resistance to
rapamycin at the permissive temperature of 25°C (Di Como
and Arndt 1996; Duvel et al. 2003). Indeed, in tap42-11
8These authors contributed equally to this work.
9Corresponding author.
E-MAIL robbie.loewith@unige.ch; FAX 41-22-379-68-68.
Article is online at http://www.genesdev.org/cgi/doi/10.1101/gad.532109.
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cells, the activation of the transcription factors Gcn4,
Gln3, Gat1, and Msn2/4, and the kinase Npr1, normally
observed after inhibition of TORC1 with rapamycin, is
partially or, in some cases, completely blocked (Schmidt
et al. 1998; Cherkasova and Hinnebusch 2003; Duvel
et al. 2003; Santhanam et al. 2004).
Sch9 is a Ser/Thr protein kinase of the AGC family. It is
directly phosphorylated by TORC1 at its C terminus on
at least five residues, and these phosphorylation events
are required for catalytic activity (Urban et al. 2007).
Replacing some or all of these residues with acidic amino
acids (SCH93E and SCH9DE alleles) yields versions of Sch9
that retain activity even in the absence of upstream sig-
nals from TORC1 (Urban et al. 2007). Sch9 mediates
TORC1 signals to a number of distal readouts: Sch9
blocks the induction of genes required for entry into G0
by directly phosphorylating, and thereby antagonizing,
the nuclear accumulation of the Ser/Thr kinase Rim15
(Wanke et al. 2008; Wei et al. 2008); Sch9 is critical for
TORC1 to antagonize eIF2a phosphorylation and thus
maintain efficient translation initiation (Urban et al.
2007); and Sch9 plays important roles in the regulated
expression of RNA polymerase II (Pol II)-dependent genes
required for ribosome biogenesis (Jorgensen et al. 2004;
Urban et al. 2007). Except for Rim15, the substrates of
Sch9 involved in these processes are not known.
Ribosome biogenesis is a highly coordinated process
requiring the concerted activity of the three nuclear RNA
polymerases (RNA Pol I–III) (Planta 1997; Venema and
Tollervey 1999). As it consumes a high amount of cellular
energy (Warner 1999), it is not surprising that ribosome
biogenesis is tightly coupled to environmental growth
conditions. Much of this regulation is mediated by
TORC1 (Zaragoza et al. 1998; Mayer and Grummt 2006).
RNA Pol I is dedicated to the transcription of 35S pre-
rRNA, which is subsequently processed to 25S, 18S, and
5.8S rRNAs (Venema and Tollervey 1999). Among other
models, RNA Pol I was proposed to be regulated by
TORC1 via recruitment of the essential initiation factor
Rrn3 (Claypool et al. 2004).
RNA Pol II transcription is required for expression of
ribosomal protein (RP) genes and ribosome biogenesis
(ribi) genes that encode proteins required for nucleolar
rRNA processing and assembly of ribosomal subunits
(Jorgensen et al. 2004). TORC1 regulates the expression
of both RP and ribi genes by controlling the activities of
several transcription factors. Some of this regulation is
mediated by Sch9 (Jorgensen et al. 2004; Urban et al. 2007).
RNA Pol III transcribes the 5S rRNA, tRNAs, and other
stable noncoding RNAs (Geiduschek and Kassavetis
2001). TORC1 regulates RNA Pol III via its conserved
repressor, Maf1 (Upadhya et al. 2002). Under favorable
growth conditions, Maf1 is highly phosphorylated and is
shuttled out of the nucleus. Inactivation of TORC1 re-
sults in the rapid dephosphorylation and nuclear accu-
mulation of Maf1 (Oficjalska-Pham et al. 2006; Roberts
et al. 2006). TORC1 has been proposed to maintain Maf1
phosphorylation by antagonizing the activity of PP2A
family phosphatases, while PKA has been proposed to be
the Maf1 kinase (Moir et al. 2006; Oficjalska-Pham et al.
2006). Dephosphorylated Maf1 binds RNA Pol III and,
consequently, blocks RNA Pol III transcription via poorly
defined mechanisms (Desai et al. 2005; Oficjalska-Pham
et al. 2006; Roberts et al. 2006).
Although many distal readouts downstream from
TORC1 are known, undoubtedly more remain to be iden-
tified. Additionally, the signaling cascades that couple
TORC1 to its known readouts remain incompletely un-
derstood. To better characterize these pathways wewished
to define the TORC1-regulated phosphoproteome. Several
liquid chromatography tandem mass spectrometry (LC-
MS/MS) approaches have been developed recently to
quantify protein phosphorylation (Domon and Aebersold
2006; Olsen et al. 2006). Most prominent among these are
protocols based on the differential isotopic labeling of
phosphopeptides enriched from protein digests that ena-
bles relative quantification between biological samples
(Zhou et al. 2001; Olsen et al. 2006). Beyond the restricted
number of biological comparisons possible, these methods
suffer additional limitations: Currently, only peptide ions
identified using MS/MS can be quantified, and the dou-
bling of peptide ion signals in isotopically labeled samples
makes the spectra more complex (Mueller et al. 2008).
These issues can be largely overcome by label-free LC-
MS-based quantitative proteomic strategies, particularly
if high mass accuracy MS is used (Rinner et al. 2007).
Thereby, every detectable phosphopeptide ion signal can
be tracked across multiple LC-MS feature maps, and each
tracked peptide can be quantified (Mueller et al. 2007). As
a result, the quantification process is applicable across
a high number of samples.
Employing these advances, we established a novel,
integrated experimental and computational pipeline for
the label-free quantification of cellular phosphorylation
patterns between a theoretically unlimited number of
related samples. We applied this technique to compare
the protein phosphorylation patterns in yeast cells upon
cycloheximide or rapamycin treatment. This led to the
identification of many phosphorylation sites that are
presumably directly or indirectly targeted by TORC1.
Repeating these assays using cells expressing TORC1-
insensitive alleles of TAP42 or SCH9 we were able to
accurately partition rapamycin-sensitive phosphopro-
teins to these two main TORC1 effector branches. These
studies led to the observation that Maf1 is directly phos-
phorylated by Sch9, and that Sch9 regulates both Maf1
localization and binding to RNA Pol III. During the course
of these experiments it became apparent that Sch9 also
regulates RNA Pol I activity. Altogether this work reveals
new effectors downstream from TORC1 and positions
Sch9 as a central coordinator of protein synthesis.
Results
Sch9 and Tap42 act in parallel to mediate
TORC1 signals
Two direct TORC1 effectors have been reported: Sch9
and Tap42. In order to test their functional relationship,
we took advantage of the SCH9DE and tap42-11 alleles
Huber et al.
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that uncouple the encoded protein from upstream regu-
lation by TORC1 (Di Como and Arndt 1996; Urban et al.
2007). In the TB50 yeast background SCH9DE or tap42-11
alone conferred only very slight resistance to rapamycin
but, together, the two alleles showed strong synthetic
rapamycin resistancewith cells still growing, albeit slowly,
in the presence of 200 nM rapamycin (;20 times the
minimal lethal concentration for this strain; Fig. 1A). This
argues that Sch9 and Tap42 function in parallel down-
stream from TORC1. The observation that the growth
of SCH9DE tap42-11 cells is still slowed by the presence
of rapamycin suggests the existence of additional direct
TORC1 substrates like Sfp1 (Lempiainen et al. 2009).
Beyond Tap42 and Sch9, the molecular events that couple
TORC1 to its diverse range of downstream readouts re-
main largely uncharacterized.
Label-free quantitative phosphoproteomic screens
To tackle this challenge on a broad scale we employed a
novel label-free quantitative phosphoproteomic approach
as follows (Fig. 1B): Exponentially dividing cells were
either treatedwith drug or mock-treatedwith drug vehicle.
Subsequently, biochemical reactions were quenched. Pro-
teins were extracted, enzymatically digested, and phos-
phopeptides were enriched using titanium dioxide-based
affinity chromatography (Pinkse et al. 2004; Bodenmiller
et al. 2007b). LC-MS feature maps, called phosphoryla-
tion patterns, were generated from each sample, and
these phosphorylation patterns were aligned using the
Superhirn algorithm (Mueller et al. 2007). Analysis of
these alignments revealed phosphorylation events that
were significantly regulated by a given treatment in a
given genetic background.
Our specific strategy employed three different screens.
First, we compared protein phosphorylation patterns of
exponentially growing wild-type cells treated or mock-
treated with cycloheximide, a translation elongation in-
hibitor that, by unknown mechanisms, hyperactivates
TORC1 (Urban et al. 2007). In a second screen, protein
phosphorylation patterns of wild-type cells and SCH93E
cells (SCH93E is functionally identical to SCH9DE) were
compared both with and without rapamycin treatment.
For the third screen, protein phosphorylation patterns of
wild-type cells and tap42-11 cells were similarly com-
pared both with and without rapamycin treatment.
In total, 30 phosphorylation patterns were generated,
containing 2256 distinct phosphopeptides mapping to 751
phosphoproteins (Supplemental Table S3; Supplemental
File F1). The numbers of significantly up-regulated and
down-regulated phosphopeptides in each screen are sum-
marized in Supplemental Table S4. The summarized list
of regulated phosphoproteins identified in both screens 2
and 3 and of proteins that were tested in independent
phosphorylation assays is shown as Table 1. The compre-
hensive lists of regulated phosphopeptides are published
as Supplemental Material (Supplemental File F2).
Figure 1. Label-free quantitative phosphoproteomic screens. (A) TAP42 and SCH9 act in parallel downstream from TORC1. Ten-fold
serial dilutions of sch9 tap42 cells complemented with indicated alleles of SCH9 and TAP42 and made prototroph with pAH149 were
spotted onto the indicated media and incubated for 2–5 d at 25°C or 37°C. (Rap) Rapamycin. (B) Strategy for label-free quantitative
phosphoproteomics. Triple arrows indicate steps performed in triplicate. (C) Venn diagram of phosphopeptides identified in both screens
2 and 3. Subsets of phosphopeptides found to be up-/down-regulated by rapamycin in each screen and their overlaps are shown. The
overlap of phosphopeptides predicted to be down-regulated in screen 3 and up-regulated in screen 2 is not statistically significant (P =
0.25). P-values associated with the overlaps enrichment. (*) P < 1012; (#) P < 1024.
Rapamycin-sensitive phosphoproteome
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Table 1. Summary of the phosphoproteomic screens
ORF
Protein
name
Regulation by
rapamycina
Regulation by
cycloheximideb
Dependent on
SCH9/TAP42 Referencec
Transcription, chromatin regulation
YBL054W Tod6 a (aWB) - SCH9, TAP42
YBL103C Rtg3 a a SCH9, TAP42 Dilova and Powers 2006
YDR005C Maf1 a (aWB) — SCH9 Moir et al. 2006
YDR169C Stb3 a (aWB, aPS) b (bWB) SCH9, TAP42
YER040W Gln3 a — Beck and Hall 1999
YER088C Dot6 a (aWB) — SCH9
YER169W Rph1 b (bWB) — (WB)
YFL021W Gat1 a — Beck and Hall 1999
YIL038C Not3 a a TAP42
Translation
YBR181C Rps6bd a b — SCH9
YGR162W Tif4631 a —
YOR204W Ded1 b (WB, bPS) a
YPL090C Rps6ad a b — SCH9
YPR041W Tif5 b —
Signal transduction
YDR028C Reg1 a (WB, PS) — (WB)
YHR082C Ksp1 a (aWB) b (bWB) TAP42
YHR205W Sch9 a - TAP42 Urban et al. 2007
YMR216C Sky1 a (aWB) b (bWB)
YNL076W Mks1 a a SCH9 Dilova et al. 2002
YPL180W Tco89 a — TAP42
YPR185W Atg13 a — TAP42 Kamada et al. 2000
Transport
YDR345C Hxt3 a — TAP42
YJR001W Avt1 a (WB) b (WB)
YNL321W Vnx1 b —
Metabolism
YML035C Amd1 a —
YMR205C Pfk2 b —
YOL061W Prs5 b —
Miscellaneous/uncharacterized
YBL051C Pin4 — (bWB) a (aWB)
YCL011C Gbp2e a b — SCH9
YCR077C Pat1 a —
YDL051W Lhp1 b (WB) — TAP42
YDL173W Par32 a b (bWB) b (aWB) TAP42
YDR348C a —
YIL047C Syg1 a (WB) — (WB)
YIL135C Vhs2 a b a SCH9, TAP42
YLR257W b —
YMR196W b —
YMR275C Bul1 b —
YNL004W Hrb1e a b — SCH9
YNL265C Ist1 a (WB) — (WB)
YOL060C Mam3 a —
YOR322C Ldb19 b a TAP42
List of phosphoproteins predicted to be regulated by rapamycin in both screens and/or tested to be rapamycin-sensitive by independent
assays. Proteins are sorted according to their reported functions.
a,b(b) Up-regulated phosphopeptides; (a) down-regulated phosphopeptides; (—) no regulated phosphopeptides. In parentheses,
regulation observed in confirmation experiments [(WB) migration shift assay in Western blot; (PS) Phosphostaining; (b) up-regulation
of phosphorylation; (a) down-regulation of phosphorylation; (—) no change in phosphorylation].
cPrevious reports showing that the phosphorylation of the indicated proteins is regulated by rapamycin in a similar manner as in the
phosphoproteomic screens.
dRps6a and Rps6b have identical protein sequences.
eThe peptides identified for Hrb1 and Gbp2 mapped to regions of the proteins that are identical in sequence and therefore could not be
attributed to one or the other.
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Quality assessment
To assess the quality of our data we first asked whether
our screens were consistent with one another, and com-
pared the phosphorylation patterns generated from in-
dependent experiments performed as part of our different
screens. The overlap between the rapamycin-sensitive
phosphopeptides of screens 2 and 3 was statistically sig-
nificant (Fig. 1C).
Importantly, rapamycin-sensitive phosphorylation was
found in proteins known to function downstream from
TORC1, including Sch9, Gln3, Gat1, Atg13, Maf1, Mks1,
and Rtg3 (Table 1). Thus, from our repeated independent
experiments we observed consistent regulatory events,
including those described in the literature. These results
show the versatility of label-free quantitation, and con-
firm that our experimental and biological pipeline is
highly reproducible.
In order to illustrate that our experimental and com-
putational pipeline generates data of high quality, we
chose to further validate the regulated phosphoryla-
tion sites (Table 1). We selected proteins from all three
screens, with preference for those found regulated in two
independent screens, showing opposite regulation by
cycloheximide and rapamycin and/or displaying a high
number of regulated phosphopeptides. HA-epitope-tagged
versions of these selected proteins were expressed in
yeast, and their migration in SDS-PAGE was monitored
by Western blotting in the hope that the regulated phos-
phorylation sites would generate a migration ‘‘shift.’’
Dot6, Tod6, Ksp1, Sky1, and Stb3 were predicted to
become hypophosphorylated after rapamycin treatment
in the phosphoproteomic screens. Consistently, rapamy-
cin treatment resulted in a faster migration of these
proteins in SDS-PAGE (Fig. 2A,B), while cycloheximide
had the inverse effect. Mutagenesis of some of the pre-
dicted phosphoserines in Dot6 and Tod6 to alanines re-
sulted in variants whose migration was no longer altered
by rapamycin treatment, indicating our protocol can
accurately assign phosphorylation sites (Supplemental
Fig. S1A). Ydl173w (renamed Par32 for phosphorylated
after rapamycin, 32 kDa) and Rph1 were predicted to
become hyperphosphorylated after rapamycin treatment
(although some additional sites in Par32were predicted to
be hypophosphorylated after rapamycin treatment) and
Pin4 was predicted to be dephosphorylated upon cyclo-
heximide addition. Rapamycin treatment resulted in a
slower migration of these proteins, while cycloheximide
had the inverse effect. Syg1 and Avt1 were predicted to
become hypophosphorylated after rapamycin treatment;
however, no migration shift was observed after rapamy-
cin or cycloheximide treatment for these two proteins.
As shifts in migration could result from other post-
translational modifications we wished to confirm that
the shifts that we had observed were indeed the result of
changes in phosphorylation. To this end we treated
selected immunoprecipitated phosphoproteins with
l-phosphatase in the absence or presence of phosphatase
inhibitors. In each case, phosphatase treatment converted
the protein to its fastest migrating species, confirming
that differential phosphorylation was responsible for the
observed migration shifts (Fig. 2C). In summary, eight of
the 14 proteins we tested in migration shift assays (Fig.
2A,B; data not shown) gave the expected rapamycin-
induced mobility shift as predicted in our phosphopro-
teomic screens. Immunoprecipitation experiments and
staining for phosphorylated residues showed that Ded1,
Figure 2. New TORC1 effectors. (A) Migration shift assays of
proteins identified in the phosphoproteomic screens. Yeast cells
expressing HA-tagged Ksp1, Sky1, Stb3, Par32, Pin4, Rph1, Syg1,
and Avt1 were grown in YPD and treated with rapamycin or
cycloheximide (CHX). Proteins were extracted under denaturing
conditions and their SDS-PAGE migration was assayed by
Western blotting. (B) Migration shift assays of phosphoproteins
found to be regulated by SCH9 or TAP42. Reporter plasmids
expressing HA-tagged Par32, Tod6, Dot6, or Maf1 were trans-
formed into cells of the indicated genotype. Cells were grown in
YPD treated as indicated with rapamycin and assayed as in A.
(C) Wild-type cells expressing HA-tagged Ksp1, Sky1, Stb3,
Dot6, Tod6, Par32, Pin4, or Rph1 were grown in YPD and
treated 15 min with rapamycin or cycloheximide where in-
dicated. Proteins were extracted under native conditions and HA
immunoprecipitates were incubated with l phosphatase in the
presence or absence of phosphatase inhibitors.
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which did not show any migration shift, becomes hyper-
phosphorylated after rapamycin treatment as predicted
(Supplemental Fig. S1B). This suggests that at least some
of the identified proteins that did not present observable
migration shifts are nonetheless rapamycin-sensitive
phosphoproteins.
The other objective of our phosphoproteome screens was
to partition rapamycin-sensitive phosphorylation events
amongst the two known TORC1 substrates, Tap42 and
Sch9 (Supplemental Fig. S2; Supplemental Files F1, F2).
Again, we used SDS-PAGE migration shift assays to de-
termine if this objective had been met. For this analysis
we chose Par32 (rapamycin-induced hyperphosphorylation
predicted to be mediated by Tap42), Tod6 (rapamycin-
induced hypophosphorylation predicted to be mediated
by Sch9 and Tap42), Dot6 (rapamycin-induced hypophos-
phorylation predicted to be mediated by Sch9), and Maf1
(rapamycin-induced hypophosphorylation predicted to be
mediated by Sch9). As predicted, the rapamycin-induced
hyperphosphorylation of Par32 was largely blocked in
tap42-11 cells (Fig. 2B). Rapamycin-induced dephosphory-
lation of Tod6 and Dot6 was blocked in SCH9DE cells and
was delayed in tap42-11 cells (Tap42 dependence was
predicted for Tod6 but not Dot6, which fell just under
the applied cutoff for Tap42 regulation) (Fig. 2B). Lastly,
Maf1 dephosphorylation showed the predicted Sch9 de-
pendency (Fig. 2B).
Altogether, these control experiments demonstrate that
our integrated experimental and computational pipeline
allowed us to identify and quantify novel rapamycin-
sensitive phosphorylation sites on a system-wide scale
and to accurately partition these signaling events down-
stream from Tap42 and Sch9.
Novel TORC1 targets
We identified >100 novel TORC1-dependent phosphory-
lation events (Supplemental Table S4; Supplemental File
F2), and we wanted to assess whether these phosphopro-
teins are important for TORC1 to regulate cell growth.
Preliminary results suggest they are: 38 of 102 corre-
sponding deletion strains tested gave amoderate to strong
rapamycin phenotype (Supplemental Fig. S3; Supplemen-
tal Table S5). Thus, from our data we can anticipate novel
functions for TORC1 and we can begin to explain how
TORC1 signals to previously established readouts:
Previous studies demonstrated a role for TORC1 in
starvation-induced developmental transitions (Cutler et al.
2001). TORC1 may mediate these transitions via Ksp1,
a protein kinase that is required for filamentous growth in
yeast (Bharucha et al. 2008).
Pin4 and Rph1were shown to become hyperphosphory-
lated upon DNA damage (EM Kim et al. 2002; Pike et al.
2004). Curiously, we found that rapamycin induced
a similar hyperphosphorylation suggesting cross-talk be-
tween TORC1 and DNA damage response pathways.
Our data suggest many new links to ribosome bio-
genesis. We found rapamycin-sensitive Sch9-dependent
phosphorylation sites in Stb3 and Dot6/Tod6 (two ho-
mologous myb-like HTH transcription factors), and these
proteins have been shown recently to function as tran-
scriptional regulators of ribi genes (Liko et al. 2007; Badis
et al. 2008; Zhu et al. 2009). Sky1 is a conserved Ser/Thr
kinase that phosphorylates pre-mRNA splicing factors of
the SR family (Siebel et al. 1999). Given the prevalence of
introns in RP genes, this could suggest that TORC1 also
plays a more direct role in ribosome biogenesis.
We chose to focus our attention on yet another protein
implicated in ribosome biogenesis regulation. Specifi-
cally, we were intrigued that Maf1, a conserved repressor
of RNA Pol III, was predicted to be regulated by TORC1
via Sch9 (Fig. 2B), as this regulation was thought to occur
via PP2A phosphatases (Oficjalska-Pham et al. 2006).
Maf1 is a direct target of Sch9
Previously, we demonstrated that Sch9 phosphorylated
two serines near the C terminus of Rps6 (Urban et al.
2007). Notably, the sequence surrounding the phospho-
serines now identified in Maf1 bears a striking similarity
to this S6 sequence (Fig. 3A). Maf1 was reported to be
dephosphorylated after rapamycin treatment, but the
mechanism by which TORC1 regulates Maf1 phosphor-
ylation was not determined (Oficjalska-Pham et al. 2006;
Roberts et al. 2006). Although PP2A family protein phos-
phatases have been implicated in Maf1 dephosphoryla-
tion, we confirmed earlier reports (Willis et al. 2004;
Willis and Moir 2007) that Tap42 does not play a role in
rapamycin-induced Maf1 dephosphorylation (Fig. 2B).
We wished to determine if Sch9 inhibition alone could
cause dephosphorylation of Maf1. In our hands, SCH9
deletion mutants grow very slowly but rapidly accumu-
late suppressive mutations potentially confounding con-
clusions derived from these strains. We therefore took
advantage of a previously described analog-sensitive allele
of SCH9 (sch9as) encoding a protein that can be specifi-
cally inhibited by the bulky ATP analog 1NM-PP1
(Jorgensen et al. 2004). Addition of 1NM-PP1 to sch9as,
but not wild-type cells, resulted in a rapid dephosphory-
lation of Maf1 (Fig. 3B).
As Maf1 was reported to be regulated by the RAS–PKA
pathway and to be phosphorylated in vitro by PKA (Moir
et al. 2006), we wished to further explore the relative
contributions of Sch9 and PKA to Maf1 phosphorylation.
PKA is encoded by three genes in yeast (TPK1, TPK2, and
TPK3) and is regulated by glucose in parallel to the TOR
pathway (Dechant and Peter 2008). Deletion of the three
TPK genes is lethal but can be rescued by the deletion of
YAK1 (Garrett and Broach 1989). We found that Maf1 is
still phosphorylated in tpk1 tpk2 tpk3 yak1 cells, and this
phosphorylation is still sensitive to rapamycin treatment
(Fig. 3C). In contrast to the results obtained with sch9as
cells, Maf1 phosphorylation was only slightly affected by
addition of 1NM-PP1 to tpk1as tpk2as tpk3as cells (Sup-
plemental Fig. S4A,B), suggesting a minor role of PKA
under these conditions. Maf1 dephosphorylation during
transit through diauxic shift did not show any significant
differences in tpk1 tpk2 tpk3 yak1 versus wild-type cells
(Supplemental Fig. S4C). In addition, Maf1 dephosphory-
lation following nitrogen starvation (Fig. 3D) was partially
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blocked in cells expressing the SCH9DE allele. Altogether,
these data suggest that Sch9 is the major kinase upstream
of Maf1 in exponentially growing cells.
While this manuscript was in preparation, Lee et al.
(2009) reported that Sch9 phosphorylates Maf1; but, in
contrast to our results, their work suggested that Sch9
and PKA perform equally important roles in Maf1 regu-
lation. We believe that this discrepancy is due to protocol
differences in the handling of yeast cells prior to protein
extract. In our studies, whenever possible, TCA was
added to growing cultures to quench all enzymatic ac-
tivity prior to further manipulations. In contrast, Lee
et al. (2009) cooled the cells on ice prior to lysis. We found
that this cooling step elicits a PKA-dependent rephos-
phorylation of Maf1 (Supplemental Fig. S8B). This obser-
vation suggests a more prominent role of PKA in Maf1
phosphorylation at lower temperatures and explains the
overestimated importance in Maf1 regulation at 30°C
assigned to PKA by Lee et al. (2009).
Next, we asked if Sch9 could directly phosphorylate
Maf1 in vitro. We found that Sch93E, but not a kinase-
deadmutant, was able to phosphorylate purified recombi-
nant Maf1 (Fig. 3E). Maf1 contains six motifs fitting the
R[R/K]xS consensus, which is often attributed to AGC
family kinases (S90, S101, S177, S178, S209, and S210).
The phosphopeptide identified in our phosphoproteomic
screens (Fig. 3A) contains two overlapping copies of this
motif. Unfortunately, neither the Sequest algorithm used
to annotate the tandemmass spectra normanual inspection
allowed us to determine with certainty which of the four
consecutive serines in this peptide were phosphorylated. To
resolve this issue we generated various alanine substituted
versions of Maf1 (Fig. 3A) and assayed the ability of Sch9 to
phosphorylate these proteins in vitro. First we replaced all
six serines fitting the R[R/K]xS consensus with alanine.
This version (Maf16A1) was still phosphorylated in vitro,
albeit very poorly, by Sch9 (Fig. 3E). Based on the phospho-
peptide that we identified in our screen we chose to
substitute an additional serine residue (S179) generating
a version of Maf1 we refer to as Maf17A. Maf17A was not
a substrate for Sch9 in vitro, suggesting that we mapped all
of the Maf1 residues phosphorylated by Sch9.
TORC1 regulates RNA Pol III through Sch9
Having established that TORC1, via Sch9, regulatesMaf1
phosphorylation we next asked whether this cascade
is physiologically important for the regulation of RNA
Pol III function. To begin, we confirmed that rapamycin
treatment causes a dramatic reduction in tRNA and 5S
rRNA synthesis as determined by 3H-uracil pulse labeling
(Fig. 4A). This drop in RNA Pol III activity was largely
blocked in cells expressing SCH9DE, whereas tap42-11
alone seemed to play little if any role in this process (Fig.
4A). These observations demonstrate that Sch9 influen-
ces RNA Pol III activity.
To extend these observations wewished to determine if
Sch9 signals to RNA Pol III via Maf1. 1NM-PP1 addition
to sch9as cells resulted in a rapid inhibition in tRNA and
5S rRNA synthesis (Fig. 4B). MAF1 deletion abrogated
the 1NM-PP1-induced reduction of tRNA synthesis but
seemingly did not abrogate the reduction of 5S rRNA syn-
thesis. An explanation for this result is explored below.
Pre-tRNAs are rapidly processed in exponentially grow-
ing cells, and their abundance can thus be used to infer
RNA Pol III activity. Quantitative RT–PCR analyses of
the pre-tRNAPro levels were consistent with the 3H-uracil
pulse labeling experiments and confirmed the epistasis
between SCH9 and MAF1 (Supplemental Fig. S5).
Figure 3. TORC1 regulates Maf1 phosphorylation via SCH9,
independently of PKA. (A) Maf1 schematic. Maf1 features in-
cluding phosphorylation sites and NLSs are pictured. Serines
predicted to be phosphorylated in the MS data are followed by
asterisks as are the Sch9 target residues in the C terminus of
Rps6. The various alanine-substituted versions of Maf1 used
in the kinase assays shown in D are summarized below the
scheme. (B) Sch9 inhibition leads to Maf1 dephosphorylation.
(C) TORC1 regulates Maf1 phosphorylation independently of
PKA. (B,C) Protein extracts were prepared from cells of the
indicated genotype following treatment (15 min in C) with the
indicated drugs (PP1: 1NM-PP1). Phosphorylation of Maf1-3HA
was determined by SDS-PAGE and Western blotting. (D) Sch9
couples nitrogen-dependent signals to Maf1. Prototroph cells of
the indicated genotype were grown to exponential phase in SD,
filtered, and resuspended in control (+NH4) or in ammonium-
deprived medium (NH4). Samples were taken at the indicated
time points and analyzed for Maf1 phosphorylation by Western
blotting. (E) Sch9 phosphorylates 7 serines in Maf1 in vitro.
Maf1 mutants, purified from Escherichia coli, were tested as
substrates for GST-Sch93E purified from yeast. GST-Sch9kd is a
point mutant lacking catalytic activity and was used as a nega-
tive control. Reactions were resolved by SDS-PAGE, proteins
were stained with Coomassie (CBB) and the dried gel was
analyzed for 32P incorporation.
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These observations prompted us to determine whether
the deregulation of tRNA synthesis observed in our
sch9as maf1 mutant could lead to an altered abundance
of tRNA relative to other RNA species. To this end we
compared 5.8S, 5S, and tRNA levels in exponentially
growing cells in the presence or absence of Sch9 and/or
Maf1 function. Although total 5S rRNA levels relative to
RNA Pol I-derived 5.8S rRNA were unchanged in any of
the strains examined, the tRNA:5.8S rRNA ratio was
approximately twofold higher in 1NM-PP1-treated sch9as
maf1 cells compared with wild-type cells (Fig. 4C,D). An
explanation for this result is explored below. To evaluate
the importance of Maf1 phosphorylation in RNA Pol III
regulation we employed Maf1 mutants where all seven
Sch9 phosphorylated residues were replaced with either
glutamate (Maf17E) or alanine residues (Maf17A). Inhibi-
tion of Sch9 in cells expressing Maf17E leads to tRNA
accumulation intermediate to that observed in MAF1
and maf1 cells; cells expressing the Maf17A mutant had
reduced basal levels of tRNA (Fig. 4C,D). 3H-uracil pulse
labeling experiments following Sch9 inhibition and rapa-
mycin treatment in MAF1, maf1, MAF17A, and MAF17E
Figure 4. TORC1 regulates RNA Pol III via Sch9 and Maf1. (A) Rapamycin inhibits 5S rRNA and tRNA synthesis via SCH9. (B) Sch9
inhibition leads to a Maf1-dependent inhibition of tRNA synthesis. (A,B) RNA synthesis in cells of the indicated genotype following the
indicated drug treatment was determined by metabolic labeling with 3H-uracil. Total RNA loaded was determined by staining with
ethidium bromide (EtBr). Asterisk (*) indicates an unstable RNA species that accumulates in maf1 cells. (C) MAF1 phosphorylation
regulates tRNA levels. Cells of the indicated genotype were grown in SC URA LEU TRP HIS 0.2% Gln 300 nM 1NM-PP1 to log
phase (OD600 < 0.8) and total RNA was extracted. Total levels of the 5S and 5.8S rRNA and tRNA were assayed by PAGE and EtBr
staining. (D) Quantification of C and two other independent experiments. 5S:5.8S and tRNA:5.8S ratios were calculated and plotted
relative to untreated wild-type control. (*) P < 0.05; (***) P < 0.001 versus wild-type control. (E) Genetic interactions between SCH9 and
MAF1. Ten-fold dilutions of the indicated strains were spotted and grown on YPD 6 1NM-PP1 (2 d, 30°C) or on YPGlycerol (4 d, 37°C).
(F) Sch9 regulates Maf1 association with RNA Pol III. Interaction of Maf1-3HAwith RNA Pol III was assessed by Rpc82-TAP pull-downs
followed by SDS-PAGE and Western blotting. Relevant genotypes and rapamycin treatments are indicated.
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strains similarly demonstrate that Maf1 phosphosite mu-
tants are partially functional (Supplemental Fig. S6A,B).
These results are consistent with Sch9 regulating RNA
Pol III via Maf1, but suggest that Maf1 phosphorylation
plays only a partial role in this regulation, implying that
Sch9 targets additional factors to regulate RNA Pol III
albeit in a Maf1-dependent manner.
Additional genetic observations further support our ob-
servations. In the presence of 1NM-PP1, sch9as cells grew
slowly, dividing every 150 min 6 8 min (compared with
103 min 6 4 min for wild-type cells). This slow growth
rate was slightly, but significantly, improved to 135 min
6 5 min by deletion of MAF1, suggesting that reduced
RNA pol III activity is one of multiple growth-limiting
consequences resulting from loss of Sch9 function. Con-
versely, we observed a synthetic growth defect when
sch9as maf1 cells were grown at 37°C on the nonferment-
able carbon source glycerol (Fig. 4E). This result fits with
the previously proposed model that accumulation of
tRNA in maf1 cells is detrimental to mitochondrial
function (Boguta et al. 1997).
Sch9 regulates Maf1 localization and association with
the RNA Pol III machinery
How does phosphorylation by Sch9 alter the ability of
Maf1 to inhibit RNA Pol III activity? We explored two
potential mechanisms by which Sch9 might regulate
Maf1: Maf1 localization and the capacity of Maf1 to bind
to RNA Pol III. Maf1 was both nuclear and cytoplasmic
in our strain background and promptly accumulated in
the nucleus upon rapamycin treatment (Supplemental
Fig. S7A,B). Sch9DE did not block the rapamycin-induced
nuclear accumulation; but, probably due to the hypomor-
phic nature of these alleles (Jorgensen et al. 2004; Urban
et al. 2007), SCH9DE and sch9as cells showed increased
basal nuclear accumulation of Maf1 that could be further
enhanced in sch9as cells by 1NM-PP1 treatment (Supple-
mental Fig. S7A–D). From these results, we propose
that Maf1 phosphorylation by Sch9 contributes but is
not sufficient to prevent Maf1 nuclear localization. This
hypothesis is consistent with previousmodels (Moir et al.
2006) suggesting that TORC1 regulates the two redun-
dant nuclear localization sequences (NLSs) found inMaf1
(Fig. 3A) independently; activity of the N-terminal NLS
was proposed to be regulated via phosphorylation (i.e.,
Sch9-dependent) while the C-terminal NLS is regulated
independently of phosphorylation (i.e., Sch9-independent).
In contrast to localization, the ability of Maf1 to di-
rectly bind to RNA Pol III appears to be a more important
mechanism by which Maf1 phosphorylation regulates
RNA Pol III activity (Oficjalska-Pham et al. 2006; Roberts
et al. 2006). Therefore we wished to test if phosphoryla-
tion by Sch9 alters the ability of Maf1 to interact with the
RNA Pol III subunit Rpc82. Using a coprecipitation assay
we confirmed that rapamycin treatment strongly in-
creases the association of Maf1 with Rpc82. Importantly,
we found that Sch9DE blocked this rapamycin-induced
interaction (Fig. 4F). Consistent with this observation,
the Maf17E mutant did not associate with Rpc82 upon
rapamycin treatment (Fig. 4F), while the Maf17A mutant
showed constitutive interaction in untreated wild-type
cells (Supplemental Fig. S8A). We were not, however, able
to detect an induction of the interaction upon Sch9
inhibition in the TB50 genetic background (Supplemental
Fig. S8A), which is likely due to Maf1 rephosphorylation
that occurs during cooling prior to nondenaturing protein
extraction (Supplemental Fig. S8B). We observed a small
induction of the interaction upon Sch9 inhibition in the
W303 background that could be further enhanced by
concomitant inhibition of PKA (Supplemental Fig. S8C).
Taken together, these results demonstrate that Sch9 (and
PKA in some conditions) regulates the capacity ofMaf1 to
bind RNA Pol III.
Sch9 mediates the TORC1 signal to RNA Pol I
As noted above (Fig. 4C,D), we observed that the ratio of
tRNA:5.8S rRNA is increased in 1NM-PP1-treated sch9as
maf1 cells relative to untreated sch9as maf1 cells. It was
not clear why tRNA should be accumulated relative to
5.8S rRNA in these exponentially growing cells; i.e.,
when rRNA expression should be fully derepressed. We
rationalized that this result could be explained if both
RNA Pol I and III activities are reduced upon Sch9 inhi-
bition, with MAF1 deletion suppressing only the latter.
Thus, tRNA synthesis was not up-regulated per se, but
rather RNA Pol I-dependent rRNA synthesis was de-
creased in these cells. This hypothesis could also explain
the apparent failure of MAF1 deletion to rescue the de-
crease in RNA Pol III-dependent 5S rRNA synthesis
resulting from Sch9 inhibition (Fig. 4B): 5S rRNA tran-
scription, we speculate, is rescued by MAF1 deletion.
However, because RNAPol I activity is reduced, 5S rRNA
is produced in excess relative to other rRNAs and, con-
sequently, is unstable and rapidly degraded. The shorter
unstable RNA species whose levels increased when Sch9
activity was inhibited in maf1 cells (asterisk in Fig. 4B)
fits well with this notion. These deductions prompted us
to test if TORC1 regulates RNA Pol I via Sch9.
We first confirmed that rapamycin treatment results
in a rapid decline in the synthesis of 25S, 18S, and 5.8S
rRNAs, as judged by 3H-uracil pulse labeling assays (Fig.
5A). This effect was dramatically blocked in SCH9DE cells
but unaltered in tap42-11 cells. Interestingly, 3H-uracil
incorporation into these rRNAs was virtually insensitive
to rapamycin in SCH9DE tap42-11 cells. Consistently,
addition of 1NM-PP1 to sch9as cells resulted in a rapid,
Maf1-independent, decrease in the synthesis of 25S, 18S
and 5.8S rRNAs (Fig. 5B).
These results clearly demonstrated that Sch9 is indeed
important in regulating the synthesis of RNA pol
I-derived rRNA species and beg the question: How? Sch9
could regulate RNA pol I transcription or rRNA processing
or a combination thereof. To begin to discriminate be-
tween these possibilities we first determined the relative
amounts of unstable rRNA species to try to gauge the flux
from pre-rRNAs to mature end products. Rapamycin
treatment and Sch9 inhibition led to decreased rRNA
processing as judged by dramatically increased 27S:25S
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and 20S:18S ratios (Fig. 5A,B). Rapamycin-induced pro-
cessing defects were largely blocked by the SCH9DE allele.
Thus, Sch9 activity promotes rRNA processing.
We also explored if Sch9 might regulate RNA Pol I
activity by several approaches. First, we used primer
extension assays to determine the relative abundance
of the short-lived 35S pre-rRNA. In wild-type cells, 35S
levels dropped approximately threefold when assayed
after 30 min of rapamycin treatment (Fig. 5C). SCH9DE
and tap42-11 cells showed slight, but significant resis-
tance, while SCH9DE tap42-11 cells showed pronounced
resistance to this rapamycin-induced drop in 35S pre-
rRNA levels. Consistent with these observations, addition
of 1NM-PP1 to sch9as cells resulted in an approximately
twofold drop in 35S pre-rRNA levels (Fig. 5D). Although it
is difficult to separate processing effects from RNA pol I
Figure 5. TORC1 regulates RNA Pol I via Sch9. (A) Rapamycin treatment decreases the processing/expression of RNA pol I-derived
rRNA species. (B) Sch9 inhibition decreases the processing/expression of RNA pol I-derived rRNA species. (A,B) Synthesis/processing of
rRNA was assayed by metabolic labeling with 3H-uracil. Total RNA loaded was determined by staining with ethidium bromide (EtBr).
(C) Rapamycin treatment decreases 35S pre-rRNA synthesis. (D) Sch9 inhibition decreases 35S pre-rRNA synthesis. (C,D) 35S and 18S
rRNA levels were determined by primer extension—gels are shown in Figure S9—and their ratios were plotted. Values are means of
three independent experiments 6 SD. (E) RNA Pol I recruitment at the rDNA locus depends on Sch9. Association of RPA190-13myc
with the rDNA locus was determined by ChIP. Values are means of four independent experiments6 SD. Statistical confidences for C–E:
(*) P < 0.05; (**) P < 0.01; (***) P < 0.001 versus wild-type control; (##) P < 0.01 versus untreated isogenic control. (F) Sch9 does not
regulate Rrn3–RNA Pol I interaction. Association of Rrn3-5HA with Rpa190-TAP was assayed using TAP pull-downs and SDS-PAGE/
Western blotting. (A–F) Relevant genotypes and rapamycin/1NM-PP1 treatment times are indicated.
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activity, these observations suggest that Sch9 and Tap42
each play a role in regulating RNA Pol I transcription.
Next, we used chromatin immunoprecipitations (ChIPs)
to more directly evaluate a role for Sch9 and/or Tap42 in
RNA Pol I activity. ChIPs with Rpa190, the catalytic
subunit of RNA Pol I, showed that RNA Pol I occupancy
at the rDNA locus decreased more than twofold follow-
ing 30 min of rapamycin treatment (Fig. 5E). Mirroring
the 3H-uracil labeling assays, this rapamycin-induced
eviction of RNA Pol I from the rDNA locus was strongly
blocked in SCH9DE cells and completely blocked in SCH9DE
tap42-11 cells. Thus, TORC1 promotes the recruitment of
RNA Pol I to the rDNA locus primarily via Sch9.
Previously, Claypool et al. (2004) had proposed that
TORC1 influenced RNA Pol I recruitment to the rDNA
locus by promoting an interaction between RNAPol I and
Rrn3, an essential initiation factor. We therefore asked
if Sch9 and/or Tap42 impinge on this Rrn3–RNA Pol
I interaction by pull-down of TAP-tagged Rpa190. This
appears not to be the case: The rapamycin-induced dis-
sociation of Rrn3 and RNAPol I in SCH9DE tap42-11 cells
was essentially indistinguishable from the dissociation
observed in wild-type cells (Fig. 5F). These data suggest
that the dissociation of Rrn3 from RNA Pol I is not the
primary mechanism by which TORC1 inhibition causes
a reduction in rDNA transcription. We do note, however,
that Rrn3 levels drop during rapamycin treatment, and
that this is blocked in SCH9DE tap42-11 cells.
Discussion
Sch9 is a central coordinator of protein synthesis
Previous work (Upadhya et al. 2002) had shown that
phosphorylation of the RNA Pol III inhibitor Maf1 is
regulated downstream from TORC1 and, consistently,
a Maf1 phosphopeptide was found to be down-regulated
after rapamycin treatment in our phosphoproteomic
screens. However, our screens further predicted that
Maf1 phosphorylation is regulated by TORC1 via Sch9.
Subsequent biochemical studies demonstrated that Maf1
is likely a direct substrate of Sch9 and genetic experi-
ments demonstrated that RNA Pol III down-regulation
upon Sch9 inhibition is Maf1-dependent. At the molecu-
lar level, we found that Maf1 phosphorylation by Sch9
was important for Maf1 association with RNA Pol III.
However, RNA Pol III activity is still sensitive to rapa-
mycin in cells expressing a ‘‘phosphomimetic’’ version of
Maf1 (Maf17E). Thus, we believe that Sch9 must target
a factor(s) in addition to Maf1 to regulate RNA Pol III
activity.
Expectedly,MAF1 deletion, which mostly affects tRNA
levels, did not suppress the sch9 growth phenotype.
However, it would be interesting in the future to study
the impact of Maf1 on other Sch9 phenotypes such as cell
size regulation and longevity (Jorgensen et al. 2004;
Kaeberlein et al. 2005). In particular, regulation of tRNA
and especially initiator tRNAMet levels by Maf1 could
affect translation and, via Gcn4, longevity as recently
observed (Steffen et al. 2008).
During the course of these studies we found that, in
addition to RNA Pol III, Sch9 also regulates the synthesis
of RNA Pol I transcripts. Specifically, Sch9 promotes both
processing of rRNA species and recruitment of RNA Pol I
to the rDNA locus. rRNA processing could be an indirect
function of Sch9 as Sch9 controls the expression of many
rRNA processing factors in the ribi regulon (Jorgensen
et al. 2004). We do not know the mechanism by which
Sch9 promotes recruitment of RNA Pol I to the rDNA
locus but it does not appear to involve the association of
RNA Pol I with its initiation factor Rrn3. Interestingly,
RNA Pol I activity was proposed to be determinant for the
expression of other ribosomal components (RPs and 5s
rRNA), which could suggest that Sch9 regulates RP genes
expression indirectly via RNA Pol I activity (Laferte et al.
2006).
Sch9 was thought previously to be the ortholog of
mammalian Akt. However, we proposed recently that
Sch9 functions more similarly to mammalian ribosomal
S6 kinase (S6K1) (Urban et al. 2007). This present study
strengthens the functional similarities between Sch9 and
S6K1: Both Sch9 and S6K1 have now been shown to
regulate the activities of the three nuclear RNA poly-
merases (Zhang et al. 2005; Woiwode et al. 2008). Recent
studies have shown that elevated RNA Pol III transcrip-
tion is necessary, or in some cases sufficient, for cellular
transformation (Johnson et al. 2008; Marshall et al. 2008).
Extrapolating from our results, it will be of interest to
determine if dysregulation of S6K1 and/or Maf1 likewise
contribute to cellular transformation.
In summary, the present study, together with previous
work, demonstrates that Sch9 regulates the activities of
all three nuclear RNA polymerases. In addition, we
showed previously that Sch9 also regulates translation
initiation (Urban et al. 2007). Thus, Sch9 appears to play
a central role in coupling environmental cues to the
coordinated expression, assembly, and activity of the
protein synthesis machinery (Fig. 6). In addition to
Maf1, our characterization of the rapamycin-sensitive
phosphoproteome also uncovered other TORC1/Sch9
targets implicated in ribosome biogenesis; namely, Stb3
and Dot6/Tod6, which have been shown previously to
respectively bind RRPE and PAC elements in ribi gene
promoters (Liko et al. 2007; Badis et al. 2008; Zhu et al.
2009). We found Sch9-dependent rapamycin-sensitive
phosphorylation sites in Stb3 and Dot6/Tod6, many of
which fit the R[R/K]xS consensus motif, suggesting that
these proteins could be directly phosphorylated by Sch9.
Western blot analyses confirmed that Dot6 and Tod6 are
indeed phosphorylated downstream from Sch9 (Fig. 2B),
and preliminary experiments suggest that Sch9 signals
antagonize the ability of Stb3, Dot6, and Tod6 to inhibit
ribi gene expression (Fig. 6; Supplemental Figs. S1A, S3;
data not shown).
Label-free quantitative phosphoproteomic screens
The integrated experimental and computational frame-
work that we present in this work enables relative
quantification of phosphorylation patterns. The procedure
Rapamycin-sensitive phosphoproteome
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is technically robust and sensitive, and the data acquired
is accurate and, as we illustrate in this manuscript, highly
reproducible. Themain advantage of our method is that it
allows us to quantify thousands of phosphorylation sites
between, in principle, an unlimited number of samples or
biological states. In addition, no a priori knowledge of
phosphopeptide ions is required for quantitation as tar-
geted LC-MS/MS methods can be employed to identify
regulated ions of interest (Schmidt et al. 2008). This
improves the sensitivity and especially the achievable
throughput compared with quantification based on iso-
tope labeling.
Although our data identified many of the rapamycin-
sensitive phosphorylation events described in the litera-
ture, many were missed. Indeed, high coverage of a given
phosphoproteome remains a major challenge in current
phosphoproteomics (Bodenmiller et al. 2007b). Neverthe-
less, this study demonstrates that even with an incom-
plete coverage of a phosphoproteome our experimental
and computational pipeline can elucidate novel and
important biological phenomena as demonstrated with
the characterization of Maf1 phosphorylation.
Materials and methods
Yeast cultures and assays
Saccharomyces cerevisiae strains and plasmids are described in
Supplemental Tables S1 and S2, respectively. Strains were con-
structed according to standard protocols. SCH9 and TAP42 were
deleted in diploid strains and complemented with plasmids
encoding wild-type alleles before sporulation. Wild-type alleles
were subsequently replaced with mutant alleles in haploids by
plasmid shuffling.
Unless specified otherwise, rapamycin was used at 200 nM
(from a 1 mM stock solution in 90% ethanol, 10% Tween-20),
1NM-PP1 at 200 nM (from a 1 mM stock in DMSO), and
cycloheximide at 25 mg/mL (from a 10 mg/mL stock solution
in H2O).
Label-free phosphoproteomics
Cells were grown in SCLEU 0.2%Gln at 23°C toOD600 0.8 and
subjected to the indicated treatments for 30min. All biochemical
activities were then quenched by the addition of trichloroacetic
acid and proteins were extracted under denaturing conditions.
Three 400-mL aliquots for each condition were processed sepa-
rately for disulfide bond reduction, cysteine alkylation, trypsin
digestion, and phosphopeptide enrichment as described in more
detail in the Supplemental Material.
The phosphopeptides were separated by reverse phase chro-
matography on an Eksigent nano-LC system and were analyzed
on a hybrid LTQ-Orbitrap mass spectrometer (Thermo Electron
Corporation) interfaced with a nano-electrospray ion source as
detailed in the Supplemental Material. The LC-MS/MS data was
searched against the SGD yeast protein database as described in
the Supplemental Material.
For the detection of the regulated features (peak picking and
integration of the area from the LC-MS data, alignment of
features over multiple runs) the SuperHirn version 2.0 algorithm
(Mueller et al. 2007; Rinner et al. 2007) was used. Of note, as we
used a label-free approach, the peptide sequence information
from all LC-MS/MS runs was usable to assign the LC-MS
features present in the SuperHirn output file, called MasterMap
(the relevant parameters used are published as Supplemental
Material). The MasterMap was post-processed as follows: Of all
of the phosphopeptide features the deconvoluted masses were
computed and the peak areas of phosphopeptides present in
different charge states were merged. Based on these areas, the
statistical significance was computed using a t-test as imple-
mented in the Corra software environment (Brusniak et al. 2008).
Phosphopeptides were considered to be cycloheximide- or
rapamycin-sensitive if their abundance relative to untreated
cells was altered twofold or more (P-value, <0.05) by cyclohex-
imide or rapamycin treatment, respectively. Rapamycin-sensitive
phosphopeptides were considered to be Sch9-dependent after
fulfilling two selection criteria. First, rapamycin-induced changes
in wild-type cells had to be blunted twofold or more in SCH93E
cells. Second, the abundance of a phosphopeptide reduced (or
induced) by rapamycin treatment in wild-type cells had to be
$1.5-fold higher (or lower) in both untreated and rapamycin-
treated SCH93E cells compared with rapamycin-treated wild-
type cells. The same criteria were used to evaluate Tap42 de-
pendence. All regulated phosphopeptide ions corresponding to the
phosphorylation sites of interest were validated.
Data availability
All MS2 information will be made available via the Phosphopep
database (http://www.phosphopep.org) (Bodenmiller et al. 2007a).
The raw data in the mzXML format can be downloaded from the
Peptide Atlas Web page at http://www.peptideatlas.org/repository
(Desiere et al. 2006).
Copurification assays
Precultures grown in plasmid-selective synthetic medium were
diluted in YPD and grown to OD600 0.7–1.0. One-hundred-
milliliter aliquots were treated as described in the text and
processed for native protein extraction as described in the
Supplemental Material. Protein concentrations were normalized
and aliquots were removed to control for input. TAP pull-downs
were performed for 2 h at 4°C with 107 magnetic beads (Epoxy
Figure 6. Model of TORC1 signaling highlighting the central
role that Sch9 plays in coordinating the expression, assembly
and activity of the protein synthesis machinery. See the Discus-
sion for details.
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M270 Dynabeads, Invitrogen) covalently coated with purified
rabbit IgG. Beads were washed three times with lysis buffer
before resuspension in SDS-PAGE sample buffer. Samples were
analyzed by SDS-PAGE and Western blotting.
3H-uracil labeling
Cells were grown at 25°C in SC URA to OD600 0.6–0.9 and
treated as described in the text. Five-milliliter aliquots were
removed, supplemented with 50 mCi 5,6-3H-uracil, and incu-
bated for 20min. Chase was performed for 20minwith a 100-fold
excess cold uracil before total RNA was extracted and analyzed
as described in the Supplemental Material.
Primer extension assays
Primer extension assays were performed as described previously
(Claypool et al. 2004) with slight modifications. The protocol is
detailed in the Supplemental Material.
Recombinant protein expression
and purification–kinase assays
Purification of GST-Sch9(3E/kd) from yeast cells was performed as
described previously (Urban et al. 2007), except that SCH93Ewas
used as the active SCH9 allele. Maf1 proteins were expressed in
bacteria, affinity-purified using the pGEX6P1 system (Invitro-
gen), and assayed as substrates for GST-SCH93E/kd as described
previously (Urban et al. 2007).
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T H E D U A L S P E C I F I C I T Y K I N A S E D Y R K 3 C O U P L E S
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M T O R C 1 S I G N A L I N G
For this work I processed the LC–MS/MS data generated using the clustering
algorithm for LC–MS/MS alignments described in chapter 7.
The manuscript included below is currently under second review.
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Summary 
Cytosolic compartmentalization through liquid-liquid unmixing, such as the 
formation of stress granules during cellular stress, is involved in many cellular 
processes and may be coupled to signal transduction, but specific molecular 
regulators of this are unknown. Here, we reveal that the dual specificity kinase 
DYRK3 is able to condense P granule-like structures and to prevent stress 
granule dissolution via its N-terminal domain when inhibited. DYRK3 couples 
this to mTORC1 signaling by sequestering mTORC1 on stress granules when 
inactive and by phosphorylating PRAS40 when active. By showing that 
DYRK3 dynamically regulates its own partitioning between SGs and the 
cytosol through its kinase activity, our work suggests a novel cyclic 
partitioning mechanism that couples compartmentalization through liquid 
phase transitions with cellular signaling.
 
 
Introduction 
The nucleus and cytosol of eukaryotic cells contain numerous nonmembrane-
bound compartments that consist of many proteins involved in complex 
reactions. Well known amongst these are different types of RNA granules, 
microscopically visible accumulations of messenger ribonucleo-protein 
(mRNP) (Anderson and Kedersha, 2009; Eulalio et al., 2007). A complex 
repertoire of mRNP-associated proteins determine whether mRNPs 
complexes remain silent, become translationally active, or are degraded 
(Buchan and Parker, 2009). Especially during stressful conditions such as 
heat, oxidative stress, virus infection, osmotic stress and UV irradiation, 
mRNPs accumulate into large granules, so called stress granules (SGs), 
where they are translationally silenced (Anderson and Kedersha, 2008).  
Recently, it has become clear that the accumulation of RNA granules is 
reminiscent of concentration-dependent liquid-liquid de-mixing of mRNA and 
proteins with low complexity domains (Hyman and Simons, 2012; Kato et al., 
2012; Weber and Brangwynne, 2012). While this may be a unifying principle 
of compartmentalization without membranes (Brangwynne et al., 2009), many 
fundamental questions remain unanswered. For instance, are there specific 
molecular regulators of this type of compartmentalization, and is it utilized to 
control signal transduction, analogous to membrane-bound compartments? 
These questions become apparent during cellular stress, when cells have to 
coordinate SG condensation and dissolution with the control of signaling 
 
pathways that initiate mRNA translation (Buchan and Parker, 2009), amongst 
which the mechanistic target of rapamycin (mTOR) signaling pathway takes a 
prominent role (Loewith and Hall, 2011; Ma and Blenis, 2009; Sengupta et al., 
2010; Zoncu et al., 2010). Interestingly, in S. cerevisiae the mTOR complex 1 
(mTORC1) partitions in heat-induced SGs, suggesting a coupling of SG 
condensation and dissolution with mTORC1 signaling (Takahara and Maeda, 
2012). How this is coupled is however unclear.  
Here, we identify the dual specificity tyrosine-phosphorylation-regulated 
kinase 3  (DYRK3) as a protein with the ability to condense P granule-like 
speckles in the cytosol and to prevent SG dissolution via its N-terminal 
domain when it is in a kinase-inactive form. DYRK3 couples this to the control 
of mTORC1 signaling by sequestering mTORC1 on SGs when inactive, and 
by phosphorylating PRAS40 in the cytosol, a negative regulator of mTORC1 
(Sancak et al., 2007; Vander Haar et al., 2007), when active. Since DYRK3 
dynamically regulates its own partitioning between SGs and the cytosol 
through its kinase activity, this suggests a novel cyclic partitioning mechanism 
that couples compartmentalization through liquid phase transitions with 
cellular signaling. 
 
RESULTS 
An image-based screen for chemical compound inhibitors that delay 
stress granule disassembly 
To study the regulation of SG dissolution, we screened a custom library of 246 
small compound kinase inhibitors in their ability to prolong the presence of 
SGs in HeLa cells during recovery from arsenite-induced oxidative stress. We 
first exposed cells to arsenite for 45 minutes, after which we allowed recovery 
for 240 minutes in the presence of small compound inhibitors at 2 different 
concentrations (Figure 1A). To monitor the occurrence of SGs, we used 
immuno-fluorescence staining against polyadenylate-binding protein 1 
(PABP1), which, upon stress, gets recruited to SGs, resulting in bright and 
easily detectable granules (Kedersha et al., 1999). Quantification of the 
fraction of cells containing SGs was performed with automated image analysis 
and machine learning.  
Compounds that were able to block SG dissolution at least more than 3 
standard deviations above the mean of all treatments were considered as 
significant hits (z-score ≥ 3; red dots). Based on this, we identified two 
compounds at 1 μM concentration, GSK-626616 and Jak3 inhibitor IV as most 
potent in blocking SG dissolution (Figure 1B, left side). At 10 μM 
concentration, we identified the compounds Harmine, Wee1/Chk1 Inhibitor, 
CDK4 Inhibitor III, CDK2 Inhibitor IV, PKR inhibitor negative control and GSK-
626616 as most potent in blocking SG disassembly (Figure 1B, right side). 
 
To validate the candidate compounds found in the initial screen, we performed 
a second stress recovery assay using time-lapse imaging of RDG3 cells 
expressing GFP-tagged Ras GTPase-activating protein-binding protein 1 
(G3BP1). These cells were previously used in a RNA interference (RNAi) 
screen to identify genes involved in mRNA granule condensation (Ohn et al., 
2008). Quantitative analysis showed that oxidative stress for 45 minutes 
caused a rapid increase of SG-positive cells, followed by a rapid decline in the 
subsequent recovery phase after arsenite washout (Figure 1C and Suppl. 
Movie S1). From the 7 compounds identified in the initial screen, we could 
confirm 5 compounds, GSK-626616, Harmine, CDK2 Inhibitor IV, CDK4 
Inhibitor III and Wee1/Chk1 Inhibitor, to reduce the decline rate of SG-positive 
cells during stress recovery in a second cell line using another SG marker.  
We further tested which of these compounds can induce SG condensation in 
the absence of stress. Treatment of cells for 240 min with these compounds in 
the absence of any stress revealed that CDK2 Inhibitor IV and to a lesser 
extent Wee1/Chk1 Inhibitor are able to induce SGs (Figure 1D). CDK4 
inhibitor III, GSK-626616, and Harmine did not cause significant SG formation 
in HeLa cells during 240 min of treatment.  
Finally, we analyzed whether the compounds have an effect on the 
phosphorylation of eukaryotic initiation factor 2 alpha (eIF2α) at Ser51, which 
is induced by arsenite treatment and causes a translational arrest and rapid 
appearance of SGs (Anderson and Kedersha, 2002). Interestingly, none of 
the compounds could trigger the phosphorylation of eIF2α on its own, but the 
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Wee1/Chk1 Inhibitor prevented dephosphorylation of eIF2α after recovery 
from oxidative stress (Figure 1D). 
Taken together, these experiments revealed that GSK-626616, Harmine and 
CDK4 Inhibitor III are able to reduce the rate of SG dissolution after oxidative 
stress without evoking de novo condensation of SGs, and without affecting 
phosphorylation and de-phosphorylation of eIF2α. Clearly, GSK-626616 was 
the most potent compound, being able to delay SG disassembly at 1 μM. 
Furthermore, Harmine was present in top 4% of all compounds tested at low 
concentrations (Figure 1B, left side), and was the top hit at 10 μM. 
Interestingly, both GSK-626616 and Harmine are known inhibitors of DYRK 
family kinases (Erickson-Miller et al., 2007; Gockler et al., 2009). GSK-626616 
has a reported IC50 for DYRK3 of 0.7 nM, but overall kinase specificity is 
unclear. To obtain a kinome-wide view on the kinase specificity of GSK-
626616, we profiled the inhibitory effect of GSK-626616 on 451 kinases in 
vitro (Karaman et al., 2008). At 0.1 μM, GSK-626616 primarily inhibits DYRK 
family kinases (Suppl. Figure S1A and Table 2) with a good selectivity (S-
Score(35) = 0.07), comparable to well studied and highly specific kinase 
inhibitors (Karaman et al., 2008). At 1 μM, GSK-626616 displays some off-
target effects in vitro, but still has reasonable selectivity against DYRK family 
kinases (S-Score(35) = 0.12). Harmine was previously tested on 67 kinases in 
vitro, and also seems to have a specific potential in inhibiting DYRK family 
kinase at 1 μM (Bain et al., 2007), in particular of DYRK1A, DYRK2, and 
DYRK3 (Gockler et al., 2009). 
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The compound screen and in vitro kinase profiling revealed that specific 
inhibitors of DYRK family kinases delay the dissolution of SGs during recovery 
from stress in a manner that does not involve classical SG condensation 
pathways via eIF2α. 
 
DYRK3 can condense P granule-like speckles and partitions in stress 
granules 
Consistent with a previous classification of DYRK family kinases by their 
subcellular localization, we found that GFP-DYRK1A and GFP-DYRK1B 
localized to the nucleus (Suppl. Figure S2A). Interestingly, GFP-DYRK3 
localized predominantly on distinct speckles distributed throughout the 
cytoplasm of the cell (Figure 2A). This subcellular localization of DYRK3 was 
not seen for DYRK2 and DYRK4, the other class 2 DYRK family members 
(Suppl. Figure S2A).  
However, at low levels of expression, GFP-DYRK3 distributed homogeneous 
throughout the cytoplasm and did not aggregate in speckles (Figure 2B). 
When we quantified this aggregating effect in a large number of cells, we 
discovered that at a defined expression-level, DYRK3 suddenly condenses in 
speckles (Figure 2B). Furthermore, following GFP-DYRK3 speckles by time-
lapse microscopy revealed that the speckles are dynamic and can merge in a 
liquid-like manner (Suppl. Figure S2B and Movie S2). These observations are 
reminiscent of P granule behavior in C. elegans (Brangwynne et al., 2009). In 
vertebrates as well as in C. elegans, GW182 is a scaffold protein of mRNA 
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processing-bodies (P-bodies), sites of mRNA decay and storage (Eulalio et 
al., 2007; Eystathioy et al., 2003). Indeed, when co-expressed, DYRK3 and 
GFP-GW182 co-localize in numerous granules that were somewhat larger 
than formed by GFP-DYRK3 expression alone (Figure 2C).   
Importantly, we observed that during oxidative and osmotic stress, 
endogenous DYRK3 and GFP-DYRK3 localize to SGs (Figure 2D and 2E). 
Furthermore, DEAD box p54 protein 6 (DDX6)-positive P-bodies, often in 
close proximity to SGs, were found docked on GFP-DYRK3-positive granules 
(Suppl. Figure S2C). Moreover, endogenous DYRK3 localized to SGs, present 
240 minutes after stress and retained by the treatment with DYRK inhibitors 
after stress (Figure 2F and S2D).   
Thus, DYRK3 has the potential to condense granules in the cytosol of human 
cells on which the mRNA-binding protein GW182 can be recruited, and 
DYRK3 localizes to SGs during oxidative and osmotic stress. 
 
The N-terminal domain of DYRK3 is required for stress granule 
localization and induces stress granules when DYRK3 kinase activity is 
compromised 
We next wondered how inhibition of DYRK3 prevents SG dissolution. 
Surprisingly, we observed that RNAi-mediated depletion of DYRK3 or of the 
other DYRKs (not shown) did not disturb the dissolution of SGs after oxidative 
stress (Figure 3A). Instead, we discovered that DYRK3 depletion, but not that 
of the other DYRKs (not shown) reduced the block in SG dissolution caused 
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by GSK-626616 treatment. This suggests that inhibited DYRK3 is in a state 
that specifically prevents the dissolution of SGs. In support of this, we 
observed that expression of the kinase-deficient point-mutant DYRK3-K218M 
is sufficient to cause the appearance of large cytoplasmic structures positive 
for mRNA granule markers, on which GFP-DYRK3-K218M accumulated, even 
in the absence of stress (Figure 3B). To test if a specific domain of DYRK3 
mediates the partitioning in RNA granules, we generated a series of DYRK3 
truncations (Figure 3C). Expression of DYRK3-NT, which consists of the N-
terminal residues 1-188 and contains a predicted low-complexity sequence, 
but which excludes the kinase domain and C-terminal end, induced the 
appearance of large granules at high expression levels, which, similar to SGs, 
had P-bodies in close proximity and stained positive for PABP1 (Figure 3D 
and 3E). Conversely, overexpression of DYRK3 without the N-terminal 
domain (DYRK3-ΔNT) did not induce cytoplasmic granules, and did not 
partition in SGs induced by oxidative stress (Figure 3F).   
Thus, inhibition of DYRK3 affects SG dissolution through a specific state of 
DYRK3 when its kinase activity is compromised. This state depends on the N-
terminal domain of DYRK3, which, when expressed alone, is able to induce 
the appearance of SGs in the absence of stress. 
 
Inhibition of DYRKs affects the phosphorylation of proteins that bind 
mRNA, partition in stress granules, and are downstream of mTORC1 
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To obtain insight into how cells couple SG condensation and dissolution to 
signal transduction, we next studied which signaling pathways are affected by 
the inhibition of DYRKs. To reveal this, we studied changes in the phospho-
proteome of cells after GSK-626616 treatment, using a quantitative label-free 
phospho-proteomic approach (Bodenmiller et al., 2010; Huber et al., 2009) 
(Figure 4A). For two different time-points, 30 minutes and 12 hours 
respectively, we monitored the abundance of phospho-peptides isolated with 
titanium dioxide-based affinity chromatography and captured by liquid 
chromatography tandem mass spectrometry (LC-MS), reflecting the 
phosphorylation state of peptides (Bodenmiller et al., 2007). Of the overall 
1,194 peptides identified, only peptides that were present in three 
independent replicate experiments, and which were significantly enriched or 
depleted in the GSK-626616-treated compared to control samples (t-test P-
value: <0.1), where taken into account (Table 3). These strict criteria yielded a 
total of 44 regulated phospho-peptides: 26 regulated phospho-peptides after 
short-term treatment and 18 regulated phospho-peptides after long-term 
treatment with GSK-626616 (Figure 4B). 6 phospho-peptides were found 
significantly enriched or depleted at both time-points.   
20 out of the 24 and 7 out of the 15 corresponding proteins that were affected 
by short- and long-term treatment with GSK-626616 respectively, were 
recently reported to associate with mRNA or mRNA granules (Baltz et al., 
2012; Castello et al., 2012; Elvira et al., 2006; Kato et al., 2012).  In addition, 
mTORC1 signaling regulates 5 of the affected proteins in each treatment (Hsu 
et al., 2011; Yu et al., 2011), such as the eukaryotic translation initiation factor 
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4E-binding protein 1 (eIF4E-BP1) at threonine 37 and 46, and the tumor 
suppressor protein programmed cell death 4 (PDCD4) at serine 457. Both 
eIF4E-BP1 and PDCD4 are translational repressors known to act downstream 
of the mTORC1-ribosomal protein S6 kinase 1 (S6K1) pathway (Brunn et al., 
1997; Burnett et al., 1998). Similar changes in the phosphorylation of eIF4E-
BP1 and PDCD4 were detected by immunoblotting using phospho-specific 
antibodies, confirming our findings (Suppl. Figure S4A). Thus, the DYRK 
kinase inhibitor GSK-626616 affects, amongst others, the phosphorylation of 
mRNA-associated proteins and proteins downstream of mTORC1 signaling. 
 
DYRK3 is required for mTORC1 activity  
To validate the impact of inhibitors targeting DYRK family kinases on 
mTORC1 signaling, we evaluated the phosphorylation state of Thr389 of 
S6K1, a phosphorylation site that is considered a direct and appropriate 
readout for mTORC1 activity (Burnett et al., 1998). GSK-626616 treatment 
abolished the phosphorylation of S6K1 at Thr389 in non-stimulated HeLa 
cells, indicating a reduction in basal mTORC1 activity (Figure 4C). A variety of 
stimuli, such as epidermal growth factor (EGF) and insulin addition, can 
increase mTORC1 activity above basal levels (Zoncu et al., 2010). GSK-
626616 treatment also reduced the phosphorylation of S6K1 at Thr389 in 
EGF- as well as insulin-stimulated HeLa cells, showing that mTORC1 activity 
is impaired (Figure 4D). The extent by which low concentrations of GSK-
626616 inhibited S6K1 phosphorylation in cells was similar to the effect of a 
rapamycin derivative (RAD-001), a well-known inhibitor of mTORC1 (Boulay 
 
et al., 2004). Also Harmine treatment was able to interfere with EGF-
stimulated S6K1 phosphorylation, although to a lesser degree  (Suppl. Figure 
S4B). Moreover, GSK-626616 treatment interfered with basal mTORC1 
activity, as well as EGF- or insulin- stimulated mTORC1 activity in 3 additional 
unrelated mammalian cell lines, indicating a general mechanism that is not 
cell line-specific (Suppl. Figure S4C). As a consequence, treatment of cells 
with GSK-626616 leads to a reduction in protein synthesis (Suppl. Figure 
S4G).    
The mTORC1 pathway integrates many different signaling inputs, and the 
DYRK kinase inhibitors may affect several of those. However, we observed no 
effect of GSK-626616 treatment on the phosphorylation status of tuberin 
(TSC2) upon stimulation of cells with either EGF or insulin (Figure 4E).  In 
addition, we observed no effect on the phosphorylation of AKT or ERK1/2 
(Suppl. Figure S4D). We also found that the PI-3 kinase inhibitor Wortmannin 
had an additive inhibitory effect on mTORC1 activity in cells treated with GSK-
626616 (Suppl. Figure S4E), further indicating that the DYRK inhibitor affects 
mTORC1 via a parallel pathway. To assess whether the DYRK inhibitors 
could affect mTORC1 activity via an off-target effect and not via inhibiting 
DYRKs, we considered the few in vitro off-targets that these inhibitors have 
(Suppl. Figure S4F). Two possible kinases, namely ERK8 and RSK3/4, that 
are weakly inhibited by GSK-626616 in vitro, might act upstream of mTORC1. 
ERK8 however, is not inhibited by Harmine (Bain et al., 2007), and both ERK 
and RSK family kinases signal to mTORC1 via TSC2, which phosphorylation 
status does not change during GSK-626616 treatment (Figure 4E). Finally, 
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siRNA- and shRNA-mediated depletion of DYRK3 (but not other DYRK family 
kinases, data not shown) also resulted in a reduced S6K1 phosphorylation 
(Figure 4F and 4G). This further supports a specific effect of the inhibitors, 
and indicates that the inhibitory effect on mTORC1 acts mainly through 
DYRK3 in a manner that is independent of the PI3K/AKT and ERK pathways, 
and does not involve TSC2. 
 
Kinase-inactive DYRK3 inhibits mTORC1 by preventing dissociation 
from SGs. 
One possibility by which inhibition of DYRK3 may result in an inhibition of 
mTORC1 signaling activity is by causing a partitioning of mTORC1 into SGs. 
That mTORC1 partitions in SGs was recently shown in S. cerevisiae 
(Takahara and Maeda, 2012). Interestingly, we found that in human cells, 
both mTOR and the mTORC1-specific component RAPTOR are recruited to 
SGs induced by either osmotic or oxidative stress, and were retained on SGs 
by GSK-626616 treatment (Figure 5A and S5A). 
While examining mTORC1 activity during and after stressful conditions, we 
observed a reduction in mTORC1 activity during stress, as reported previously 
(Inoki et al., 2003), and a hyper-activation of mTORC1 after recovery (Figure 
5B). The reactivation of mTORC1 was blocked by the presence of GSK-
626616 during recovery. To test whether this is a consequence of prolonged 
mTORC1 sequestration on SGs, we made use of the SG-dissolving property 
of cycloheximide (CHX), which rapidly increases the rate of SG disassembly 
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and accelerates mTORC1 reactivation (Buchan and Parker, 2009; Takahara 
and Maeda, 2012). When we added CHX to cells during recovery from stress, 
both SG disassembly and reactivation of mTORC1 were enhanced (Figure 5B 
and 5C). However, addition of CHX to cells during recovery from stress in the 
presence of GSK-626616, led to rapid disassembly of SGs, but not to a full 
reactivation of mTORC1. This indicates that DYRK inhibitors reduce mTORC1 
signaling by blocking SG dissolution as well as by a second mechanism, 
independent of mTORC1 partitioning in SGs.  
 
DYRK3 also controls mTORC1 by direct phosphorylation of PRAS40 
To find this second mechanism, we used a microarray for kinase substrate 
identification consisting of more than 9,000 different human recombinant 
proteins. We identified 26 candidate proteins to be directly phosphorylated in 
vitro by wild type DYRK3 but not in by kinase-deficient DYRK3-K218M (Suppl. 
Figure S6A and Table 4). The second most strongly phosphorylated protein 
we identified the proline-rich AKT substrate of 40 kDa (PRAS40), also known 
as AKT1 substrate 1, which has been shown to interact directly with the 
mTORC1 complex and to negatively regulate mTOR kinase activity (Sancak 
et al., 2007; Vander Haar et al., 2007). Other proteins on the microarray that 
are known to regulate mTORC1 activity were not directly phosphorylated by 
DYRK3 (Table 4).  
Phosphorylation of PRAS40 by AKT1 at Thr246 has been shown to release it 
from the mTORC1 complex, thereby abolishing the inhibitory effect of 
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PRAS40 on mTOR, which allows further activation (Sancak et al., 2007; 
Vander Haar et al., 2007). Using recombinant DYRK3 and PRAS40, we found 
that DYRK3 directly phosphorylates Thr246 of PRAS40 in an in vitro kinase 
assay (Figure 6A). Addition of GSK-626616 to this assay blocked the 
phosphorylation reaction in a dose-dependent manner (Suppl. Figure S6B). 
Moreover, in cultured cells, GSK-626616 treatment reduced the 
phosphorylation of PRAS40 at Thr246 in response to EGF treatment (Figure 
6B). Using co-immunoprecipitation experiments, we observed that GSK-
626616 increases the fraction of bound PRAS40 to mTORC1 (Figure 6C), 
which is known to interfere with binding and activation of mTOR substrates 
(Vander Haar et al., 2007). Thus, DYRK3 directly phosphorylates PRAS40 at 
Thr246, a phosphorylation site responsible for regulation of PRAS40, resulting 
in decreased binding of PRAS40 to mTORC1, allowing activation of mTORC1 
signaling in unstressed cells and reactivation of mTORC1 during stress 
recovery. 
 
DYRK3 regulates its own partitioning between SGs and the cytosol in a 
cyclic manner through its kinase activity  
Finally, we studied the dynamics of how DYRK3 couples SG partitioning with 
mTORC1 regulation. To reveal this, we performed fluorescence recovery after 
photo-bleaching (FRAP) experiments. In unstressed cells expressing GFP-
DYRK3 and displaying cytoplasmic speckles, we observed that photo-
bleached speckles quickly recovered their fluorescence signal to initial levels 
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within 150 seconds (Figure 7A). Interestingly, treatment of GSK-626616 
during stress recovery resulted in an entrapment of 55% of GFP-DYRK3 on 
granules, which did not exchange with unbleached cytosolic DYRK3-GFP. 
Similarly, when we photo-bleached the cytoplasmic aggregates induced by 
the kinase-deficient mutant of DYRK3 (GFP-DYRK3-K218M), we observed 
that 69% of the signal could not be exchanged with unbleached cytosolic 
signal. Thus, DYRK3 displays dynamic cycles of association to and 
dissociation from SGs. Association requires the N-terminal domain (deletion of 
this domain abolishes partitioning in SGs, see Figure 3F), while dissociation 
requires kinase activity.  
Based on this, we propose the following mechanism by which DYRK3 couples 
SG condensation and dissolution with mTORC1 signaling. When SGs 
condense, such as during stress, DYRK3 will partition in SGs via its N-
terminal domain where it contributes to preventing SG dissolution, leading to 
partitioning of the mTORC1 complex in SGs, preventing it from signaling to 
downstream effectors. To dissolve SGs, the kinase activity of DYRK3 is 
required, leading to partitioning of the mTORC1 complex in the cytosol, where 
DYRK3 allows mTORC1 to be activated by phosphorylating PRAS40. Thus, 
DYRK3 represents a new type of regulator that dynamically couples phase 
transition-mediated compartmentalization to signal transduction via its kinase 
activity.
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Discussion 
In this study we identify chemical compounds targeting DYRK family kinases 
as inhibitors of SG dissolution, and show that these compounds act mainly via 
DYRK3. We reveal that DYRK3 has the potential to condense P-granule-like 
structures in the cytosol, and localizes to SGs after stress. Not the absence of 
DYRK3, but kinase-inhibited DYRK3 prevents SG dissolution via its N-
terminal domain. This domain is, when expressed alone or as part of a 
kinase-deficient mutant of DYRK3, able to induce the appearance of SG-like 
structures even in the absence of stress. We also show that inhibition of 
DYRKs affects the phosphorylation status of a number of mRNA-binding 
proteins and of proteins downstream of mTORC1 signaling. We explain this 
by demonstrating that DYRK3 blocks mTORC1 signaling by keeping 
mTORC1 partitioned in SGs when inactive, and phosphorylates the mTORC1 
inhibitor PRAS40 when active, which reduces the binding of PRAS40 to 
mTORC1, allowing subsequent activation. 
The condensation of SGs via liquid-liquid de-mixing depends on low 
complexity domains in proteins (Hyman and Simons, 2012; Kato et al., 2012; 
Weber and Brangwynne, 2012). Also the N-terminal domain of DYRK3 
contains a predicted low complexity sequence, which may explain how it 
allows partitioning into stress granules and contribute to liquid-liquid unmixing. 
This is however not a constitutive property of the DYRK3 protein, but is 
regulated by its own kinase activity in a cyclic manner.  
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Such a kinase-activity-dependent cycle provides an RNA granule sensing 
mechanism. When SGs condense during stress, DYRK3 senses this through 
its ability to cycle between SGs and the cytosol, while mTORC1 partitions in 
SGs, which prevent signaling to downstream effectors. When stress signals 
are gone, the kinase activity of DYRK3 will dissolve SGs by ʻinactivatingʼ the 
SG condensation property of its N-terminal domain, and possibly by 
phosphorylating mRNA-binding proteins, and will allow activation of mTORC1 
by preventing binding to PRAS40. In addition, DYRK3 might be a sensor of 
RNA granules that are formed under conditions different than stress, such as 
during cell division, cell polarization and cell differentiation, and to link their 
appearance to the control of mTORC1 signaling or other signal transduction 
pathways. We expect that following up on the numerous other proteins which 
phosphorylation status is affected by inhibition of DYRKs, or which can be 
phosphorylated by DYRK3 in vitro will provide further detail into this. 
Several lines of evidence suggest that the properties of DYRK3 that we have 
uncovered here is a conserved mechanistic principle for DYRK family 
members. DYRKs have been functionally linked to the cellular stress 
response in organisms across the eukaryotic kingdom, ranging from nutrient 
starvation, osmotic stress, irradiation, and genotoxic stress (Aranda et al., 
2010; Moriya et al., 2001; Seifert and Clarke, 2009; Taira et al., 2007; 
Taminato et al., 2002; Zhang et al., 2005). Furthermore, DYRKs are 
constitutively active kinases, believed to be regulated by changing their 
subcellular localization (Aranda et al., 2010). The dynamic cycling mechanism 
of DYRK3 between SGs and the cytosol shares striking resemblance with that 
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of Pom1, a DYRK kinase in S. pombe (Hachet et al., 2011). Pom1 cycles 
between a membrane-associated state, driven by auto-phosphorylation, and a 
cytosolic state, driven by phosphatase-mediated dephosphorylation of its N-
terminus. Our results support a similar mechanism for DYRK3. An 
unphosphorylated N-terminal low complexity domain might partition in SGs, 
while auto-phosphorylation of this domain might abolish this property, keeping 
it in the cytosol. This would explain how kinase-inactive DYRK3 becomes 
trapped in SGs, as its N-terminal domain now constitutively partitions into 
SGs. However, an autophosphorylation event in the N-terminal domain of 
DYRK3 remains to be identified, as well as a phosphatase that would 
dephosphorylate it.  
At least two other DYRK family members have been functionally linked to 
intracellular granules or speckles. MBK-2, a C. elegans DYRK, has been 
observed in speckles in the cytoplasm (Stitzel et al., 2006), and is essential 
for the asymmetric distribution of P granules in the first cell division of the C. 
elegans embryo (Pang et al., 2004). This process depends on specifically 
lowering the condensation point for P granules at one site of the dividing 
embryo (Brangwynne et al., 2009). Analogous to the properties of DYRK3, 
MBK-2 might thus be involved in P granule condensation in C. elegans. 
Furthermore, mammalian DYRK1A accumulates in nuclear splicing speckles 
(see also Suppl. Figure S2A) and is capable of dissolving speckles, 
depending on its kinase activity (Alvarez et al., 2003). We also observed that 
DYRK2, most closely related to DYRK3, localized to SGs in its inhibited state 
where it is partly responsible for blocking SG dissolution (data not shown).  
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This suggests that DYRKs are a family of kinases that couple 
compartmentalization through liquid phase transitions with cellular signaling 
through a novel kinase-dependent cyclic partitioning mechanism. Future work 
combining structural studies and detailed mechanistic analysis of DYRK 
cycling in and out liquid-unmixed compartments with the identification of 
possible upstream factors that influence this cycle will provide further insight 
into how this is utilized in the regulation of various cellular processes.
 
Experimental Procedures 
Materials  
Antibodies were obtained from the following sources: antibody to DYRK3 was 
from Aviva Systems Biology, PABP1, c-myc and mTOR were from Santa Cruz 
Biotechnology; antibodies to S6K1, pThr389-S6K1, pThr308-Akt, eIF4E-BP1, 
pThr37/46-eIF4-BP1, PRAS40, pThr246-PRAS40, eIF2α, pSer51-eIF2α, 
TSC2 and pThr1462-TSC2 were from Cell Signaling Technology; antibody to 
pThr202/pTyr204-ERK1/ pThr184/pTyr186-ERK2 was from BD Transduction; 
antibody to DDX6 was from Bethyl Laboratories Inc.; antibodies to beta-
Tubulin, PDCD4 and pSer457-PDCD4 were from Abcam; antibody to GST 
was from Sigma Aldrich, secondary antibodies conjugated to Alexa Fluorʼs 
were from Molecular Probes, secondary antibodies conjugated to were from 
Dianova. 
Lipofectamine 2000, DMEM and Glutamax were from Invitrogen; Human 
recombinant insulin, DMSO, sodium-arsenite, Harmine, sorbitol, Triton X-100, 
DAPI, L-glutathione reduced, myelin basic protein (MBP) from bovine brain, 
Albumin from bovine serum (BSA) and fetal bovine serum were from Sigma 
Aldrich; Paraformaldehyde (PFA) solution was from Electron Microscopy 
sciences; γ33P-ATP was from PerkinElmer; RAD-001 was from Selleck 
Chemicals; human recombinant EGF was from Millipore; human recombinant 
PRAS40 was from Biomol; GSK-626616 (PubChem CID: 15981157) was 
obtained from Andreas Tako (Institute for Organic Chemistry, University of 
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Innsbruck, Austria). Remaining compounds were from EMD Calbiochem (Cat. 
No. 539743 and 539746).  
Cell Lines and Tissue Culture  
HeLa cells were from Marino Zerial (MPI-CBG, Dresden), RDG3 were from 
Paul J. Anderson (Division of Rheumatology, Immunology and Allergy, 
Brigham and Women's Hospital, Boston), A431 and MEF were from ATCC 
(Molsheim Cedex). All cells were maintained at 37°C under 5% CO2 in DMEM 
supplemented with 10% fetal bovine serum FBS and Glutamax. 
Prior treatments, cells were washed and serum deprived for 14 hours. 
Stress granule assembly and disassembly assay  
Cells were grown in 384-well plates (for initial screen, Greiner) or 8-well Lab-
Tek chambers (for life cell imaging, VWR) in DMEM containing 10% FBS. 3 
hours prior to the experiment, the medium was exchanged to DMEM without 
FBS. Cells were treated for 45 minutes with 0.5mM arsenite, washed twice 
with Medium and allowed to recover for 240 minutes in DMEM suplememted 
with compound inhibitors at indicated concentrations. Treatment was stopped 
by addition of PFA to a final concentration of 4%. SGs were stained by 
immuno-fluorescence against PABP1 and images were acquired using on an 
ImageXpress Micro microscope (Molecular Devices). Life cell imaging was 
carried out on a VisiScope Confocal Cell Explorer. Automatic cell detection 
was performed using CellProfiler (Carpenter et al., 2006), and features 
describing intensities and textures were used for cell classification by support 
vector machine learning using CellClassifier (Ramo et al., 2009).  
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In vitro kinase profiling  
GSK-626616 compound was profiled against 451 kinases in an high-
throughput active site-directed competition binding assay (KINOMEscanTM, 
DiscoveRX) at concentrations of 0.1 μM and 1 μM. Data was visualized using 
TREEspotTM Compound Profile Visualization Tool. 
Immuno-fluorescence and confocal microscopy  
HeLa cells were grown on coverslips until the appropriate assay was 
performed. Cells were fixed by adding PFA to a final concentration of 4% and 
permeabilized with 0.1% Triton X-100. Unspecific binding was reduced by 
incubation in 1% BSA for 30 minutes. Cells were incubated with primary 
antibodies for 1 hour, followed by incubation with labeled secondary antibody 
for 1 hour. Nuclei were stained using DAPI. Imaging was carried on: Leica 
SP2-FCS confocal microscope equipped with a 63x 1.4-0.6NA DIC, Oil, HCX 
Plan-Apochromat objective; Leica SP5 Mid UV-VIS equipped with a 63x 1.4-
0.6NA DIC, Oil, HCX Plan-Apochromat; Zeiss LSM710 equipped with a 63x 
1.4NA Oil DIC Plan-Apochromat objective. Images were processed using 
ImageJ (http://rsb.info.nih.gov/ij/).    
Phospho-proteomics  
Cells were exposed to GSK-626616 or DMSO only in DMEM without FBS for 
30 minutes and 12 hours respectively, washed with PBS and harvested in 
lysis-buffer (150 mM NaCl, 10 mM Tris pH 7.2, 10 mM EDTA, 1 mM Na3VO4, 
200 nM Ocadaic acid, 20 nM Calyculin A, EDTA free protease inhibitor 
(Roche), 1 mM PMSF and 0.1% RapiGestTM (Waters)). Three replicas were 
independently collected and processed separately. The isolation of phospho-
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peptides using titanium-dioxid, mass spectrometry analysis and quantitative 
analysis was performed as described previously (Huber et al., 2009). 
Candidate protein classes were determined using PANTHER database 
(www.pantherdb.org). 
In vitro kinase substrate identification   
ProtoArray® Human Protein Microarrays (PAH052406, Invitrogen) were 
blocked with 1% BSA in PBS for 3 hours at 4°C. Kinase Buffer (100 mM 
MOPS pH 7.2, 1% Nonidet P40, 100 mM NaCl, 10 mg/ml BSA, 5 mM MgCl2, 
5 mM MnCl2), supplemented with 33 nM γ33P-ATP and 0.5 μg recombinant 
GST-DYRK3 or GST-DYRK3-K218M were added per array and incubated for 
1h. Arrays were washed with 0.5 % SDS, dried and exposed to Amersham 
Hyperfilm (GE Healthcare) for 3 hours. Analysis was carried out with 
ProtoArray® Prospector (Invitrogen).  
RNAi  
Cells were reverse transfected using Lipofectamine 2000 according to the 
manufacturerʼs instructions with siRNA targeting DYRK3 
(UAUAUGUGUAGAGCUUCUGGUACUC, Invitrogen). Experiments were 
carried out 72 hours post- transfection. shRNAs (shRNA-1 
CCGGATGATCTTACAAACCTGCAAACTCGAGTTTGCAGGTTTGTAAGATC
ATTTTTT, shRNA-2 CCGGGCCAGGGTCTATGATCACAAACTCGAGTTTGT-
GATCATAGACCCTGGCTTTTT, shRNA-3 CCGGTGTTCAAATGTACTCTG-
CAATCTCGAGATTGCAGAGTACATTTGAACATTTTT, shRNA-4 CCGGGTA-
GGTCCAAATGCCAAGAAACTCGAGTTTCTTGGCATTTGGACCTACTTTTT) 
 
were transfected using Lipofectamine 2000 according to the manufacturerʼs 
instructions. 
Construction of plasmids, mutants and truncations  
Full length DYRK3 cDNA clone (IRATp970D0168D, ImaGenes) was amplified 
using the primer 5´-CAC CAT GAA GTG GAA AGA GAA GTT GGG-3´ and 5´-
CTA GCT AAT CAG TTT TGG CAA TAC AC-3´. The PCR product was 
inserted into the Gateway® system entry vector pENTRTM/D-TOPO® 
(Invitrogen). The Gateway® LR recombination reaction was then performed 
between pENTRTM/D-TOPO®-DYRK3 and its destination vector pcDNA5-
FRT/TO-GFP or pcDNA5-FRT/TO-myc respectively (kindly provided by 
Manuel Bauer). The constructs pENTR-DYRK2, pENTR-DYRK3-K218M, 
pENTR-DYRK4, were a generous gift from by Markku Varjosalo (Institute of 
Molecular Systems Biology, ETH Zurich) and cloned into destination vectors 
as described above. Truncations of DYRK3 were created by amplification 
from the full length DYRK 3 using the primer pairs 5´-CAC CAT GAA GTG 
GAA AGA GAA GTT GGG-3´ and 5ʼ-CTA TCG ATA AGC TAG ATG GTC 
TCG A-3ʼ for DYRK3 (NT: 1-188), 5ʼ-CAC CCG ATA TGA GGT GCT GAA A-
3ʼ and 5´-CTA GCT AAT CAG TTT TGG CAA TAC AC-3´ for DYRK3 (ΔNT: 
189-568), 5ʼ-CAC CAA ACG TGC CAA GTA CTT TAT T-3ʼ, subsequently 
insertion into pENTRTM/D-TOPO® and cloning into designated destination 
vectors. pGEX-4T1-DYRK3 and pGEX-4T1-DYRK3-K218M for recombinant 
expression in E.coli were produced by amplifying full length wild type DYRK3 
and DYRK3-K218M with the primer pair 5ʼ-CCG GAA TTC ATG AAG TGG 
AAA GAG-3ʼ and 5ʼ- ATG CGG CCG CTC CTA GCT AAT CA-3ʼ and insertion 
 
into pGEX-4T/1-GST (Amersham) with BamHI and EcoRI. phrGFP-GW182 
was kindly provided by Edward Chan (Department of Molecular and 
Experimental Medicine, The Scripps Research Institute, La Jolla). pEGFP-
G3BP1 and pCI-puro-mRFP-DCP1a were from Paul J. Anderson (Division of 
Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, 
Boston). pRK5-myc-PRAS40 was a gift from Do-Hyung Kim (Addgene 
#15476). pRK5-myc-RPTOR was a gift from David Sabatini (Addgene #1859). 
Cells were transiently transfected using Lipofectamine 2000 according to the 
manufacturerʼs instructions.  
In vitro kinase assays  
Recombinant DYRK3 wild type and kinase-dead DYRK3-K218M GST-fusion 
proteins were produced in E.coli containing pGEX-4T-1-DYRK3 or pGEX-4T-
1-DYRK3-K218M. Bacterial culture was harvested by centrifugation, lysed in 
PBS supplemented with 0.5 M NaCl, 2 mM EDTA, 10 mM DTT, 250 μM 
PMSF and EDTA free protease inhibitor (Roche) and sonicated. GST-fusion 
protein was purified using Glutathione sepharose 4B gravity-flow columns (GE 
Healthcare), eluted with 20 mM L-glutathione reduced in 50 mM Tris pH 8, 0.5 
M NaCl and dialyzed against 50 mM Tris pH 8, 0.5 M NaCl. In vitro kinase 
assay was carried out in kinase buffer (25 mM Hepes, 5 mM MgCl2, 5 mM 
MnCl2, 0.5 mM DTT and 10 μM ATP), supplemented with 2 μCi γ33P-ATP per 
reaction, 8 μg MBP and 2 μg DYRK3 for 30 minutes at room temperature. 
Proteins were separated by SDS-PAGE and γ33P-incorporation was detected 
on a phosphorimager. In the in vitro kinase assay of DYRK3 and recombinant 
 	
PRAS40-myc, the phosphorylation of 0.5 μg PRAS40-myc was detected by 
separation of proteins with SDS-PAGE and immunoblotting as discribed.  
Cell lysis and Immunoprecipitations  
Cells were rinsed once with cold PBS and lysed in buffer (150 mM NaCl, 1% 
Triton X-100, 1 mM EDTA, 10 mM Tris pH 7.2, 10 μM PMSF, EDTA free 
protease inhibitor and PhosSTOP (Roche), 20 nM Calyculin A and 1 mM 
Na3VO4). For immunoprecipitations, cells were lysed in CHAPS buffer (120 
mM NaCl, 0.3% CHAPS, 2 mM EDTA, 40 mM HEPES (pH 7.4), EDTA free 
protease inhibitor and PhosSTOP (Roche)) and cleared by centrifugation at 
13,000 rpm for 10 minutes at 4°C. Primary antibody was added and incubated 
for 90 minutes with rotation. Immuno-complexes were captured by addition of 
protein G Sepharose slurry and incubation for 2 hours, followed by 7 wash 
steps with CHAPS buffer. Proteins were denatured by the addition sample 
buffer and boiling for 5 min. Proteins were resolved by SDS-PAGE and 
analyzed by immunoblotting as described. 
FRAP analysis  
HeLa cells were grown on 18mm cover slips, transfected with either pcDNA5-
FRT/TO-GFP-DYRK3 or pcDNA5-FRT/TO-GFP-DYRK3-K218M using 
Lipofectamine 2000. Cells were monitored on a Leica SP5 Mid UV-VIS 
equipped with a 63x 1.4-0.6NA DIC, Oil, HCX Plan-Apochromat at a frame 
rate of 1 frame per 2.6 seconds. A defined region was bleached 3 times at full 
laser power using the 488 nm and 405 nm laser line after 5 frames. Recovery 
was monitored over a minimum of 150 seconds. FRAP analysis was carried 
out on using ImageJ (http://rsb.info.nih.gov/ij/). Recovery curves were fitted 
 

and values were calculated with the formula f(t) = f0 + (fmax - f0)*(1 - exp(-τt)) 
using  Prism5 (GraphPad). 
Relative quantification of transcripts  
RNA was exctracted using Trizol reagent (Invitrogen) according to the 
manufacturerʼs instruction 72 hours post transfection. Reverse transcription 
was performed using the QuantiTect Reverse Transcription Kit (Qiagen). 
Quantitative real-time RT- PCR was carried out in an Mx3005P QPCR System 
(Stratagene) using primers against DYRK3 (5ʼ-TCC TTC TGA ACC ACC TCC 
AC-3ʼ and 5ʼ-CCT TCA TCT CAC CTC CAT CC-3ʼ) and RPL13A (5ʼ-GAG 
AAA GCC AAG ATC CAC TAC C-3ʼ and 5ʼ- TTG AGG ACC TCT GTG TAT 
TTG TC-3ʼ). Relative change was calculated to control siRNA treatment and 
by using RPL13A as an internal standard for each sample. 
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